sentence_id,sentence,concept,concept_start,concept_end,concept_start_end_list,cue,cue_start,cue_end,label
NCT01959425_exc_0_T3_T2,"OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis, previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard echo performed at 3-months follow-up).",AF,40,42,,not,25,28,N
NCT02831166_exc_497_T35_T36,Documented chronic peripheral arterial disease preventing the use of the femoral technique;,femoral technique,73,90,,preventing,47,57,N
NCT00391690_inc_1052_T46_T47,Patients with psychiatric or addictive disorders which prevent them from giving their informed consent must not enter the study.,giving informed consent,,,"[(73, 79), (73, 89)]",prevent,55,62,N
NCT02664558_exc_1482_T118_T117,"History of malignancy within the last 5 years, except nonmelanoma skin cancer and cervical carcinoma in situ treated with curative intent.",cervical carcinoma in situ,82,108,,except,47,53,N
NCT02664558_exc_1482_T116_T117,"History of malignancy within the last 5 years, except nonmelanoma skin cancer and cervical carcinoma in situ treated with curative intent.",nonmelanoma skin cancer,54,77,,except,47,53,N
NCT03355469_inc_79_T8_T7,Not diagnosed with Type 2 diabetes.,Type 2 diabetes,19,34,,Not,0,3,N
NCT03355469_inc_115_T10_T9,Not currently engaged in > 60 min/wk of exercise,engaged in exercise,,,"[(14, 24), (14, 22)]",Not,3,6,N
NCT00480129_inc_0_T6_T7,"Clinical diagnosis of allergic rhinitis based on sneeze attacks, runny/blocked/itchy nose in the absence of a common cold during the previous 12 months.",common cold,110,121,,absence,97,104,N
NCT00480129_inc_0_T4_T7,"Clinical diagnosis of allergic rhinitis based on sneeze attacks, runny/blocked/itchy nose in the absence of a common cold during the previous 12 months.",blocked nose,,,"[(71, 78), (71, 75)]",absence,97,104,N
NCT01205334_inc_690_T31_T32,Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study.,antineoplastic therapy,52,74,,been off,21,29,N
NCT02315287_inc_15_T4_T3,No treatment with insulin or oral agents for 6 months,treatment,3,12,,No,0,2,N
NCT03499639_inc_36_T3_T4,"naive to HCV treatment,",HCV treatment,9,22,,naive,0,5,N
NCT03221231_exc_0_T4_T3,"Currently dependent on any substance other than cannabis, alcohol or nicotine;",cannabis,48,56,,other than,37,47,N
NCT03221231_exc_0_T5_T3,"Currently dependent on any substance other than cannabis, alcohol or nicotine;",alcohol,58,65,,other than,37,47,N
NCT03221231_exc_0_T6_T3,"Currently dependent on any substance other than cannabis, alcohol or nicotine;",nicotine,69,77,,other than,37,47,N
NCT02944292_inc_215_T15_T14,Physician-led sedation (if sedated; as opposed to nurse-led protocol),nurse-led protocol,50,68,,as opposed to,36,49,N
NCT00962364_inc_107_T11_T12,"dilated cardiomyopathy due to valvular heart disease, hypertensive heart disease, history of myocarditis (no active myocardial infection present)",myocardial infection,116,136,,no,106,108,N
NCT02783859_exc_15_T4_T3,"Underlying chronic illness other than asthma (e.g. bronchiectasis, cyanotic congenital heart disease or cardiac failure, neuromuscular disorders, immunodeficiency) that could potentially influence the current illness",asthma,38,44,,other,27,32,N
NCT02431559_exc_416_T56_T57,"Subjects with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or, within six months prior to Day 1 of this study, history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage.",controlled,120,130,,not,116,119,N
NCT02431559_exc_963_T89_T90,"History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti-arrhythmic medication.",atrial fibrillation,175,194,,except,164,170,N
NCT02431559_exc_1378_T108_T109,"Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit.",surgically,100,110,,non,96,99,N
NCT02431559_exc_1378_T110_T111,"Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit.",permanent deficit,123,140,,without,115,122,N
NCT02431559_exc_1378_T107_T112,"Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit.",ischemia,29,37,,except,39,45,N
NCT02431559_exc_1849_T136_T138,"Vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted.",requiring systemic treatment,93,121,,not,134,137,N
NCT02431559_exc_2110_T147_T148,"Other malignancy within 2 years prior to Day 1 of the study, except for those treated with surgical intervention only.",surgical intervention,91,112,,except for,61,71,N
NCT02431559_exc_3392_T199_T200,Subjects must not donate blood while on study and for at least 90 days following the last MEDI4736 treatment.,donate blood,18,30,,not,14,17,N
NCT02431559_exc_3105_T191_T188,-Female subjects should refrain from breastfeeding throughout this period.,breastfeeding,37,50,,refrain from,24,36,N
NCT02431559_exc_2871_T181_T180,Lack of availability for immunological and clinical follow-up assessment.,immunological follow-up assessment,,,"[(25, 38), (25, 45)]",Lack of,0,7,N
NCT02431559_exc_2871_T189_T180,Lack of availability for immunological and clinical follow-up assessment.,clinical follow-up assessment,43,72,,Lack of,0,7,N
NCT02939872_inc_139_T12_T10,"No history of death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding",death,14,19,,No,0,2,N
NCT02939872_inc_139_T19_T10,"No history of death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding",bleeding,95,103,,No,0,2,N
NCT02939872_inc_139_T15_T10,"No history of death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding",stroke,52,58,,No,0,2,N
NCT02939872_inc_139_T14_T10,"No history of death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding",myocardial infarction,29,50,,No,0,2,N
NCT02939872_inc_139_T17_T10,"No history of death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding",revascularization,67,84,,No,0,2,N
NCT03073603_exc_479_T26_T29,Use of oral steroids for no greater than 14 days given for a non-MS condition is not exclusionary.,oral steroids,7,20,,not,81,84,N
NCT03073603_exc_842_T48_T47,Cancers other than basal cell skin cancers within the last 5 years,basal cell skin cancers,19,42,,other than,8,18,N
NCT02965027_exc_138_T9_T10,Diagnosis of a primary or secondary HA disorder other than PTHA,PTHA,59,63,,other than,48,58,N
NCT02965027_exc_412_T29_T31,"Continuous HAs of any kind (i.e., persistent daily HAs with no HA-free period less than 8 hours between attacks)",HA-free period between attacks,,,"[(63, 77), (63, 78)]",no,66,68,N
NCT02965027_exc_1759_T98_T99,"Meets Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for any Substance Use Disorder except caffeine-related disorders, or tobacco-related disorders.",caffeine-related disorders,128,154,,except,121,127,N
NCT02965027_exc_1759_T100_T99,"Meets Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for any Substance Use Disorder except caffeine-related disorders, or tobacco-related disorders.",tobacco-related disorders,159,184,,except,121,127,N
NCT02965027_exc_2229_T122_T121,"Women of childbearing potential must not be pregnant, planning to become pregnant during the study period, or nursing.",pregnant,44,52,,not be,37,43,N
NCT02965027_exc_2229_T124_T121,"Women of childbearing potential must not be pregnant, planning to become pregnant during the study period, or nursing.",pregnant,44,52,,not be,37,43,N
NCT02003339_exc_0_T3_T4,Invasive hepatocellular carcinoma without any isolated tumor,isolated tumor,46,60,,without,34,41,N
NCT02003339_exc_107_T8_T13,"Thrombosis extending into the porta(thrombosis of one of left or right branch authorized), extra hepatic metastasis",thrombosis,36,46,,authorized,78,88,N
NCT02003339_exc_107_T6_T13,"Thrombosis extending into the porta(thrombosis of one of left or right branch authorized), extra hepatic metastasis",Thrombosis,0,10,,authorized,78,88,N
NCT02003339_exc_325_T23_T22,"No antiangiogenic concomitant treatment, 15 days before and 15 days after radioembolization, including Sorafenib",antiangiogenic treatment,,,"[(3, 17), (3, 12)]",No,0,2,N
NCT00235170_exc_301_T15_T14,Transmural myocardial infarction within the previous seven days and CK has not returned to normal;,normal,91,97,,has not returned,71,87,N
NCT01884337_exc_193_T27_T29,"Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days other than the elective knee/hip surgery",elective knee surgery,,,"[(97, 110), (97, 104)]",other than,85,95,N
NCT01884337_exc_193_T28_T29,"Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days other than the elective knee/hip surgery",elective hip surgery,,,"[(97, 105), (97, 108)]",other than,85,95,N
NCT02141061_exc_3_T17_T18,"Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy",menstrual period,127,143,,without,117,124,N
NCT02141061_exc_3_T21_T18,"Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy",oophorectomy,174,186,,without,117,124,N
NCT02141061_exc_3_T19_T18,"Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy",hysterectomy,154,166,,without,117,124,N
NCT01807897_inc_189_T11_T10,No change in active cardiac medications for 4 weeks prior to randomization,change,3,9,,No,0,2,N
NCT00445029_inc_607_T12_T14,"No history of PPD allergic contact dermatitis, with a negative PPD patch test.",allergic contact dermatitis,18,45,,No,0,2,N
NCT01824537_exc_0_T3_T1,Volunteers must not have been vaccinated against HPV-Gardasil-9 (both partners),vaccinated,30,40,,not,16,19,N
NCT02242188_inc_158_T19_T17,No previous iron supplementation,iron supplementation,12,32,,No,0,2,N
NCT02242188_inc_191_T22_T20,No previous blood transfusion,blood transfusion,12,29,,No,0,2,N
NCT02952378_inc_0_T5_T4,"For healthy individuals: Healthy, without allergies and with the age of 18 years or above.",allergies,42,51,,without,34,41,N
NCT01401335_exc_0_T5_T6,Age less than 15 or greater than 25 and not participating in the day care center       ,participating in the day care center,44,80,,not,40,43,N
NCT02973035_exc_84_T4_T5,Planned cardiac surgery or planned major non-cardiac surgery within the study period.,cardiac,8,15,,non,41,44,N
NCT02973035_exc_317_T24_T23,A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.,superficial squamous skin cancer,,,"[(34, 54), (34, 45)]",other than,28,38,N
NCT02973035_exc_317_T25_T23,A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.,basal cell skin cancer,58,80,,other than,23,33,N
NCT00344318_exc_584_T39_T77,"Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations",vaccines,155,163,,with the exception of,133,154,N
NCT00344318_exc_1085_T55_T58,"History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease.",febrile convulsion,100,118,,does not apply,36,50,N
NCT02579733_inc_134_T9_T8,Newly diagnosed or without steroid use during last 1 year,steroid,27,34,,without,19,26,N
NCT02867618_inc_194_T15_T17,"In addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.",diffuse large B cell lymphomas (DLBCL),42,80,,other than,31,41,N
NCT02867618_inc_322_T25_T27,Patients with DLBCL and HL will be eligible if there is no available standard therapy.,standard therapy,69,85,,no,56,58,N
NCT02867618_inc_502_T33_T34,Patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.,diffuse large B cell lymphomas (DLBCL),29,67,,other than,18,28,N
NCT02867618_inc_617_T43_T45,Patients with DLBCL will be eligible if there is no available standard therapy.,standard therapy,62,78,,no,49,51,N
NCT03079141_exc_765_T47_T48,No hyperfluorescence on ICGA;,hyperfluorescence,3,20,,No,0,2,N
NCT00426751_inc_0_T4_T5,"Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e. women of child bearing potential are not allowed to be included into the study.",menstrual period,52,68,,without,44,51,N
NCT00426751_inc_0_T8_T11,"Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e. women of child bearing potential are not allowed to be included into the study.",women,99,104,,not,136,139,N
NCT00426751_inc_0_T9_T11,"Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e. women of child bearing potential are not allowed to be included into the study.",child bearing potential,108,131,,not,136,139,N
NCT03491059_exc_0_T1_T3,not a regular user of e-cigarettes,regular user,6,18,,not,0,3,N
NCT02678962_exc_0_T5_T4,"Preexisting ocular diseases or conditions other than age related cataracts, have contraindications for cataract surgery;",cataracts,65,74,,other than,42,52,N
NCT02609425_exc_0_T3_T2,Any patient with esophageal cancer who is not deemed a surgical candidate or who is not deemed a candidate for the Ivor Lewis technique of esophagectomy (with intrathoracic anastomosis).,candidate,64,73,,not,42,45,N
NCT02609425_exc_0_T5_T4,Any patient with esophageal cancer who is not deemed a surgical candidate or who is not deemed a candidate for the Ivor Lewis technique of esophagectomy (with intrathoracic anastomosis).,candidate,64,73,,not,42,45,N
NCT02867618_exc_3_T15_T16,Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.,recovered,120,129,,not,116,119,N
NCT02867618_exc_207_T22_T23,Systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs.,stabilized,37,47,,not,28,31,N
NCT01774019_exc_53_T7_T6,"Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers",pancreatic cancer,53,70,,other than,42,52,N
NCT01774019_exc_53_T8_T6,"Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers",distal CBD cholangiocarcinoma,72,101,,other than,42,52,N
NCT01774019_exc_53_T9_T6,"Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers",other periampullary cancers,42,69,,other than,42,52,N
NCT01774019_exc_187_T12_T14,"Surgically altered biliary tract anatomy, not including prior cholecystectomy",cholecystectomy,62,77,,not,42,45,N
NCT02637076_exc_0_T5_T6,"use of any sedative hypnotics, tranquilizers, anticonvulsants, antihistamines (except non-sedating), benzodiazepines, clonidine or any medication known to affect dopamine at start of baseline period",non-sedating,86,98,,except,79,85,N
NCT02531971_inc_890_T14_T24,"Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)",pain,73,77,,no,14,16,N
NCT02531971_inc_2315_T57_T56,"Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block.",pathologic Q wave abnormalities,65,96,,not,24,27,N
NCT02531971_inc_890_T18_T24,"Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)",pain,73,77,,no,14,16,N
NCT02531971_inc_890_T20_T24,"Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)",respiratory compromise,99,121,,no,14,16,N
NCT02531971_inc_890_T21_T24,"Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)",asthma,139,145,,no,14,16,N
NCT02531971_inc_890_T26_T24,"Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)",constipation,150,162,,no,14,16,N
NCT02531971_inc_2315_T58_T56,"Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block.",ST-T wave changes,110,127,,not,24,27,N
NCT02531971_inc_2315_T59_T56,"Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block.",left ventricular hypertrophy,129,157,,not,24,27,N
NCT02531971_inc_2315_T60_T56,"Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block.",right bundle branch block,159,184,,not,24,27,N
NCT02531971_inc_2315_T61_T56,"Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block.",left bundle branch block,129,153,,not,24,27,N
NCT02281643_inc_0_T7_T11,M. perstans mg-positive status Good general health without any clinical condition requiring long-term medication.,clinical condition requiring long-term medication,63,112,,without,51,58,N
NCT02467686_exc_0_T2_T1,Women did not have breast cancer,breast cancer,19,32,,not,10,13,N
NCT02467686_exc_33_T3_T5,do not use tamoxifen or aromatase inhibitor,tamoxifen,11,20,,not,3,6,N
NCT02467686_exc_33_T4_T5,do not use tamoxifen or aromatase inhibitor,aromatase inhibitor,24,43,,not,3,6,N
NCT02467686_exc_77_T10_T9,not in menopause and not have hot flashes,hot flashes,30,41,,not,0,3,N
NCT02467686_exc_77_T8_T7,not in menopause and not have hot flashes,menopause,7,16,,not,0,3,N
NCT02804646_exc_0_T37_T36,"1) pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;2) existing severe acute infection and is not controlled; or purulent and chronic infection, delayed healing wounds; 3) the original severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension; 4) suffering from neurological and psychiatric diseases or mental disorders is not easy to control, poor compliance, and can not be described with treatment responders; primary brain or central nervous metastasis disease has not been controlled, with significant cranial hypertension or neuropsychiatric symptoms; 5) have bleeding tendencies; 6) other researchers believe that patients should not participate in the present trial.",controlled,167,177,,not,89,92,N
NCT00989261_exc_1386_T64_T68,"Use of concomitant drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors are prohibited with the exception of antibiotics, antifungals, and other antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient.",antibiotics,120,131,,with the exception of,98,119,N
NCT00989261_exc_1386_T65_T68,"Use of concomitant drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors are prohibited with the exception of antibiotics, antifungals, and other antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient.",antifungals,133,144,,with the exception of,98,119,N
NCT00989261_exc_1386_T66_T68,"Use of concomitant drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors are prohibited with the exception of antibiotics, antifungals, and other antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient.",antimicrobials,156,170,,with the exception of,98,119,N
NCT00989261_exc_2113_T99_T102,"History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the possible exception of patients in complete remission       ",skin cancer,57,68,,except,19,25,N
NCT02502734_inc_183_T11_T12,Subjects must be pre-adolescent without any signs of puberty (Tanner Stage 1).,signs of puberty,44,60,,without any,32,43,N
NCT02502734_inc_698_T31_T34,There should be no Short acting beta-agonist (SABA) use within 4 hours of this measurement.,Short acting beta-agonist (SABA),19,51,,no,16,18,N
NCT02502734_inc_1172_T46_T47,There must be no ICS use within 2 weeks of Visit 1 (Screening).,ICS,17,20,,no,14,16,N
NCT02590822_inc_367_T22_T21,"Poorly managed diet controlled diabetes (with HbA1c > 6.5% , not currently taking any glucose lowering therapy, meeting BMI inclusion range)",glucose lowering therapy,86,110,,not,61,64,N
NCT02344888_exc_74_T8_T7,Presence of any infertility factor other than anovulatory PCOS.,anovulatory PCOS,46,62,,other than,35,45,N
NCT02705222_inc_0_T10_T9,"Perimenopausal women complaining of abnormal uterine bleeding (menorrhagia, metrorrhagia, polymenorrhoea or polymenorrhagia) without local gynecological cause.",local gynecological cause,133,158,,without,125,132,N
NCT00426751_exc_0_T57_T56,Subjects not able to give informed consent,give informed consent,21,42,,not,9,12,N
NCT02596555_exc_989_T21_T24,"Need for long-term treatment with a low molecular weight heparin, vitamin K antagonists or NOAC, for an indication other than the index PE episode, or for antiplatelet agents except acetylsalicylic acid at a dosage =100 mg/day;",PE episode,136,146,,other,115,120,N
NCT02596555_exc_989_T27_T23,"Need for long-term treatment with a low molecular weight heparin, vitamin K antagonists or NOAC, for an indication other than the index PE episode, or for antiplatelet agents except acetylsalicylic acid at a dosage =100 mg/day;",acetylsalicylic acid,182,202,,except,175,181,N
NCT02788045_inc_0_T1_T2,Are negative for human immunodeficiency virus (HIV) infection at screening,human immunodeficiency virus (HIV),17,51,,negative,4,12,N
NCT03124329_inc_212_T9_T10,No prior surgical treatment in the sites planned for therapy,surgical treatment,9,27,,No,0,2,N
NCT03124329_inc_314_T14_T15,Absence of cervical restorations extending to the CEJ,cervical restorations extending to the CEJ,11,53,,Absence,0,7,N
NCT02765035_inc_339_T12_T11,Person was never fitted with microprocessor controlled prosthetic knee joint.,prosthetic knee joint,55,76,,never,11,16,N
NCT02862314_exc_41_T4_T3,"patients without health insurance,",health insurance,17,33,,without,9,16,N
NCT01491763_inc_236_T10_T11,"Patients without functional impairment of organs: liver function: total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease.",functional impairment of organs,17,48,,without,9,16,N
NCT01491763_inc_236_T31_T30,"Patients without functional impairment of organs: liver function: total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease.",severe chronic respiratory disease,375,409,,absence of,364,374,N
NCT01650792_exc_0_T3_T4,Patients with a history of an untreated malignancy (except local skin cancers),local skin cancers,59,77,,except,52,58,N
NCT03339284_exc_61_T5_T6,no co-operation or inadequate finnish language skills,co-operation,3,15,,no,0,2,N
NCT03339284_exc_61_T7_T6,no co-operation or inadequate finnish language skills,inadequate finnish language skills,19,53,,no,0,2,N
NCT02464813_inc_143_T11_T12,No contraindication for Pregabalin use,contraindication,3,19,,No,0,2,N
NCT01032109_inc_72_T6_T4,no previous treatment,treatment,12,21,,no,0,2,N
NCT02596555_inc_264_T10_T11,"Absence of hemodynamic collapse, or decompensation, at presentation; Hemodynamic collapse or decompensation",hemodynamic collapse,11,31,,Absence,0,7,N
NCT02596555_inc_264_T12_T11,"Absence of hemodynamic collapse, or decompensation, at presentation; Hemodynamic collapse or decompensation",hemodynamic decompensation,,,"[(11, 22), (11, 25)]",Absence,2,9,N
NCT00730301_exc_45_T6_T8,Pleural or interstitial disease that precludes surgery.,surgery,47,54,,precludes,37,46,N
NCT02334631_exc_0_T7_T6,"Patients with a contraindication to VCE (small bowel strictures, oropharyngeal dysphagia, pregnancy, patients who are not surgical candidates)",surgical candidates,122,141,,not,118,121,N
NCT02334631_exc_0_T3_T6,"Patients with a contraindication to VCE (small bowel strictures, oropharyngeal dysphagia, pregnancy, patients who are not surgical candidates)",small bowel strictures,41,63,,not,118,121,N
NCT02334631_exc_0_T4_T6,"Patients with a contraindication to VCE (small bowel strictures, oropharyngeal dysphagia, pregnancy, patients who are not surgical candidates)",oropharyngeal dysphagia,65,88,,not,118,121,N
NCT02334631_exc_0_T5_T6,"Patients with a contraindication to VCE (small bowel strictures, oropharyngeal dysphagia, pregnancy, patients who are not surgical candidates)",pregnancy,90,99,,not,118,121,N
NCT02519777_exc_860_T49_T48,"Other CNS conditions: non-opportunistic primary or metastatic brain tumors, uncontrolled seizure disorder, progressive multiple sclerosis, stroke with neurological sequelae, or dementia due to causes other than HIV (eg, Alzheimer's disease)",HIV,211,214,,other than,200,210,N
NCT01217671_inc_45_T3_T6,If a report of past CT scan is not available at site documenting then a CT scan is to be performed at screening,CT scan,20,27,,not available,31,44,N
NCT01217671_inc_1428_T62_T64,No significant abnormalities in ECG per investigator judgment.,abnormalities in ECG,15,35,,No,0,2,N
NCT01217671_inc_1546_T72_T73,"AAT deficient patients who are either naïve (not receiving IV augmentation therapy) or AAT deficient patients (receiving IV augmentation therapy), if they have been stable on regular therapy for at least 3 months prior to the screening visit and are willing to continue the same regime throughout this trial.",IV augmentation therapy,59,82,,not receiving,45,58,N
NCT01217671_inc_2124_T82_T83,"Non-pregnant, non-lactating female patients, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator, or who are at least 2 years post-menopausal or surgically sterilized.",pregnant,4,12,,Non,0,3,N
NCT01217671_inc_2124_T84_T85,"Non-pregnant, non-lactating female patients, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator, or who are at least 2 years post-menopausal or surgically sterilized.",lactating,18,27,,non,14,17,N
NCT02612181_exc_201_T21_T20,High-grade block in the absence of a functioning pacemaker.,pacemaker,49,58,,in the absence of,17,34,N
NCT00094861_inc_495_T39_T38,Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization,transfusional support,58,79,,without,50,57,N
NCT00094861_inc_495_T40_T38,Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization,growth factor use,83,100,,without,50,57,N
NCT00094861_inc_639_T48_T47,Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization,growth factor use,78,95,,without,70,77,N
NCT01214096_exc_369_T21_T22,Ischemic heart failure without the revascularization or undergone the revascularization within last 6 months;,revascularization,35,52,,without,23,30,N
NCT01214096_exc_369_T23_T22,Ischemic heart failure without the revascularization or undergone the revascularization within last 6 months;,revascularization,35,52,,without,23,30,N
NCT01214096_exc_1286_T73_T74,Childbearing-aged female subject who is unmarried or dose not bear child;,bear child,5,15,,not,58,61,N
NCT02332291_exc_0_T4_T3,"Current or past diagnoses of other Axis I psychiatric disorders, except for generalized anxiety disorder (GAD) symptoms occurring during a depressive episode",generalized anxiety disorder (GAD),76,110,,except for,65,75,N
NCT02332291_exc_792_T47_T53,"Occasional use of benzodiazepines or non-benzodiazepine sedatives (such as zolpidem, eszopiclone, or zaleplon) during this period is allowable.",benzodiazepines sedatives,,,"[(18, 33), (18, 27)]",is allowable,140,152,N
NCT02332291_exc_792_T48_T53,"Occasional use of benzodiazepines or non-benzodiazepine sedatives (such as zolpidem, eszopiclone, or zaleplon) during this period is allowable.",non-benzodiazepine sedatives,37,65,,is allowable,120,132,N
NCT03299517_inc_130_T14_T12,No signs of poor peripheral perfusion,poor peripheral perfusion,12,37,,No,0,2,N
NCT03299517_inc_168_T15_T16,Absence of dyspnea,dyspnea,11,18,,Absence of,0,10,N
NCT03299517_inc_187_T18_T17,Absence of severe angina,angina,18,24,,Absence of,0,10,N
NCT03260881_inc_64_T7_T8,"Adult patients with T2DM who are indicated to receive liraglutide, not as first-line therapy, in addition to diet and exercise to improve glycemic control",first-line therapy,74,92,,not,67,70,N
NCT01064752_inc_143_T10_T14,Off antiretroviral therapy (ART) for > 6 weeks before the study and no plans to begin treatment for the study duration.,plans to begin,71,85,,no,68,70,N
NCT03338296_inc_435_T23_T22,Participants and their families not planning to move away from the area for the duration of the study,planning to move away,36,57,,not,32,35,N
NCT03171987_inc_538_T15_T16,A primary complaint of pain in the area between the 12th rib and buttock crease without leg pain,leg pain,88,96,,without,80,87,N
NCT02406495_inc_542_T22_T23,Has clear corneas and no active ocular disease,ocular disease,32,46,,no,22,24,N
NCT02884401_inc_248_T12_T11,"Not in treatment with anti-resorptive agents (like bisphosphonates and denosumab) for more than 4 consecutive years, in order to reduce the risk of medication-related osteonecrosis of the jaws (Lo et al., 2010).",anti-resorptive agents,22,44,,Not,0,3,N
NCT03231982_exc_2144_T128_T129,History of malignancy including leukemia and lymphoma within recent 5 years except for localized basal cell carcinoma of the skin),localized basal cell carcinoma of the skin,87,129,,except for,76,86,N
NCT03231982_exc_2734_T169_T168,"Pregnant or lactating women and female volunteers of childbearing potential (except for women who are surgically sterile) who are not willing to use an adequate method of contraception (oral contraceptives, intrauterine device, condom, etc.) during the study.",willing to,134,144,,not,130,133,N
NCT01217671_exc_278_T25_T24,"Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study.",respiratory disease,,,"[(58, 69), (58, 65)]",except for,47,57,N
NCT01217671_exc_278_T26_T24,"Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study.",liver disease,73,86,,except for,47,57,N
NCT01217671_exc_862_T52_T56,Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator.,contraception,53,66,,not,33,36,N
NCT01997580_exc_0_T3_T4,DSM-IV-TR substance-related disorders (except nicotine),nicotine,46,54,,except,39,45,N
NCT00609531_inc_222_T11_T12,Free of psychoactive medication for at least: one month for fluoxetine; two weeks for other SSRIs and neuroleptics; and five days for stimulants prior to MRI scanning [excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder],psychoactive medication,8,31,,Free of,0,7,N
NCT00609531_inc_222_T22_T27,Free of psychoactive medication for at least: one month for fluoxetine; two weeks for other SSRIs and neuroleptics; and five days for stimulants prior to MRI scanning [excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder],anticonvulsant medication,231,256,,excepting,168,177,N
NCT03083197_inc_238_T20_T21,Clinically suspected scrub typhus: defined as acute undifferentiated fever with no clear focus of infection and negative malaria blood smear and/or negative malaria RDT.,focus of infection,89,107,,no clear,80,88,N
NCT03140488_inc_153_T12_T11,"Reassuring fetal health assessment (no abnormal findings in fetal assessment, see below)",abnormal findings,39,56,,no,36,38,N
NCT02489045_exc_37_T5_T4,Patients not scheduled for trans-jugular liver biopsy,scheduled,13,22,,not,9,12,N
NCT02935855_inc_33_T3_T4,nondiabetic patients,diabetic,3,11,,non,0,3,N
NCT02589977_exc_327_T21_T22,HYPERTENSIVE: known cardiovascular disease or risk factors aside from hypertension or use of cardiac medications,cardiovascular risk factors from hypertension,,,"[(20, 34), (20, 32), (20, 37)]",aside from,61,71,N
NCT02589977_exc_327_T23_T22,HYPERTENSIVE: known cardiovascular disease or risk factors aside from hypertension or use of cardiac medications,cardiac medications,93,112,,aside from,59,69,N
NCT02704754_exc_0_T3_T2,"Psychiatric disorders other than insomnia, PTSD and specific phobias; including bipolar and psychotic disorders and meeting criteria for DSM-5 moderate alcohol or drug use disorders within the past year.",insomnia,33,41,,other,22,27,N
NCT02704754_exc_0_T4_T2,"Psychiatric disorders other than insomnia, PTSD and specific phobias; including bipolar and psychotic disorders and meeting criteria for DSM-5 moderate alcohol or drug use disorders within the past year.",PTSD,43,47,,other,22,27,N
NCT02704754_exc_0_T5_T2,"Psychiatric disorders other than insomnia, PTSD and specific phobias; including bipolar and psychotic disorders and meeting criteria for DSM-5 moderate alcohol or drug use disorders within the past year.",phobias,61,68,,other,22,27,N
NCT02704754_exc_204_T18_T17,Diagnosis of a sleep disorder other than insomnia including PSG findings of apnea/hypopnea or periodic limb movement indices > 10/hour;,insomnia,41,49,,other,30,35,N
NCT02652572_exc_1143_T94_T95,Presence of an active systemic or local cancer or tumor of any kind (with the exception of non-melanoma skin cancer),non-melanoma skin cancer,91,115,,with the exception of,69,90,N
NCT02823808_exc_0_T10_T9,"The use of weight-lowering drugs, any investigational blood-glucose or lipid-lowering agent (other than statins or ezetimibe) within the past 3 months",statins,104,111,,other,93,98,N
NCT02823808_exc_0_T11_T9,"The use of weight-lowering drugs, any investigational blood-glucose or lipid-lowering agent (other than statins or ezetimibe) within the past 3 months",ezetimibe,115,124,,other,93,98,N
NCT03190304_exc_1502_T96_T99,"Presence of haemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to LV dilatation.",mitral regurgitation,41,61,,except,77,83,N
NCT03373669_inc_91_T9_T7,"Good health condition, without clinically significant medical history (by participant or guardian, in case of minor)",medical history,54,69,,without,23,30,N
NCT03373669_inc_208_T11_T10,Not pregnant for female subjects.,pregnant,4,12,,Not,0,3,N
NCT02535299_inc_106_T7_T6,"Seronegative for antibodies against insulin, islet cells and glutamic acid decarboxylase (GAD);",antibodies,17,27,,Seronegative,0,12,N
NCT03480607_exc_110_T8_T9,failure to gain consent of parents.,consent of parents,16,34,,failure to gain,0,15,N
NCT02015923_exc_182_T14_T16,"Other neoplastic disease in the 5 previous years, except squamous or basal cell skin carcinoma or cervical ""in situ"" carcinoma",squamous cell skin carcinoma,,,"[(57, 65), (57, 76)]",except,52,58,N
NCT02015923_exc_182_T15_T16,"Other neoplastic disease in the 5 previous years, except squamous or basal cell skin carcinoma or cervical ""in situ"" carcinoma","cervical ""in situ"" carcinoma",98,126,,except,50,56,N
NCT02015923_exc_182_T13_T16,"Other neoplastic disease in the 5 previous years, except squamous or basal cell skin carcinoma or cervical ""in situ"" carcinoma",basal cell skin carcinoma,69,94,,except,50,56,N
NCT02970773_exc_0_T2_T3,Any anti-coagulation therapy (apart from rivaroxaban for second objective),rivaroxaban,41,52,,apart from,30,40,N
NCT02399033_inc_378_T23_T22,No other surgical contraindications.,other surgical contraindications,3,35,,No,0,2,N
NCT02399033_inc_571_T37_T36,Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment;,sperm donation,65,79,,prohibited,41,51,N
NCT02399033_inc_571_T43_T36,Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment;,donation,52,60,,prohibited,41,51,N
NCT02399033_inc_712_T45_T44,All patients must be prohibited donation during the treatment process and in 28 days after treatment;,donation,32,40,,prohibited,21,31,N
NCT03355469_exc_154_T18_T17,Subjects who have not been weight stable (>2 kg weight change in past 3 months),weight stable,27,40,,not,18,21,N
NCT02968602_exc_33_T8_T9,DSM-IV diagnosis of Alcohol or Substance Dependence within the last six months (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine),nicotine,87,95,,except,80,86,N
NCT02968602_exc_33_T13_T14,DSM-IV diagnosis of Alcohol or Substance Dependence within the last six months (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine),nicotine,87,95,,except,80,86,N
NCT02968602_exc_33_T11_T14,DSM-IV diagnosis of Alcohol or Substance Dependence within the last six months (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine),Substance Use Disorder,31,53,,except,80,86,N
NCT02968602_exc_216_T20_T21,DSM-IV diagnosis of Alcohol or Substance Abuse within the last one month (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine),nicotine,81,89,,except,74,80,N
NCT02968602_exc_216_T25_T26,DSM-IV diagnosis of Alcohol or Substance Abuse within the last one month (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine),nicotine,81,89,,except,74,80,N
NCT02968602_exc_571_T45_T47,Treatment with oral contraceptives (unless a second form of birth control is used and documented),birth control,60,73,,unless,36,42,N
NCT03195153_exc_0_T1_T2,not diabetic patient;,diabetic,4,12,,not,0,3,N
NCT00343668_inc_685_T45_T47,No prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed.,chemotherapy,9,21,,No,0,2,N
NCT00343668_inc_797_T51_T56,"(but, prior adjuvant chemotherapy with capecitabine or S-1 or camptothecin analogues was excluded)",adjuvant chemotherapy,12,33,,excluded,89,97,N
NCT00343668_inc_897_T57_T59,No prior radiation therapy for at least 4 weeks before enrollment in the study,radiation therapy,9,26,,No,0,2,N
NCT00343668_inc_685_T48_T62,No prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed.,adjuvant chemotherapy,32,53,,was allowed,99,110,N
NCT03623789_inc_323_T24_T27,No use of non-steroid anti-inflammatory agent one week before operation,non-steroid anti-inflammatory agent,10,45,,No,0,2,N
NCT03463564_exc_91_T7_T6,lack of ability to use the study devices,ability to use the study devices,8,40,,lack of,0,7,N
NCT02749617_exc_637_T34_T35,"Women of Childbearing potential without proper contraceptive measures, pregnancy or breast feeding",contraceptive measures,47,69,,without,32,39,N
NCT02019628_exc_325_T41_T40,"Other medical complications that might preclude one from participating in the study, i.e., recent heart attack or stroke or chronic kidney disease.",participating in the study,57,83,,preclude,39,47,N
NCT02637453_inc_0_T2_T3,"No response to more than one antiarrhythmic drug, or unwilling to receive long-term drug treatment.",response,3,11,,No,0,2,N
NCT01490034_inc_304_T12_T13,No allergies to any test foods,allergies,3,12,,No,0,2,N
NCT01490034_inc_421_T20_T21,Not diabetic,diabetic,4,12,,Not,0,3,N
NCT01490034_inc_435_T22_T24,No history of GI pathology,GI pathology,14,26,,No,0,2,N
NCT01490034_inc_336_T16_T19,Not planning to change use of medications known to influence appetite or metabolism,medications known to influence appetite,30,69,,Not,0,3,N
NCT01490034_inc_336_T17_T19,Not planning to change use of medications known to influence appetite or metabolism,medications known to influence metabolism,,,"[(30, 60), (30, 40)]",Not,0,3,N
NCT01490034_inc_463_T25_T26,Non-smoker for one year or more,smoker,4,10,,Non,0,3,N
NCT02961582_exc_185_T10_T11,Anatomical limitations preventing placement of an electrode,placement of an electrode,34,59,,preventing,23,33,N
NCT02940912_exc_516_T23_T22,Patient with health problems or a skin disease precluding continuous subcutaneous infusion,continuous subcutaneous infusion,58,90,,precluding,47,57,N
NCT02940912_exc_636_T29_T31,"Cardiac dysrhythmia precluding treatment with domperidone or apomorphine (increased QTc = 440 ms in men, QTc = 450 ms in women)",domperidone,46,57,,precluding,20,30,N
NCT02940912_exc_636_T30_T31,"Cardiac dysrhythmia precluding treatment with domperidone or apomorphine (increased QTc = 440 ms in men, QTc = 450 ms in women)",apomorphine,61,72,,precluding,20,30,N
NCT01728194_exc_169_T16_T15,Presence of any Axis I psychiatric disorder (other than unipolar major depression) or substance abuse;,unipolar major depression,56,81,,other than,45,55,N
NCT01728194_exc_169_T17_T15,Presence of any Axis I psychiatric disorder (other than unipolar major depression) or substance abuse;,substance abuse,86,101,,other than,45,55,N
NCT01728194_exc_272_T21_T20,"History of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (bipolar disorder, hypomania, and dysthymia are exclusion criteria);",unipolar major depression,44,69,,other than,33,43,N
NCT01728194_exc_272_T22_T20,"History of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (bipolar disorder, hypomania, and dysthymia are exclusion criteria);",generalized anxiety disorder,73,101,,other than,33,43,N
NCT02195024_exc_331_T26_T25,"Have other medical implants that may interact with MRI, e.g. abandoned implantable cardioverter defibrillator (ICD) leads or pacemaker leads other than MRI conditional, lead extensions, other active medical devices, non-MRI compatible devices, mechanical valve",MRI conditional,51,66,,other than,5,15,N
NCT01352598_inc_159_T20_T19,Extension of local tumor to involve adjacent organs other than seminal vesicles (T4),seminal vesicles,63,79,,other than,52,62,N
NCT01352598_inc_306_T30_T29,Prior pelvic radiotherapy except as part of combination therapy for prostate cancer,combination therapy,44,63,,except,26,32,N
NCT02773173_inc_101_T7_T6,No cognitive deficits,cognitive deficits,3,21,,No,0,2,N
NCT02406495_exc_200_T9_T10,Has a history of not achieving comfortable CL wear (5 days per week; > 8 hours/day),comfortable CL wear,31,50,,not,17,20,N
NCT01177891_inc_286_T22_T25,No cases of fragile X syndrome in the family or blepharophimosis syndrome,fragile X syndrome,12,30,,No,0,2,N
NCT01177891_inc_286_T24_T25,No cases of fragile X syndrome in the family or blepharophimosis syndrome,blepharophimosis syndrome,48,73,,No,0,2,N
NCT01177891_inc_868_T52_T54,Lack of land autoimmune (no history of thyroid disease or diabetes type 1),thyroid disease,39,54,,no,25,27,N
NCT01177891_inc_868_T53_T54,Lack of land autoimmune (no history of thyroid disease or diabetes type 1),diabetes type 1,58,73,,no,25,27,N
NCT03209011_inc_0_T14_T13,"HBsAg and HBeAg positive for more than 6 months, HBV DNA detectable with ALT level abnormal lasted for three months and at least time190 IU/L or liver puncture biopsy demonstrated apparent inflammation, never treated before enrolled.",treated,209,216,,never,203,208,N
NCT01701219_exc_187_T26_T27,"For subjects in Cohort B: previous therapy for more than 48 hours with any parenteral antibiotic with activity against MRSA, except vancomycin and/or daptomycin, within 72 hours of positive blood culture results confirming persistence.",vancomycin,132,142,,except,125,131,N
NCT01701219_exc_187_T28_T27,"For subjects in Cohort B: previous therapy for more than 48 hours with any parenteral antibiotic with activity against MRSA, except vancomycin and/or daptomycin, within 72 hours of positive blood culture results confirming persistence.",daptomycin,150,160,,except,125,131,N
NCT01701219_exc_550_T45_T46,Osteomyelitis or prosthetic joint infection except new onset nonhardware-associated vertebral osteomyelitis.,vertebral osteomyelitis,84,107,,except,44,50,N
NCT01709981_exc_272_T19_T20,Use of oral steroids or non-steroidal anti-inflammatory agents other than aspirin within 72 hours or 3 times the agent's half-life (whichever is longer),aspirin,74,81,,other than,63,73,N
NCT03132259_inc_60_T9_T8,No narcotic before surgery as premedication,narcotic,3,11,,No,0,2,N
NCT02348918_inc_340_T18_T16,"Treatment naïve, i.e., no previous anti-VEGF treatment in the study eye or no anti-VEGF treatment in the 45 days prior to study enrollment.",anti-VEGF treatment,35,54,,no,23,25,N
NCT02348918_inc_340_T21_T20,"Treatment naïve, i.e., no previous anti-VEGF treatment in the study eye or no anti-VEGF treatment in the 45 days prior to study enrollment.",anti-VEGF treatment,35,54,,no,23,25,N
NCT02348918_inc_622_T38_T39,"Intra-Ocular Pressure (IOP) is under control (i.e., IOP ≤ 25 mm in the study eye) and study eye is not receiving any IOP lowering drops.",IOP lowering drops,23,41,,not,99,102,N
NCT00806936_exc_250_T16_T17,"Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods",adequate,113,121,,not,103,106,N
NCT01116882_exc_1225_T45_T47,Note: This exclusion criterion does not apply to post-STEMI patients.,STEMI,54,59,,not,36,39,N
NCT01116882_exc_2184_T82_T83,"Any target lesion requires treatment with a device other than percutaneous transluminal coronary angioplasty (PTCA) prior to stent placement (e.g. but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.).",percutaneous transluminal coronary angioplasty (PTCA),62,115,,other than,51,61,N
NCT03499639_exc_132_T8_T9,non-genotype 4,genotype 4,4,14,,non,0,3,N
NCT02996916_inc_102_T9_T11,Essential hypertension who had never received angiotensin II receptor antagonists and calcium channel blockers,angiotensin II receptor antagonists,46,81,,never,31,36,N
NCT02996916_inc_102_T10_T11,Essential hypertension who had never received angiotensin II receptor antagonists and calcium channel blockers,calcium channel blockers,86,110,,never,31,36,N
NCT03351608_exc_0_T6_T5,"Has any clinically significant condition or situation (eg, anatomical malformation that complicates intubation) other than the condition being studied that, in the opinion of the investigator, would interfere with the trial evaluations or optimal participation in the trial.",the condition being studied,113,140,,other than,112,122,N
NCT02340169_inc_136_T8_T7,Clinical diagnosis of stable plaque psoriasis with involvement of = 10% body surface area (excluding face and scalp),face,80,84,,excluding,91,100,N
NCT02340169_inc_136_T9_T7,Clinical diagnosis of stable plaque psoriasis with involvement of = 10% body surface area (excluding face and scalp),scalp,110,115,,excluding,91,100,N
NCT02340169_inc_136_T11_T7,Clinical diagnosis of stable plaque psoriasis with involvement of = 10% body surface area (excluding face and scalp),and,106,109,,excluding,91,100,N
NCT02384850_exc_201_T6_T8,Uncontrolled active infection (Hepatitis B and C infection are NOT exclusion criteria) and/or known HIV infection; 4.,Hepatitis B infection,,,"[(31, 42), (31, 40)]",NOT,63,66,N
NCT02384850_exc_201_T7_T8,Uncontrolled active infection (Hepatitis B and C infection are NOT exclusion criteria) and/or known HIV infection; 4.,Hepatitis C infection,,,"[(31, 40), (31, 42)]",NOT,63,66,N
NCT02022709_inc_236_T8_T7,Never receiving adequate treatment or stop receiving treatment for at least 8 weeks,treatment,25,34,,Never,0,5,N
NCT02022709_inc_236_T11_T10,Never receiving adequate treatment or stop receiving treatment for at least 8 weeks,treatment,25,34,,stop,38,42,N
NCT02015923_inc_89_T7_T8,no contraindications for chemotherapy,contraindications,3,20,,no,0,2,N
NCT02015923_inc_127_T9_T10,"absence of peritoneal carcinomatosis, central nervous system o bone metastasis.",peritoneal carcinomatosis,11,36,,absence,0,7,N
NCT02015923_inc_127_T12_T10,"absence of peritoneal carcinomatosis, central nervous system o bone metastasis.",bone metastasis,63,78,,absence,0,7,N
NCT02015923_inc_127_T11_T10,"absence of peritoneal carcinomatosis, central nervous system o bone metastasis.",central nervous system metastasis,,,"[(38, 60), (38, 48)]",absence,3,10,N
NCT02015923_inc_392_T25_T27,not pregnancy or breastfeeding,pregnancy,4,13,,not,0,3,N
NCT02015923_inc_392_T26_T27,not pregnancy or breastfeeding,breastfeeding,17,30,,not,0,3,N
NCT03351608_inc_495_T30_T29,"If female, may participate if she is not pregnant, not breastfeeding, and at least one of the following: 1) Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment.",pregnant,41,49,,not,37,40,N
NCT03351608_inc_495_T32_T31,"If female, may participate if she is not pregnant, not breastfeeding, and at least one of the following: 1) Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment.",breastfeeding,55,68,,not,37,40,N
NCT03351608_inc_495_T34_T35,"If female, may participate if she is not pregnant, not breastfeeding, and at least one of the following: 1) Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment.",woman of childbearing potential (WOCBP),114,153,,Not,108,111,N
NCT03351608_inc_495_T36_T35,"If female, may participate if she is not pregnant, not breastfeeding, and at least one of the following: 1) Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment.",WOCBP,147,152,,Not,108,111,N
NCT01117181_inc_1317_T37_T38,"No change to AD medications within the month preceding randomization, including starting, stopping, or dosage modifications",change to AD medications,3,27,,No,0,2,N
NCT03223909_exc_242_T14_T13,Subjects (females) with active sexual life that do not use a contraceptive method.,contraceptive method,61,81,,not,51,54,N
NCT02788045_exc_1204_T63_T64,"For participants who received an experimental vaccine (except HIV vaccine) more than 12 months ago, documentation of the identity of the experimental vaccine must be provided to the sponsor, who will determine eligibility on a case-by-case basis       ",HIV vaccine,62,73,,except,55,61,N
NCT02788045_exc_313_T15_T20,Active syphilis documented by serology unless positive serology is due to past treated infection,serology,30,38,,unless,39,45,N
NCT02788045_exc_313_T14_T20,Active syphilis documented by serology unless positive serology is due to past treated infection,serology,30,38,,unless,39,45,N
NCT02788045_exc_411_T27_T17,Has had a thyroidectomy or active thyroid disease requiring medication during the last 12 months (not excluded: a stable thyroid supplementation),thyroid supplementation,10,33,,not excluded,98,110,N
NCT02589691_exc_200_T12_T13,absence of affiliation to social security,affiliation to social security,11,41,,absence,0,7,N
NCT02408120_inc_344_T23_T21,and <400 mg/dL without laboratory evidence of diabetic ketoacidosis,diabetic ketoacidosis,46,67,,without,15,22,N
NCT02315287_exc_169_T12_T11,Not appropriate for oral antidiabetic agent,appropriate,4,15,,Not,0,3,N
NCT03013790_exc_365_T22_T21,Patients who do not speak English or Spanish,speak English,20,33,,not,16,19,N
NCT03013790_exc_365_T23_T21,Patients who do not speak English or Spanish,speak Spanish,,,"[(20, 25), (20, 27)]",not,24,27,N
NCT02785549_inc_208_T11_T13,No antibiotic treatment in the last 2 weeks,antibiotic treatment,3,23,,No,0,2,N
NCT02785549_inc_270_T15_T16,No significant comorbidities**,comorbidities,15,28,,No,0,2,N
NCT00401245_exc_0_T2_T17,History of a seizure disorder other than a single childhood febrile seizure.,childhood febrile seizure,50,75,,other than,30,40,N
NCT02570347_inc_140_T12_T10,No prior antibiotic treatment,antibiotic treatment,9,29,,No,0,2,N
NCT03338855_exc_1150_T30_T31,Use of antidiabetic drugs other than metformin within 3 months prior to screening.,metformin,37,46,,other than,26,36,N
NCT01009359_inc_84_T7_T10,No significant disease or drug use,disease,15,22,,No,0,2,N
NCT01009359_inc_84_T6_T10,No significant disease or drug use,drug use,26,34,,No,0,2,N
NCT01009359_inc_120_T13_T16,Absence of any sign of dementia/cognitive impairment in neuropsychological examinationsPatients for brain imaging:,sign of dementia,15,31,,Absence of,0,10,N
NCT01009359_inc_120_T14_T16,Absence of any sign of dementia/cognitive impairment in neuropsychological examinationsPatients for brain imaging:,sign of cognitive impairment,,,"[(15, 22), (15, 35)]",Absence of,0,10,N
NCT03637946_inc_81_T6_T7,Absent irreversible pulpal alteration;,irreversible pulpal alteration,7,37,,Absent,0,6,N
NCT03519568_inc_159_T11_T10,"the subjects have completed the basic immunization of 2 needle recombinant hepatitis B vaccine, there is no inoculation history of EV71 vaccine, and no history of EV71 infection",history,120,127,,no,105,107,N
NCT03519568_inc_159_T13_T8,"the subjects have completed the basic immunization of 2 needle recombinant hepatitis B vaccine, there is no inoculation history of EV71 vaccine, and no history of EV71 infection",inoculation,108,119,,no,105,107,N
NCT03519568_inc_159_T7_T8,"the subjects have completed the basic immunization of 2 needle recombinant hepatitis B vaccine, there is no inoculation history of EV71 vaccine, and no history of EV71 infection",needle recombinant hepatitis B vaccine,56,94,,no,105,107,N
NCT03519568_inc_159_T12_T8,"the subjects have completed the basic immunization of 2 needle recombinant hepatitis B vaccine, there is no inoculation history of EV71 vaccine, and no history of EV71 infection",EV71 infection,131,145,,no,105,107,N
NCT03519568_inc_562_T23_T22,"there is no inoculation history of EV71 vaccine, and there is no history of EV71 infection",inoculation,12,23,,no,9,11,N
NCT03519568_inc_562_T28_T26,"there is no inoculation history of EV71 vaccine, and there is no history of EV71 infection",EV71 infection,35,49,,no,9,11,N
NCT01261832_exc_352_T27_T29,"Patients already taking warfarin, cilostazol or any other type of anti-platelet agents except aspirin and clopidogrel",aspirin,94,101,,except,87,93,N
NCT01261832_exc_352_T28_T29,"Patients already taking warfarin, cilostazol or any other type of anti-platelet agents except aspirin and clopidogrel",clopidogrel,106,117,,except,87,93,N
NCT02558504_exc_15_T4_T3,"Lack of informed consent signed,",informed consent signed,8,31,,Lack of,0,7,N
NCT02558504_exc_606_T39_T40,"Surgical treatment history (except anti-reflux treatment) or esophageal radiotherapy,",anti-reflux treatment,35,56,,except,28,34,N
NCT02231892_inc_993_T48_T62,"The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal,",Cholesterol,87,98,,disqualify,63,73,N
NCT02231892_inc_993_T54_T62,"The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal,",LFTs,154,158,,disqualify,63,73,N
NCT02231892_inc_993_T52_T62,"The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal,",WBC,135,138,,disqualify,63,73,N
NCT02231892_inc_993_T50_T62,"The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal,",Hemoglobin,111,121,,disqualify,63,73,N
NCT01793519_exc_700_T43_T42,Absence of documentation in the medical record of clinical remission for the last 6 months,clinical remission,50,68,,Absence of,0,10,N
NCT01793519_exc_831_T50_T48,"Absence of documentation of negative tuberculin skin test, negative QuantiFERON-TB Gold test, or treatment for latent tuberculosis prior to starting treatment with the anti-TNF agent",tuberculin skin test,37,57,,Absence of,0,10,N
NCT01793519_exc_1263_T71_T73,"Absence of documentation of negative hepatitis B serologies, absence of completion of treatment for chronic hepatitis B, or absence of suppressive antiviral treatment",hepatitis B serologies,37,59,,Absence of,0,10,N
NCT01793519_exc_1263_T78_T79,"Absence of documentation of negative hepatitis B serologies, absence of completion of treatment for chronic hepatitis B, or absence of suppressive antiviral treatment",suppressive antiviral treatment,135,166,,absence,61,68,N
NCT01793519_exc_1263_T75_T76,"Absence of documentation of negative hepatitis B serologies, absence of completion of treatment for chronic hepatitis B, or absence of suppressive antiviral treatment",chronic hepatitis B,100,119,,absence of,61,71,N
NCT03040024_exc_18_T8_T6,"Monitored Anesthesia Care (i.e., regional anesthesia alone without plans for general anesthesia)",general anesthesia,77,95,,without,59,66,N
NCT02892968_exc_576_T27_T28,Patients with hip fractures not requiring surgery (e.g. greater trochanter avulsion) will also be excluded.,requiring surgery,32,49,,not,28,31,N
NCT01483118_exc_411_T29_T31,"Hormonal treatment involving estrogen or progesterone 3 months prior to or during the study period, with the exception of medroxyprogesterone acetate for withdrawal bleeding.",medroxyprogesterone acetate,122,149,,exception,109,118,N
NCT02790593_inc_123_T9_T10,No evidence of arterial disease (Arterial Duplex or Ankle Brachial Pressure Index >0.9),arterial disease,15,31,,No,0,2,N
NCT02643381_exc_127_T11_T12,Patients who require endotracheal intubation without sedative medication.,sedative medication,53,72,,without,45,52,N
NCT02609048_inc_807_T55_T56,"For male subjects, use of appropriate contraception (e.g., condoms), so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dose",pregnant,134,142,,not become,123,133,N
NCT02743598_exc_242_T13_T12,Weight loss drugs other than metformin,metformin,29,38,,other,18,23,N
NCT02201316_inc_833_T30_T31,"A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, ""documented"" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-international units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) [<147 picomole per liter] is confirmatory].",childbearing potential,62,84,,Non,58,61,N
NCT02759861_inc_137_T6_T5,"HCV treatment-naïve, as defined as no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent",treatment,4,13,,naïve,14,19,N
NCT02759861_inc_137_T9_T11,"HCV treatment-naïve, as defined as no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent",Interferon (IFN),60,76,,no,35,37,N
NCT02759861_inc_137_T8_T11,"HCV treatment-naïve, as defined as no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent",RBV,78,81,,no,35,37,N
NCT02759861_inc_895_T44_T45,Liver biopsy within 2 years of Screening showing absence of cirrhosis,cirrhosis,60,69,,absence,49,56,N
NCT02759861_inc_1113_T56_T57,Liver imaging within 6 months of Baseline/Day 1 to exclude hepatocellular carcinoma HCC) is required,hepatocellular carcinoma HCC),59,88,,exclude,51,58,N
NCT02759861_inc_1511_T81_T83,INR = 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.,hemophilia,41,51,,unless,16,22,N
NCT02759861_inc_1511_T82_T83,INR = 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.,stable on an anticoagulant regimen affecting INR,58,106,,unless,16,22,N
NCT01793831_exc_42_T7_T5,"No history of using 5-ASA, biological or immunomodulatory therapy",5-ASA,20,25,,No,0,2,N
NCT01793831_exc_42_T8_T5,"No history of using 5-ASA, biological or immunomodulatory therapy",therapy biological,,,"[(58, 65), (58, 68)]",No,1,3,N
NCT01793831_exc_42_T9_T5,"No history of using 5-ASA, biological or immunomodulatory therapy",immunomodulatory therapy,41,65,,No,0,2,N
NCT01082549_exc_100_T17_T18,"Past or current history of neoplasm other than the entry diagnosis, with the exception of treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences.",evidence of recurrences,256,279,,no,61,63,N
NCT01082549_exc_100_T7_T15,"Past or current history of neoplasm other than the entry diagnosis, with the exception of treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences.",non-melanoma skin cancer,98,122,,with the exception of,68,89,N
NCT01082549_exc_100_T10_T15,"Past or current history of neoplasm other than the entry diagnosis, with the exception of treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences.",carcinoma in-situ,126,143,,with the exception of,68,89,N
NCT01082549_exc_100_T11_T15,"Past or current history of neoplasm other than the entry diagnosis, with the exception of treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences.",cancers,177,184,,with the exception of,68,89,N
NCT01082549_exc_610_T39_T41,"Patients who have stable, rate-controlled atrial fibrillation are eligible for study enrollment.",atrial fibrillation,42,61,,are eligible,62,74,N
NCT01082549_exc_736_T54_T56,"Patients with treated brain metastases are eligible, if (1) radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids.",disease progression,159,178,,no,156,158,N
NCT01082549_exc_736_T57_T58,"Patients with treated brain metastases are eligible, if (1) radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids.",steroids,213,221,,not,201,204,N
NCT01082549_exc_736_T50_T49,"Patients with treated brain metastases are eligible, if (1) radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids.",are eligible,39,51,,are eligible,39,51,N
NCT01082549_exc_100_T17_T15,"Past or current history of neoplasm other than the entry diagnosis, with the exception of treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences.",evidence of recurrences,256,279,,with the exception of,68,89,N
NCT02558504_inc_1629_T75_T77,"No mediastinal or celiac, or suspected metastatic lymph nodes by EUS,",lymph nodes,50,61,,No,0,2,N
NCT02558504_inc_1751_T80_T79,"Lack of participation in another clinical study,",participation in clinical study,,,"[(8, 24), (8, 22)]",Lack of,17,24,N
NCT01684501_exc_368_T11_T16,"the sound-side (contralateral) lower extremity must be free of impediments that affect gait, range of motion, or limb muscle activity",impediments that affect gait,63,91,,free,55,59,N
NCT01684501_exc_368_T12_T16,"the sound-side (contralateral) lower extremity must be free of impediments that affect gait, range of motion, or limb muscle activity",impediments that affect range of motion,,,"[(63, 86), (63, 78)]",free,55,59,N
NCT01684501_exc_368_T13_T16,"the sound-side (contralateral) lower extremity must be free of impediments that affect gait, range of motion, or limb muscle activity",impediments that affect limb muscle activity,,,"[(63, 86), (63, 83)]",free,55,59,N
NCT02982577_inc_49_T4_T5,Lucid and without diagnosis of any psychiatric disorder;,psychiatric disorder,35,55,,without,10,17,N
NCT02726009_exc_429_T22_T21,Cancer within the last 5 years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin,prostate cancer,38,53,,except,31,37,N
NCT02726009_exc_429_T24_T21,Cancer within the last 5 years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin,basal cell carcinoma of the skin,,,"[(77, 82), (77, 103)]",except,37,43,N
NCT03400735_exc_115_T12_T11,Antibiotic use except study drugs,study drugs,22,33,,except,15,21,N
NCT01117181_exc_1019_T60_T66,"Treatment with psychotropic medications in the 2 weeks prior to randomization with the exception of approved treatments for dementia (ChEIs and memantine), selective serotonin reuptake inhibitor antidepressants, and trazodone (if used as an aid to facilitate sleep and not as an antidepressant); other psychotropics (with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis.",treatments for dementia,109,132,,with the exception of,10,31,N
NCT01117181_exc_1019_T64_T66,"Treatment with psychotropic medications in the 2 weeks prior to randomization with the exception of approved treatments for dementia (ChEIs and memantine), selective serotonin reuptake inhibitor antidepressants, and trazodone (if used as an aid to facilitate sleep and not as an antidepressant); other psychotropics (with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis.",selective serotonin reuptake inhibitor antidepressants,156,210,,with the exception of,10,31,N
NCT01117181_exc_1019_T65_T66,"Treatment with psychotropic medications in the 2 weeks prior to randomization with the exception of approved treatments for dementia (ChEIs and memantine), selective serotonin reuptake inhibitor antidepressants, and trazodone (if used as an aid to facilitate sleep and not as an antidepressant); other psychotropics (with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis.",trazodone,216,225,,with the exception of,10,31,N
NCT01117181_exc_1019_T70_T71,"Treatment with psychotropic medications in the 2 weeks prior to randomization with the exception of approved treatments for dementia (ChEIs and memantine), selective serotonin reuptake inhibitor antidepressants, and trazodone (if used as an aid to facilitate sleep and not as an antidepressant); other psychotropics (with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis.",antipsychotics,339,353,,with the exclusion of,10,31,N
NCT02548013_exc_3_T2_T3,Patient with equivocal diagnosis of rupture of membranes,rupture of membranes,36,56,,equivocal,13,22,N
NCT02590822_exc_600_T32_T34,Inability to exercise or undertake a MRP,exercise,13,21,,Inability,0,9,N
NCT02759861_exc_369_T5_T10,Malignancy diagnosed or treated within 5 years (recent localized treatment of squamous or non-invasive basal cell skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to screening); subjects under evaluation for a malignancy are not eligible.,treatment,65,74,,permitted,130,139,N
NCT02759861_exc_369_T12_T13,Malignancy diagnosed or treated within 5 years (recent localized treatment of squamous or non-invasive basal cell skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to screening); subjects under evaluation for a malignancy are not eligible.,cervical carcinoma in situ,141,167,,allowed,171,178,N
NCT01997580_inc_59_T7_T8,durg-naive or drug-free,drug,14,18,,free,19,23,N
NCT01997580_inc_59_T5_T6,durg-naive or drug-free,durg,0,4,,naive,5,10,N
NCT01184638_inc_32_T2_T4,Without basal disorders of neurology and psychiatrics,basal disorders of neurology,8,36,,Without,0,7,N
NCT01184638_inc_32_T3_T4,Without basal disorders of neurology and psychiatrics,basal disorders of psychiatrics,,,"[(8, 26), (8, 20)]",Without,1,8,N
NCT03016741_exc_1341_T64_T65,"Patients with a ""currently active"" second malignancy other than non-melanoma skin cancers are not eligible.",non-melanoma skin cancers,64,89,,other than,53,63,N
NCT02664558_inc_313_T32_T31,"If PCWP is not available, then mean left atrial pressure or left ventricular end-diastolic pressure ≤15 mmHg in the absence of left atrial obstruction.",left atrial obstruction,36,59,,absence,116,123,N
NCT02664558_inc_922_T54_T56,Have a ventilation-perfusion scan that rules out thromboembolic disease.,thromboembolic disease,49,71,,rules out,39,48,N
NCT03228017_exc_73_T9_T8,"Autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic arthritis",psoriasis,64,73,,not,60,63,N
NCT03228017_exc_73_T10_T8,"Autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic arthritis",psoriatic arthritis,77,96,,not,60,63,N
NCT02150590_exc_277_T27_T26,"internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (>20 cigarettes per day), inability to perform 6 min walk test.",6 min walk test,163,178,,inability,142,151,N
NCT02937779_exc_0_T1_T2,Women refusing HBs Ag test,HBs Ag test,15,26,,refusing,6,14,N
NCT02205931_exc_30_T4_T3,No secure diagnosis of epilepsy,epilepsy,23,31,,No,0,2,N
NCT02804646_inc_165_T53_T52,"According to IASLC2009 new TNM staging of lung cancer stage <U+2162>B or <U+2163>, previously untreated or relapsed after 1 year of lung cancer resection; 3) have at least one evaluable lesions,according to version 1.1 of the standard in accordance with a judgment RECIST(longest diameter on a spiral CT at least 10mm,on a regular CT longest diameter at least 20mm); 4) Male or female, aged 18 to 75 years; 5) ECOG PS 0 or 1; 6) expected survival at least 3 months; 7) adequate hematological function: absolute neutrophil count (ANC) at least 2×10^9/L and platelet count at least 100×10^9/L and hemoglobin at least 9 g/dL; 8) adequate liver function: total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN); 9) adequate renal function: serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min; 10) ECG is normal, there is no non-healing wounds on the body; 11) had not received previous treatment anticancer drugs, or had only received for previous non-metastatic tumors adjuvant or neoadjuvant chemotherapy, but when you start to study treatment has ended more than 6 months; 12) have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered; 13) have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days.",non-healing wounds on the body,1008,1038,,no,692,694,N
NCT02804646_inc_165_T56_T57,"According to IASLC2009 new TNM staging of lung cancer stage <U+2162>B or <U+2163>, previously untreated or relapsed after 1 year of lung cancer resection; 3) have at least one evaluable lesions,according to version 1.1 of the standard in accordance with a judgment RECIST(longest diameter on a spiral CT at least 10mm,on a regular CT longest diameter at least 20mm); 4) Male or female, aged 18 to 75 years; 5) ECOG PS 0 or 1; 6) expected survival at least 3 months; 7) adequate hematological function: absolute neutrophil count (ANC) at least 2×10^9/L and platelet count at least 100×10^9/L and hemoglobin at least 9 g/dL; 8) adequate liver function: total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN); 9) adequate renal function: serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min; 10) ECG is normal, there is no non-healing wounds on the body; 11) had not received previous treatment anticancer drugs, or had only received for previous non-metastatic tumors adjuvant or neoadjuvant chemotherapy, but when you start to study treatment has ended more than 6 months; 12) have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered; 13) have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days.",anticancer drugs,1080,1096,,not received,1048,1060,N
NCT02804646_inc_165_T61_T57,"According to IASLC2009 new TNM staging of lung cancer stage <U+2162>B or <U+2163>, previously untreated or relapsed after 1 year of lung cancer resection; 3) have at least one evaluable lesions,according to version 1.1 of the standard in accordance with a judgment RECIST(longest diameter on a spiral CT at least 10mm,on a regular CT longest diameter at least 20mm); 4) Male or female, aged 18 to 75 years; 5) ECOG PS 0 or 1; 6) expected survival at least 3 months; 7) adequate hematological function: absolute neutrophil count (ANC) at least 2×10^9/L and platelet count at least 100×10^9/L and hemoglobin at least 9 g/dL; 8) adequate liver function: total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN); 9) adequate renal function: serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min; 10) ECG is normal, there is no non-healing wounds on the body; 11) had not received previous treatment anticancer drugs, or had only received for previous non-metastatic tumors adjuvant or neoadjuvant chemotherapy, but when you start to study treatment has ended more than 6 months; 12) have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered; 13) have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days.",chemotherapy,1178,1190,,not received,1048,1060,N
NCT02301962_exc_64_T7_T6,History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.,active disease,96,110,,no,12,14,N
NCT02301962_exc_64_T16_T17,History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.,evidence of disease,296,315,,without,288,295,N
NCT02301962_exc_64_T22_T21,History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.,disease,103,110,,without,288,295,N
NCT02301962_exc_64_T25_T26,History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.,prostate cancer,448,463,,without,288,295,N
NCT02301962_exc_64_T4_T29,History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.,Malignancy,38,48,,except,30,36,N
NCT02301962_exc_64_T14_T29,History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.,treated,49,56,,except,30,36,N
NCT02301962_exc_1648_T88_T87,"=7 days before first dose of study treatment, or not yet recovered from prior minor surgery Note: uncomplicated placement of vascular access device, fine needle aspiration, thoracocentesis or paracentesis >=3 days prior to first dose of study treatment is acceptable.",recovered,57,66,,not yet,49,56,N
NCT02301962_exc_3063_T140_T142,=14 days prior to first dose of study treatment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection).,urinary tract infection,85,108,,with the exception of,49,70,N
NCT02301962_exc_3063_T143_T142,=14 days prior to first dose of study treatment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection).,upper respiratory tract infection,112,145,,with the exception of,49,70,N
NCT02301962_exc_64_T11_T29,History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.,recurrence,183,193,,except,30,36,N
NCT00625742_inc_354_T12_T14,Are not currently taking melatonin.,melatonin,25,34,,not,4,7,N
NCT02339844_inc_195_T12_T11,"(Diagnostic and Statistical Manual version 4 /5), Age 18-45 years, Never treated with antipsychotic compounds or central nervous system (CNS) stimulants, Legally competent",antipsychotic compounds,86,109,,Never,67,72,N
NCT02339844_inc_195_T13_T11,"(Diagnostic and Statistical Manual version 4 /5), Age 18-45 years, Never treated with antipsychotic compounds or central nervous system (CNS) stimulants, Legally competent",central nervous system (CNS) stimulants,113,152,,Never,67,72,N
NCT02339844_inc_396_T20_T19,"Matching patients on age (+/- 2 years), sex and parental socioeconomic status, Age 18-45 years, No psychiatric or physical disease.",psychiatric disease,,,"[(99, 110), (99, 106)]",No,97,99,N
NCT02339844_inc_396_T21_T19,"Matching patients on age (+/- 2 years), sex and parental socioeconomic status, Age 18-45 years, No psychiatric or physical disease.",physical disease,114,130,,No,96,98,N
NCT01084993_exc_0_T9_T8,"Intolerance or allergy to ASA, clopidogrel or ticlopidine precluding treatment for 12 months",treatment,69,78,,precluding,58,68,N
NCT02510404_inc_3_T14_T15,Diagnosis of primary immunodeficiency with established plan to undergo myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant for treatment thereof or diagnosis of a form of primary immunodeficiency for which hematopoietic stem cell transplantation is not indicated.,hematopoietic stem cell transplantation,117,156,,not indicated,278,291,N
NCT02106598_inc_852_T56_T57,"At the discretion of the operating surgeon, Bilirubin level of < 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert's).",Gilbert's disease,106,123,,in the absence of,31,48,N
NCT02106598_inc_1017_T61_T62,"For melanoma patients, If patients have a history of malignancy other than melanoma, and other skin cancers in the past five years, their inclusion is up to the discretion of the physician.",melanoma,4,12,,other than,64,74,N
NCT00250640_inc_313_T8_T13,No prior treatment with Ventavis or other active treatments for primary pulmonary hypertension within 6 weeks of date of study inclusion (unless otherwise advised by Bayer Schering Pharma),treatment with Ventavis,9,32,,No,0,2,N
NCT00250640_inc_313_T10_T13,No prior treatment with Ventavis or other active treatments for primary pulmonary hypertension within 6 weeks of date of study inclusion (unless otherwise advised by Bayer Schering Pharma),treatments,49,59,,No,0,2,N
NCT03337581_inc_227_T15_T12,no history of anesthesia medication allergy.,allergy,36,43,,no,0,2,N
NCT02502734_exc_662_T44_T45,"Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.",resolved,134,142,,not,130,133,N
NCT02502734_exc_1189_T63_T69,No major surgery requiring general anaesthesia for at least 3 months prior to the screening visit.,major surgery,3,16,,No,0,2,N
NCT02502734_exc_1289_T68_T76,No febrile illnesses with temperature >39 degree celsius for more than five consecutive days within the week preceding the Screening Visit.,febrile illnesses,3,20,,No,0,2,N
NCT00679341_exc_333_T21_T30,"History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those previously mentioned.",carcinoma in situ of the cervix,86,117,,except for,53,63,N
NCT00679341_exc_333_T24_T30,"History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those previously mentioned.",non-melanoma skin carcinoma,119,146,,except for,53,63,N
NCT00679341_exc_333_T25_T30,"History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those previously mentioned.",uterine cancer,156,170,,except for,53,63,N
NCT02366819_exc_0_T8_T5,"Previous or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the patient has been previously treated and the lifetime recurrence risk is less than 30%",cervical cancer,114,129,,except,35,41,N
NCT03096613_exc_821_T52_T51,"Treatment with levothyroxine must not be initiated in patients with acute myocardial infarction, acute myocarditis, or acute pancarditis.",Treatment,0,9,,not be initiated,34,50,N
NCT03479502_inc_138_T8_T7,absence of abnormal findings on X-ray.,abnormal findings,11,28,,absence of,0,10,N
NCT02201316_exc_0_T8_T9,"Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).",Gilbert's syndrome,110,128,,exception,97,106,N
NCT02201316_exc_0_T10_T9,"Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).",gallstones,145,155,,exception,97,106,N
NCT02287259_exc_0_T2_T1,don't have Diabetes and abnormal metabolism of sugar,Diabetes,11,19,,don't have,0,10,N
NCT02287259_exc_0_T3_T1,don't have Diabetes and abnormal metabolism of sugar,abnormal metabolism of sugar,24,52,,don't have,0,10,N
NCT02287259_exc_53_T7_T5,not noticed as bipolar disorder,bipolar disorder,15,31,,not,0,3,N
NCT02287259_exc_147_T13_T12,don't have heart disease,heart disease,11,24,,don't have,0,10,N
NCT00752310_inc_0_T1_T2,"Non-smoking, or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to selection",smoking,4,11,,Non,0,3,N
NCT00752310_inc_0_T3_T2,"Non-smoking, or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to selection",smoking,4,11,,Non,0,3,N
NCT00752310_inc_319_T24_T22,"Healthy on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, medical history, electrocardiogram (ECG), vital signs, and the results of blood biochemistry, blood coagulation, and hematology tests and a urinalysis carried out at screening.",abnormality,97,108,,absence,62,69,N
NCT01809041_exc_0_T1_T2,Patients are not expected to be alive for longer than 3 months.,expected to be alive,17,37,,not,13,16,N
NCT02332291_inc_23_T10_T9,"Current diagnosis of major depressive disorder (DSM-IV-TR), single episode, recurrent or chronic, without psychotic features, as detected by MINI and clinical exam.",psychotic features,106,124,,without,98,105,N
NCT02965443_exc_0_T4_T3,"Use of any oral antidiabetic treatment except for metformin (i.e., sulphonylureas, DPP-IV inhibitors, thiazolidinediones, SGLT-2 inhibitors (Sodium dependent glucose transporter) or GLP-1 analogues (glucagone like peptide) within the last three months prior to Screening",metformin,50,59,,except for,39,49,N
NCT02965443_exc_1797_T106_T105,Presence of psychiatric disorder or intake of anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI's (selective serotonin reuptake inhibitor),benzodiazepines,109,124,,with the exception of,87,108,N
NCT02965443_exc_1797_T107_T105,Presence of psychiatric disorder or intake of anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI's (selective serotonin reuptake inhibitor),SSRIs,129,134,,with the exception of,87,108,N
NCT02965443_exc_1797_T108_T105,Presence of psychiatric disorder or intake of anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI's (selective serotonin reuptake inhibitor),SNRI's,135,141,,with the exception of,87,108,N
NCT01959425_inc_35_T5_T4,Documented freedom from AF recurrence (symptomatic or asymptomatic arrhythmic recurrences lasting longer than 30 seconds) 3 months after successful cardiac ablation (AF recurrence during 3-month blanking period is excluded).,AF recurrence,24,37,,freedom,11,18,N
NCT02251249_inc_249_T25_T15,"No previous treatment with Clopidogrel, Prasugrel or Ticagrelor.",treatment,12,21,,No,0,2,N
NCT00679341_inc_210_T12_T14,No prior chemotherapy for their metastatic breast cancer (MBC).,chemotherapy,9,21,,No,0,2,N
NCT01116882_inc_1598_T68_T69,Target lesions(s) is (are) located in an infarct (if not treated with primary PCI) or non-infarct-related artery with a 70% or greater stenosis (by visual estimate) more than 72 hours following the ST segment elevation myocardial infarction (STEMI).,primary PCI,70,81,,not,53,56,N
NCT03560310_exc_516_T38_T39,Any condition other than coronary artery disease with a life expectancy <12 months,coronary artery disease,25,48,,other than,14,24,N
NCT03560310_exc_682_T51_T50,Atrioventricular block II and III in patients without pacemaker,pacemaker,54,63,,without,46,53,N
NCT01373684_inc_126_T16_T17,HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a,Telbivudine,58,69,,except,51,57,N
NCT03012984_exc_374_T37_T36,"Preoperative left ventricular ejection fraction < 30%, sick sinus syndrome, severe sinus bradycardia (< 50 beats per minute), or second-degree or above atrioventricular block without pacemaker;",pacemaker,183,192,,without,175,182,N
NCT03062358_inc_0_T7_T8,"Has a HCC diagnosis confirmed by radiology, histology, or cytology (fibrolamellar, and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible)",mixed hepatocellular/cholangiocarcinoma subtype,87,134,,not eligible,140,152,N
NCT03062358_inc_0_T6_T8,"Has a HCC diagnosis confirmed by radiology, histology, or cytology (fibrolamellar, and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible)",subtype fibrolamellar,,,"[(127, 134), (127, 140)]",not eligible,140,152,N
NCT03062358_inc_155_T18_T20,Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy and not amenable to a curative treatment approach,amenable to a curative treatment approach,85,126,,not,81,84,N
NCT02900443_exc_356_T26_T27,Current treatment with prednisone/prednisolone and/or immunosuppressive medication for an indication other than autoimmune hepatitis,autoimmune hepatitis,112,132,,other,101,106,N
NCT02872090_exc_46_T6_T5,previous history of respiratory disease other than COPD,COPD,51,55,,other than,40,50,N
NCT03134378_exc_301_T20_T18,"Patients are known to have impaired liver function, evidenced by ALT values within normal limits, and no previous liver disease.",liver disease,36,49,,no,14,16,N
NCT02924870_exc_0_T5_T4,"osteoarticular, neuromuscular or cognitive limitation that prevents ambulation",ambulation,68,78,,prevents,59,67,N
NCT02413970_inc_159_T9_T8,Documentation the subject not effectively treated with CPAP therapy.,CPAP therapy,55,67,,not,26,29,N
NCT02339974_exc_814_T27_T28,Implantation of a permanent pacemaker is excluded.,permanent pacemaker,18,37,,excluded,41,49,N
NCT02371200_exc_3_T7_T9,Does not have a documented history of generalized seizures.,generalized seizures,38,58,,not,5,8,N
NCT02371200_exc_67_T10_T11,Has not had a GTC seizure within the last year AND is not expected to have a reduction of anti-epileptic drugs during their hospital admission.,GTC seizure,14,25,,not,4,7,N
NCT02371200_exc_67_T14_T17,Has not had a GTC seizure within the last year AND is not expected to have a reduction of anti-epileptic drugs during their hospital admission.,reduction of anti-epileptic drugs,77,110,,not,4,7,N
NCT02371200_exc_262_T20_T21,The subject's upper arm circumference not adequate for proper fit of the EMG monitor (less than 14cm).,adequate for proper fit of the EMG monitor,42,84,,not,38,41,N
NCT03472508_inc_19_T8_T9,"(2)A diagnosis or previous diagnosis of essential hypertension, including anyone currently taking antihypertensive drugs; or for those who have not taken antihypertensive drugs within the last 2 weeks, two consecutive examinations were conducted at least one day apart, and both sitting blood pressure (mean value of 3 measurements) met the following criteria: diastolic blood pressure (DBP)",antihypertensive drugs,98,120,,not,144,147,N
NCT03472508_inc_19_T5_T9,"(2)A diagnosis or previous diagnosis of essential hypertension, including anyone currently taking antihypertensive drugs; or for those who have not taken antihypertensive drugs within the last 2 weeks, two consecutive examinations were conducted at least one day apart, and both sitting blood pressure (mean value of 3 measurements) met the following criteria: diastolic blood pressure (DBP)",essential hypertension,40,62,,not,144,147,N
NCT02385448_exc_0_T3_T2,Operative findings not suggestive of endometriotic cyst,suggestive,23,33,,not,19,22,N
NCT00970866_inc_180_T9_T10,HIV negative or status unknown (as from the Ante-natal card),HIV,0,3,,negative,4,12,N
NCT02437045_exc_0_T3_T2,Patient not expected to survive more than 4 days,more than 4 days,32,48,,not,8,11,N
NCT02437045_exc_408_T18_T17,Use of concomitant antimicrobials in the first 4 days after enrolment with known activity against Gram-negative bacilli (except trimethoprim/sulphamethoxazole may be continued as Pneumocystis prophylaxis).,rimethoprim/sulphamethoxazole,129,158,,except,121,127,N
NCT02519777_inc_2204_T28_T27,There should be no plasma HIV-1,plasma HIV-1 RNA,19,35,,no,16,18,N
NCT02519777_inc_2380_T42_T43,HAND is defined as at least mild impairment on neurocognitive testing (more than one standard deviation below appropriate normative data in two domains of functioning) and no severely confounding factors.,severely confounding factors,175,203,,no,122,124,N
NCT03196843_inc_529_T24_T25,without evidence of distant metastases.,distant metastases,20,38,,without,0,7,N
NCT03196843_inc_569_T27_T29,No contraindication to chemoradiotherapy.,contraindication,3,19,,No,0,2,N
NCT00527826_exc_179_T13_T16,"Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and systemic lupus erythematosus).",COPD,62,66,,other than,51,61,N
NCT02874092_exc_596_T42_T43,"Patients considered to be at risk of bradycardic events (e.g., known sick sinus syndrome or second or third degree atrioventricular [AV)] block) unless already treated with a permanent pacemaker",permanent pacemaker,175,194,,unless,145,151,N
NCT02874092_exc_1026_T70_T74,Females of child bearing potential not using acceptable method of birth control prior to or during study,method of birth control,56,79,,not,35,38,N
NCT01815580_inc_163_T15_T13,"No prior ART, including prior administration of pre- and post-exposure prophylaxis in the last 30 days",ART,9,12,,No,0,2,N
NCT01815580_inc_163_T17_T13,"No prior ART, including prior administration of pre- and post-exposure prophylaxis in the last 30 days",administration,30,44,,No,0,2,N
NCT03088280_exc_43_T9_T8,Patients who are planning to receive mycophenolate instead of everolimus,everolimus,62,72,,instead of,51,61,N
NCT00894712_inc_174_T7_T8,Patients must not have received prior radiation therapy to the breast.,radiation therapy,38,55,,not,14,17,N
NCT00894712_inc_246_T10_T13,Patients must not have active local-regional disease prior to registration.,local-regional disease,30,52,,not,14,17,N
NCT03344887_inc_0_T1_T2,All patients (excluding neonates) requiring one or more allogeneic RBC transfusions for the treatment of anemia will be included.,neonates,24,32,,excluding,14,23,N
NCT02225548_exc_796_T39_T40,"Subject with any underlying cardiovascular condition, including unstable angina pectoris, which preclude sexual activity",sexual activity,105,120,,preclude,96,104,N
NCT02225548_exc_1292_T57_T59,"Subjects with a history of surgical procedures for the treatment of benign prostate hypertrophy are permitted, with the exception of cryosurgery, cryotherapy or cryoablation",surgical procedures,27,46,,permitted,100,109,N
NCT02225548_exc_1292_T60_T100,"Subjects with a history of surgical procedures for the treatment of benign prostate hypertrophy are permitted, with the exception of cryosurgery, cryotherapy or cryoablation",cryosurgery,133,144,,with the exception of,9,30,N
NCT02225548_exc_1292_T61_T100,"Subjects with a history of surgical procedures for the treatment of benign prostate hypertrophy are permitted, with the exception of cryosurgery, cryotherapy or cryoablation",cryotherapy,146,157,,with the exception of,9,30,N
NCT02225548_exc_1292_T62_T100,"Subjects with a history of surgical procedures for the treatment of benign prostate hypertrophy are permitted, with the exception of cryosurgery, cryotherapy or cryoablation",cryoablation,161,173,,with the exception of,9,30,N
NCT02225548_exc_2478_T121_T120,Subject with a history of malignancy within the past 5 years (other than squamous or basal cell skin cancer),squamous skin cancer,,,"[(73, 81), (73, 84)]",other than,81,91,N
NCT02225548_exc_2478_T122_T120,Subject with a history of malignancy within the past 5 years (other than squamous or basal cell skin cancer),basal cell skin cancer,85,107,,other than,62,72,N
NCT02225548_exc_0_T171_T170,"Subject unwilling to cease use of any treatment for erectile dysfunction during the study, including oral medication, vacuum devices, constrictive devices, injections, urethral suppositories, gels, any over-the-counter or nonprescription medications, and products purchased via the internet",cease use of,21,33,,unwilling,8,17,N
NCT03004261_inc_172_T16_T14,"Ejection fraction = 50%, no severe arrhythmia.",arrhythmia,35,45,,no,25,27,N
NCT03004261_inc_172_T12_T14,"Ejection fraction = 50%, no severe arrhythmia.",Ejection fraction,0,17,,no,25,27,N
NCT03465397_exc_907_T38_T37,Patients with any neoplasm except localized skin cancer and who is receiving adequate treatment.,localized skin cancer,34,55,,except,27,33,N
NCT02053246_exc_0_T2_T3,"Other causes of heart failure other than diastolic dysfunction, such as restrictive cardiomyopathy or infiltrative cardiomyopathy",diastolic dysfunction,41,62,,other than,30,40,N
NCT02053246_exc_230_T16_T15,"Causes of PH other than that of heart failure, such as: chronic thromboembolic PH, sickle-cell disease, or sarcoidosis",heart failure,32,45,,other than,13,23,N
NCT03216447_exc_0_T3_T2,Patient has previously received or is receiving an organ transplant other than a liver.,liver,81,86,,other than,68,78,N
NCT03216447_exc_210_T13_T14,Patient has received a liver transplant from a non-heart beating donor,heart beating,51,64,,non,47,50,N
NCT03216447_exc_569_T44_T43,"Patient has a current malignancy or a history of malignancy (within the past 5 years), except hepatocellular carcinoma within UCSF Criteria and basal or non-metastatic squamous cell carcinoma of skin that has been treated successfully.",UCSF Criteria,126,139,,except,87,93,N
NCT03216447_exc_569_T45_T43,"Patient has a current malignancy or a history of malignancy (within the past 5 years), except hepatocellular carcinoma within UCSF Criteria and basal or non-metastatic squamous cell carcinoma of skin that has been treated successfully.",basal cell carcinoma of skin,,,"[(144, 149), (144, 166)]",except,94,100,N
NCT03216447_exc_569_T46_T43,"Patient has a current malignancy or a history of malignancy (within the past 5 years), except hepatocellular carcinoma within UCSF Criteria and basal or non-metastatic squamous cell carcinoma of skin that has been treated successfully.",squamous cell carcinoma of skin,168,199,,except,87,93,N
NCT03380429_inc_1104_T29_T28,"Subject must have been on maintenance therapy (Fixed dose combination ICS/LABA) for 3 months, cannot have changed dose in the month prior to screening and be able to change to an equivalent dose of RELVAR/BREO for the duration of the study.",changed dose,106,118,,cannot,94,100,N
NCT03013790_inc_0_T3_T4,Non-ventilated Patients over the age of 65,ventilated,4,14,,Non,0,3,N
NCT03340740_exc_46_T4_T5,Chronic Pulmonary Condition other than asthma,asthma,39,45,,other,28,33,N
NCT00730301_inc_357_T28_T27,6-min walk of > 50m (without rehabilitation) or > 100m (with rehabilitation),rehabilitation,29,43,,without,21,28,N
NCT00730301_inc_578_T37_T38,The patient has no child bearing potential,child bearing potential,19,42,,no,16,18,N
NCT03099408_exc_221_T20_T19,Contraindications for Lactobacillus Vaginal Suppositories(those without sexual history),sexual history,72,86,,without,64,71,N
NCT02748330_inc_426_T26_T25,"History of coronary revascularization, i.e., percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG), not including the elective PCI during the index hospitalization",PCI,81,84,,not,126,129,N
NCT03171987_exc_324_T25_T24,Use of pain medication (except paracetamol) within 3 days,paracetamol,31,42,,except,24,30,N
NCT03253796_exc_1959_T100_T106,Has had a malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured),squamous carcinomas of the skin,,,"[(69, 77), (69, 91)]",exceptions,72,82,N
NCT03253796_exc_1959_T101_T106,Has had a malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured),basal cell carcinomas of the skin,82,115,,exceptions,54,64,N
NCT03253796_exc_1959_T102_T106,Has had a malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured),carcinoma in situ,93,110,,exceptions,54,64,N
NCT03253796_exc_2299_T118_T120,Has a transplanted organ (with the exception of a corneal transplant performed >= 3 months prior to baseline),corneal transplant,50,68,,exception of,35,47,N
NCT03033745_inc_1061_T39_T38,The dose (volume) per injection site should not exceed 25 mL.,exceed 25 mL.,48,61,,not,44,47,N
NCT03073603_inc_461_T15_T19,No evidence of recent new inflammatory disease activity (inactive by the Lublin criteria16) with no new relapse for at least five years and no new MRI lesion for at least three years,inflammatory disease,26,46,,No,0,2,N
NCT03073603_inc_461_T20_T22,No evidence of recent new inflammatory disease activity (inactive by the Lublin criteria16) with no new relapse for at least five years and no new MRI lesion for at least three years,relapse,104,111,,no,97,99,N
NCT03073603_inc_461_T24_T27,No evidence of recent new inflammatory disease activity (inactive by the Lublin criteria16) with no new relapse for at least five years and no new MRI lesion for at least three years,lesion,151,157,,no,97,99,N
NCT01581749_inc_383_T48_T49,No prior prostate radiation or other definitive therapy,prostate radiation,9,27,,No,0,2,N
NCT01581749_inc_383_T50_T49,No prior prostate radiation or other definitive therapy,definitive therapy,37,55,,No,0,2,N
NCT02926235_exc_54_T4_T3,All patients who cannot participate in an outpatient physical therapy program for 3 days per week after surgery,physical therapy,53,69,,cannot,17,23,N
NCT03376763_exc_138_T10_T11,"Subjects with a current DSM-<U+2163>-TR or 5 diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnesia, Borderline, Paranoid, Histrionic, Schizotypal, Schizoid, Antisocial or other cognitive or personality disorders.",schizophrenia,66,79,,other than,55,65,N
NCT01320579_inc_202_T18_T17,"Good general health ascertained by medical history, physical examination and laboratory determinations, showing no signs of clinically significant findings, except chronic atopic dermatitis",signs of clinically significant findings,115,155,,no,112,114,N
NCT01320579_inc_202_T21_T22,"Good general health ascertained by medical history, physical examination and laboratory determinations, showing no signs of clinically significant findings, except chronic atopic dermatitis",chronic atopic dermatitis,164,189,,except,157,163,N
NCT01700790_inc_83_T10_T8,Taking an NNRTI or integrase containing regimen without prior history of use of PI for more than 2 weeks,PI,80,82,,without,48,55,N
NCT01700790_inc_910_T39_T40,"Tolerating tuberculosis therapy containing rifampin for the 2 weeks prior to screening,except for persons taking protease inhibitors at time of diagnosis of TB.,.",protease inhibitors,113,132,,except,87,93,N
NCT03335904_inc_81_T6_T4,no medical history of cardiovascular and respiratory disease,cardiovascular disease,,,"[(22, 36), (22, 29)]",no,2,4,N
NCT03335904_inc_81_T7_T4,no medical history of cardiovascular and respiratory disease,respiratory disease,41,60,,no,0,2,N
NCT03335904_inc_142_T12_T11,not taking medications other than oral contraceptives,oral contraceptives,34,53,,other than,23,33,N
NCT03335904_inc_142_T10_T9,not taking medications other than oral contraceptives,medications,11,22,,not,0,3,N
NCT03335904_inc_196_T15_T14,free from sleep apnea,sleep apnea,10,21,,free from,0,9,N
NCT02573168_exc_144_T9_T8,Patients with a history of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic or euthyroid for 6 months;,thyroid medication,31,49,,unless,42,48,N
NCT02573168_exc_558_T23_T22,"malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications;",basal cell carcinoma,19,39,,except,12,18,N
NCT02573168_exc_558_T31_T30,"malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications;",metastasis,175,185,,without,167,174,N
NCT02573168_exc_558_T32_T30,"malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications;",recurrence,193,203,,without,167,174,N
NCT02904785_inc_246_T16_T17,"Absence of skin injures, infections or tumor in the target knee;",skin injures,11,23,,Absence,0,7,N
NCT02904785_inc_246_T18_T17,"Absence of skin injures, infections or tumor in the target knee;",infections,25,35,,Absence,0,7,N
NCT02904785_inc_246_T19_T17,"Absence of skin injures, infections or tumor in the target knee;",tumor,39,44,,Absence,0,7,N
NCT01768195_inc_0_T1_T3,treatment-naive patients with B-cell lymphoma,treatment,0,9,,naive,10,15,N
NCT01373684_exc_1257_T71_T70,"Other significant medical illness that might interfere with this study: significant pulmonary dysfunction in the previous 6 months, malignancy other than skin basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant)",cornea transplant,,,"[(303, 309), (303, 313)]",other than,304,314,N
NCT01373684_exc_1257_T72_T70,"Other significant medical illness that might interfere with this study: significant pulmonary dysfunction in the previous 6 months, malignancy other than skin basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant)",hair transplant,314,329,,other than,143,153,N
NCT01373684_exc_1257_T64_T63,"Other significant medical illness that might interfere with this study: significant pulmonary dysfunction in the previous 6 months, malignancy other than skin basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant)",skin basocellular carcinoma,154,181,,other than,143,153,N
NCT01720394_inc_104_T7_T8,no PROM,PROM,3,7,,no,0,2,N
NCT01720394_inc_160_T15_T16,no contra-indication for medical induction of labor,contra-indication,3,20,,no,0,2,N
NCT01720394_inc_212_T20_T18,no clinical signs of infection,infection,21,30,,no,0,2,N
NCT02958072_exc_402_T28_T29,Breast-feeding women or fertile women not agreeing to use an effective method of contraception,agreeing to use an effective method of contraception,42,94,,not,38,41,N
NCT00050349_inc_0_T12_T18,"Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy",irradiated,215,225,,not been,195,203,N
NCT00050349_inc_0_T13_T18,"Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy",irradiated,215,225,,not been,195,203,N
NCT00050349_inc_312_T20_T21,"The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)",major impairment of hepatic function,,,"[(19, 38), (19, 35)]",no,16,18,N
NCT00050349_inc_312_T19_T21,"The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)",major impairment of renal function,,,"[(19, 44), (19, 27)]",no,16,18,N
NCT00050349_inc_0_T10_T54,"Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy",bone,173,177,,other than,59,69,N
NCT00846703_exc_0_T6_T1,No Down syndrome,Down syndrome,3,16,,No,0,2,N
NCT00846703_exc_17_T7_T2,"No other major disease that prohibits study treatment (e.g., severe congenital heart disease)",major disease,9,22,,No,0,2,N
NCT00846703_exc_206_T18_T4,No complications due to other interventions,complications,3,16,,No,0,2,N
NCT02863120_inc_0_T3_T4,Male or non-pregnant female between the ages of 18-65,pregnant,12,20,,non,8,11,N
NCT03530124_exc_588_T40_T41,Known cause of apnea other than apnea of prematurity,apnea of prematurity,15,35,,other than,21,31,N
NCT02196285_exc_507_T31_T39,"Chronic use of any medication, except homeopathy, and trivial ones, as nasal physiologic solution and vitamins;",homeopathy,38,48,,except,31,37,N
NCT02196285_exc_1341_T78_T79,"Convulsions, except the ones caused by fever, before 2 years old;",caused by fever,29,44,,except,13,19,N
NCT02196285_exc_1784_T116_T115,Asplenia (absence of spleen or its removal);,spleen,21,27,,absence of,10,20,N
NCT02196285_exc_1784_T117_T115,Asplenia (absence of spleen or its removal);,spleen removal,,,"[(21, 27), (21, 28)]",absence of,10,20,N
NCT02196285_exc_507_T35_T39,"Chronic use of any medication, except homeopathy, and trivial ones, as nasal physiologic solution and vitamins;",trivial ones,54,66,,except,31,37,N
NCT02823808_inc_34_T6_T5,"Patient who had been diagnosed within the previous 12 months with HbA1c levels of 8.0-12.0%, did not have a medical history related to diabetes, and did not display proliferative retinopathy",proliferative retinopathy,165,190,,not,97,100,N
NCT02823808_inc_34_T8_T7,"Patient who had been diagnosed within the previous 12 months with HbA1c levels of 8.0-12.0%, did not have a medical history related to diabetes, and did not display proliferative retinopathy",medical history related to diabetes,108,143,,not,97,100,N
NCT03366779_exc_749_T50_T58,"Any metabolic disease bone disease that has not been stabilized for at least three months (e.g., Paget's disease, osteomalacia, osteogenesis imperfecta, thyroid and/or parathyroid gland disorder, etc.).",been stabilized,48,63,,not,44,47,N
NCT03366779_exc_1368_T76_T89,"If the absolute arterial pressure is below 50mm of Hg at the calf or ankle level, then the patient is to be excluded) or other peripheral vascular disease).",absolute arterial pressure,7,33,,excluded,108,116,N
NCT03366779_exc_1368_T85_T89,"If the absolute arterial pressure is below 50mm of Hg at the calf or ankle level, then the patient is to be excluded) or other peripheral vascular disease).",peripheral vascular disease,127,154,,excluded,108,116,N
NCT03366779_exc_2393_T139_T138,"A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years.",signs or symptoms of the malignancy,162,197,,no,60,62,N
NCT03366779_exc_2393_T135_T142,"A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years.",non-melanoma skin cancer,60,84,,except,53,59,N
NCT03366779_exc_2705_T152_T153,"Currently taking anticoagulants, other than aspirin, unless the patient can be taken off the anticoagulant for surgery.",aspirin,44,51,,other than,33,43,N
NCT01322464_exc_623_T21_T24,Subjects were not to have donated plasma within 90 days prior to study initiation.,donated plasma,26,40,,not,14,17,N
NCT01322464_exc_409_T16_T25,Subjects were not to have a postural drop of 20 mmHg or more in systolic blood pressure at screening.,postural drop of 20 mmHg,28,52,,not,14,17,N
NCT01322464_exc_707_T26_T27,Subjects were not to have donated blood within 90 days prior to study initiation.,donated blood,26,39,,not,14,17,N
NCT01322464_exc_790_T30_T36,Subjects were not to have had an abnormal diet or substantial changes in eating habits within 30 days prior to study initiation.,abnormal diet,33,46,,not,14,17,N
NCT01322464_exc_790_T31_T36,Subjects were not to have had an abnormal diet or substantial changes in eating habits within 30 days prior to study initiation.,changes in eating habits,62,86,,not,14,17,N
NCT01322464_exc_1092_T42_T45,Subjects were to have no history of known hypersensitivity or idiosyncratic reaction to the study drug or related compounds.,hypersensitivity,42,58,,no,22,24,N
NCT01322464_exc_1092_T43_T45,Subjects were to have no history of known hypersensitivity or idiosyncratic reaction to the study drug or related compounds.,idiosyncratic reaction,62,84,,no,22,24,N
NCT01322464_exc_1218_T46_T50,Subjects were not to use any prescription medication within 14 days prior to or during the study.,prescription medication,29,52,,not,14,17,N
NCT01322464_exc_1317_T54_T55,Subjects were not to use any over-the-counter medication within 7 days prior to or during the study.,over-the-counter medication,29,56,,not,14,17,N
NCT01322464_exc_1419_T57_T66,Subjects were not to have a history of alcohol or drug abuse within 2 years prior to the study (subjects with a history of previous use of cannabis were not excluded unless they had used cannabis or cannabinoid based medicine within 30 days prior to study drug administration or were unwilling to abstain for the duration of the study).,alcohol abuse,,,"[(39, 46), (39, 44)]",not,14,17,N
NCT01322464_exc_1419_T56_T66,Subjects were not to have a history of alcohol or drug abuse within 2 years prior to the study (subjects with a history of previous use of cannabis were not excluded unless they had used cannabis or cannabinoid based medicine within 30 days prior to study drug administration or were unwilling to abstain for the duration of the study).,drug abuse,50,60,,not,14,17,N
NCT02445339_exc_266_T17_T16,Lack of capacity or willingness to consent,capacity to consent,,,"[(8, 16), (8, 18)]",Lack of,4,11,N
NCT02445339_exc_266_T15_T16,Lack of capacity or willingness to consent,willingness to consent,20,42,,Lack of,0,7,N
NCT02445339_exc_309_T23_T22,Currently prescribed pharmacotherapy for alcohol dependence (not including treatment of acute alcohol withdrawal syndrome),treatment,75,84,,not including,61,74,N
NCT02445339_exc_495_T34_T33,"Pregnant, nursing, or not using effective methods of birth control",birth control,53,66,,not,22,25,N
NCT02445339_exc_495_T31_T33,"Pregnant, nursing, or not using effective methods of birth control",Pregnant,0,8,,not,22,25,N
NCT02445339_exc_495_T32_T33,"Pregnant, nursing, or not using effective methods of birth control",nursing,10,17,,not,22,25,N
NCT02579928_exc_192_T17_T18,History of substance dependence diagnosis by MINI-KID (excluding tobacco) or positive urine toxicology.,tobacco,65,72,,excluding,55,64,N
NCT02579928_exc_374_T27_T26,Inability to provide written informed consent according to the Yale Human Investigation Committee (HIC) guidelines in English.,written informed consent,21,45,,Inability to provide,0,20,N
NCT03275584_exc_15_T5_T4,Claustrophobic patient unable to undergo the examination,examination,45,56,,unable,23,29,N
NCT02946892_exc_297_T34_T32,"Sustained or symptomatic ventricular dysrhythmias uncontrolled by drug therapy or the use of an implantable defibrillator, and/or significant cardiac conduction defects, e.g., 2nd degree or 3rd degree AV block, or sick sinus syndrome, unless a functioning pacemaker is in place",pacemaker,256,265,,unless,235,241,N
NCT02946892_exc_1846_T124_T122,"Pregnancy or possible pregnancy at time of randomization, or female of child bearing potential who are lactating, or sexually active and not taking adequate contraceptive precautions (e.g., intrauterine device or oral contraceptives for 3 months prior to entry into the study)",contraceptive precautions,157,182,,not,137,140,N
NCT02469610_inc_52_T5_T7,No known allergy to Bupivacaine.,allergy,9,16,,No,0,2,N
NCT03589105_inc_29_T24_T23,Patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features: (i) at least one clinical relapse over a 6-month period prior to screening; (ii) AND/OR at least one T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI) performed over a 3 months period prior to screening with no change of Disease-Modifying Treatment(s),change of,399,408,,no,396,398,N
NCT02231892_exc_4591_T70_T73,Pregnant women or women with reproductive potential who are sexually active and not using an acceptable form of contraception.,contraception,112,125,,not,80,83,N
NCT02231892_exc_2919_T100_T101,"Meet current DSM V criteria for moderate to severe substance use disorder (excluding nicotine), smoke daily, or urine toxicology positive for any illicit substance inconsistent with history given.",nicotine,85,93,,excluding,75,84,N
NCT02231892_exc_3706_T129_T132,"Have met DSM V criteria for moderate to severe substance use disorder (excluding nicotine, alcohol and cannabis) in the past, or have met DSM V criteria for moderate to severe substance use disorder for cannabis or alcohol in the past 5 years.",nicotine,81,89,,excluding,71,80,N
NCT02231892_exc_3706_T130_T132,"Have met DSM V criteria for moderate to severe substance use disorder (excluding nicotine, alcohol and cannabis) in the past, or have met DSM V criteria for moderate to severe substance use disorder for cannabis or alcohol in the past 5 years.",alcohol,91,98,,excluding,71,80,N
NCT02231892_exc_3706_T131_T132,"Have met DSM V criteria for moderate to severe substance use disorder (excluding nicotine, alcohol and cannabis) in the past, or have met DSM V criteria for moderate to severe substance use disorder for cannabis or alcohol in the past 5 years.",cannabis,103,111,,excluding,71,80,N
NCT02231892_exc_1104_T201_T200,"Cardiac pacemakers, neural stimulators, implantable defibrillator, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head that precludes MRI scanning.",MRI scanning,320,332,,precludes,310,319,N
NCT00183885_inc_1551_T34_T35,Patients may not have ascites or the ascites must be responsive to diuretics.,ascites,22,29,,may not have,9,21,N
NCT03537924_inc_0_T7_T6,"Healthy men and women, age 40-75 yrs, without any disease and need of medication.",any disease,46,57,,without,38,45,N
NCT03537924_inc_0_T9_T6,"Healthy men and women, age 40-75 yrs, without any disease and need of medication.",medication,70,80,,without,38,45,N
NCT03338855_inc_406_T16_T17,"Patients are on no other anti-diabetic drug treatment, or on stable maximum 3000 mg daily dose metformin treatment and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months5.",anti-diabetic drug treatment,25,53,,no,16,18,N
NCT03338855_inc_406_T21_T17,"Patients are on no other anti-diabetic drug treatment, or on stable maximum 3000 mg daily dose metformin treatment and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months5.",metformin,95,104,,no,16,18,N
NCT03338855_inc_406_T23_T17,"Patients are on no other anti-diabetic drug treatment, or on stable maximum 3000 mg daily dose metformin treatment and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months5.",DPPIV inhibitor,142,157,,no,16,18,N
NCT03288428_inc_0_T15_T11,elective Laparoscopic myomectomy patients 24hr post-operative patient controlled analgesia analgesia no mild or severe liver or renal disfunction,liver disfunction,,,"[(119, 124), (119, 130)]",no,101,103,N
NCT03288428_inc_0_T14_T11,elective Laparoscopic myomectomy patients 24hr post-operative patient controlled analgesia analgesia no mild or severe liver or renal disfunction,renal disfunction,128,145,,no,101,103,N
NCT02851303_exc_92_T10_T9,"Primary substance exposure in-utero was buprenorphine, or was not opioids",opioids,66,73,,not,62,65,N
NCT01963754_inc_202_T11_T10,Absence of oral lesions,oral lesions,11,23,,Absence,0,7,N
NCT02137369_exc_2193_T80_T79,"Contraindications for MRI, including, but not limited to pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices for birth control.",pacemaker,57,66,,not,42,45,N
NCT02137369_exc_2193_T81_T79,"Contraindications for MRI, including, but not limited to pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices for birth control.",aneurysm clips,68,82,,not,42,45,N
NCT02137369_exc_2193_T82_T79,"Contraindications for MRI, including, but not limited to pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices for birth control.",neurostimulators,84,100,,not,42,45,N
NCT02137369_exc_2193_T83_T79,"Contraindications for MRI, including, but not limited to pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices for birth control.",cochlear implants,102,119,,not,42,45,N
NCT02137369_exc_2193_T84_T79,"Contraindications for MRI, including, but not limited to pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices for birth control.",metal,121,126,,not,42,45,N
NCT02137369_exc_2193_T86_T79,"Contraindications for MRI, including, but not limited to pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices for birth control.",steel worker,136,148,,not,42,45,N
NCT02137369_exc_2193_T87_T79,"Contraindications for MRI, including, but not limited to pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices for birth control.",intra-uterine devices,150,171,,not,42,45,N
NCT02137369_exc_2451_T90_T96,"Hypnotic medication prescribed or approved by the study physician, (up to a three doses per week) for insomnia, as long if not the night before a PET/MRI or clinic ratings visit.",Hypnotic medication,0,19,,not,3,6,N
NCT00319748_inc_1587_T72_T73,Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens,amenable to curative treatment,77,107,,not,73,76,N
NCT00319748_inc_1810_T91_T92,"Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens.",amenable to curative treatment,140,170,,not,136,139,N
NCT00319748_inc_1131_T55_T101,"Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma).",epithelial carcinoma,64,84,,not,144,147,N
NCT02607748_inc_563_T5_T4,"have no prior CAD associated event (no prior myocardial infarction, acute coronary syndrome, coronary angiogram, or PCI),",CAD,14,17,,no,5,7,N
NCT02443623_exc_787_T43_T42,Is a transplant recipient (except for corneal transplant).,corneal transplant,38,56,,except,27,33,N
NCT02443623_exc_1207_T62_T61,Subjects with kidney disease (except kidney stones).,kidney stones,14,27,,except,30,36,N
NCT01799681_exc_0_T2_T3,any neurological conditions other than PD;,PD,39,41,,other than,28,38,N
NCT02175186_exc_314_T29_T30,"Patients who tool medicine such as PPI, APA,H2blocker, Muscarine receptor antagonist, anti-gastic agent, antacid, anticaogulant, Bisphosphonate agents, Cytotoxic drug, NSAID, adrenal cortex hormone agents (topical treatment is allowed)",topical treatment,206,223,,allowed,227,234,N
NCT02510404_exc_375_T28_T30,Unable to wean steroids to ≤0.5,wean,10,14,,Unable,0,6,N
NCT01895946_exc_60_T10_T11,"Spinal cord compression or brain metastases unless asymptomatic, treated and stable (not requiring steroids)",steroids,99,107,,not,85,88,N
NCT01895946_exc_60_T5_T6,"Spinal cord compression or brain metastases unless asymptomatic, treated and stable (not requiring steroids)",asymptomatic,51,63,,unless,44,50,N
NCT01895946_exc_60_T7_T6,"Spinal cord compression or brain metastases unless asymptomatic, treated and stable (not requiring steroids)",treated,65,72,,unless,44,50,N
NCT01895946_exc_60_T8_T6,"Spinal cord compression or brain metastases unless asymptomatic, treated and stable (not requiring steroids)",stable,77,83,,unless,44,50,N
NCT03338296_exc_1491_T68_T67,"Significant renal or hepatic disease as evidenced by a serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome",Gilbert's syndrome,215,233,,absence of,204,214,N
NCT03338296_exc_3173_T147_T149,oral steroids (topical and inhaled steroids are acceptable),inhaled steroids,27,43,,acceptable,48,58,N
NCT03338296_exc_3504_T184_T183,"History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease",prediabetes,153,164,,other than,142,152,N
NCT03338296_exc_3504_T191_T192,"History or evidence of clinically significant disease (eg, malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease) other than prediabetes (impaired fasting glucose or impaired glucose tolerance), type 2 diabetes treated with oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents, obstructive sleep apnea, dyslipidemia, and nonalcoholic fatty liver disease",sulfonylurea,289,301,,excluding,279,288,N
NCT03338296_exc_6565_T344_T345,Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation,sexual activity,109,124,,refrain,96,103,N
NCT03338296_exc_6565_T342_T345,Are currently abstinent and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period and for 28 days after study drug discontinuation,double-barrier method,50,71,,refrain,96,103,N
NCT03338296_exc_6763_T355_T354,"Are using hormonal contraceptives, but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).",stable dose,52,63,,not,43,46,N
NCT03338296_exc_3173_T148_T149,oral steroids (topical and inhaled steroids are acceptable),topical steroids,,,"[(15, 22), (15, 23)]",acceptable,78,88,N
NCT01082549_inc_675_T32_T30,Mixed tumors with small cell anaplastic elements are not eligible.,small cell anaplastic elements,18,48,,not,53,56,N
NCT01082549_inc_1148_T43_T46,Patients who have received chemo/radiation for locally advanced NSCLC are not eligible.,chemo,27,32,,not,74,77,N
NCT01082549_inc_1148_T44_T46,Patients who have received chemo/radiation for locally advanced NSCLC are not eligible.,radiation,33,42,,not,74,77,N
NCT01082549_inc_1794_T70_T71,Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the upper limit of normal if no liver involvement or ≤5 times the upper limit of normal with liver involvement.,liver involvement,111,128,,no,11,13,N
NCT01082549_inc_1794_T75_T71,Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the upper limit of normal if no liver involvement or ≤5 times the upper limit of normal with liver involvement.,liver involvement.,111,129,,no,11,13,N
NCT03247738_exc_609_T40_T41,Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection,pacemaker,72,81,,without,64,71,N
NCT00527826_inc_172_T8_T9,Females must be of Non Child Bearing Potential.,Child Bearing Potential,23,46,,Non,19,22,N
NCT00527826_inc_220_T10_T11,"The definition of Non Child Bearing Potential is as following: Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy, or females who are post-menopausal.",Child Bearing Potential,22,45,,Non,18,21,N
NCT02822001_exc_42_T4_T3,Any patient whose condition will not allow for placement of the electrode PadSet.,allow,37,42,,not,33,36,N
NCT02822001_exc_124_T7_T9,Patients whose tracheas were not extubated in OR or PACU.,extubated,33,42,,not,29,32,N
NCT03036462_exc_139_T11_T10,"Anaemia not attributed to iron deficiency, e.g. other microcytic anaemia",iron deficiency,26,41,,not,8,11,N
NCT03506477_exc_0_T3_T2,"Form of diagnosed psoriasis other than chronic plaque psoriasis (i.e. guttate, erythrodermic, pustular)",chronic plaque psoriasis,39,63,,other than,28,38,N
NCT03506477_exc_641_T28_T29,"Use of oral estrogen therapy, excluding oral contraceptive pills",oral contraceptive pills,7,31,,excluding,30,39,N
NCT02969187_exc_78_T8_T17,"open abdominal surgeries except simple appendectomy and common OB/GYN procedures in the pelvis (hysterectomy, C-section, and oophorectomy, tubal ligation)",simple appendectomy,32,51,,except,25,31,N
NCT02969187_exc_78_T9_T17,"open abdominal surgeries except simple appendectomy and common OB/GYN procedures in the pelvis (hysterectomy, C-section, and oophorectomy, tubal ligation)",common OB/GYN procedures,56,80,,except,25,31,N
NCT02969187_exc_233_T21_T22,laparoscopic bowel or solid organ resection except laparoscopic cholecystectomy,laparoscopic cholecystectomy,0,28,,except,44,50,N
NCT03034837_exc_0_T1_T2,Can not cooperate with the treatment,cooperate with the treatment,8,36,,not,4,7,N
NCT03034837_exc_37_T4_T3,Can not obtain the child's parental consent,child's parental consent,19,43,,not,4,7,N
NCT02546856_exc_154_T12_T13,Without phone,phone,8,13,,Without,0,7,N
NCT00401245_inc_345_T18_T19,Hysterectomized without bilateral oophorectomy and with serum FSH levels >40 mIU/mL.,bilateral oophorectomy,24,46,,without,16,23,N
NCT02912182_exc_266_T17_T16,psychic disorder (not including mild depression),mild depression,32,47,,not,18,21,N
NCT00720031_inc_80_T6_T7,transit nodules not surgically resectable,surgically resectable,20,41,,not,16,19,N
NCT00720031_inc_217_T17_T18,No chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy in the last 4 weeks before infusion.,Deticene,38,46,,except for,27,37,N
NCT00720031_inc_217_T15_T16,No chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy in the last 4 weeks before infusion.,chemotherapy,3,15,,No,0,2,N
NCT00720031_inc_217_T22_T16,No chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy in the last 4 weeks before infusion.,immunotherapy,112,125,,No,0,2,N
NCT00720031_inc_217_T21_T16,No chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy in the last 4 weeks before infusion.,radiotherapy,96,108,,No,0,2,N
NCT03008005_exc_1500_T53_T55,"inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia), as determined by self-report and/or a preliminary session in a mock scanner","tolerate small, enclosed spaces without anxiety",13,60,,inability,0,9,N
NCT01978028_inc_445_T33_T34,Stable pharmacological therapy during the last 4 weeks (with the exception of diuretics),diuretics,78,87,,with the exception of,56,77,N
NCT01891383_inc_570_T21_T24,No history of traumatic brain injury of sufficient severity to have resulted in medical attention (ascertained via the Ohio State University TBI Identification Questionnaire—OSU TBI-ID),traumatic brain injury,14,36,,No,0,2,N
NCT02858804_exc_315_T22_T21,pregnancy or baby nursing period or un-contracepted child bearing period woman.,contracepted,39,51,,un-,36,39,N
NCT02964715_inc_56_T10_T9,"Any anti-diabetic agent except SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists)",SGLT2 inhibitors,31,47,,except,24,30,N
NCT02964715_inc_56_T11_T9,"Any anti-diabetic agent except SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists)",TZDs,49,53,,except,24,30,N
NCT02964715_inc_56_T13_T9,"Any anti-diabetic agent except SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists)",DPP4 inhibitors,,,"[(75, 79), (75, 85)]",except,28,34,N
NCT02964715_inc_56_T15_T9,"Any anti-diabetic agent except SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists)",GLP1 RAs,118,126,,except,24,30,N
NCT00994786_exc_0_T3_T2,Patients with any other primary DSM-IV psychiatric diagnosis in addition to Obsessive Compulsive Disorder.,Obsessive Compulsive Disorder,76,105,,in addition to,61,75,N
NCT00994786_exc_1838_T47_T46,"Patients with a current seizure disorder, organic brain disorder or a history of seizure disorders (except for febrile seizures in childhood).",febrile seizures,111,127,,except,100,106,N
NCT00994786_exc_1981_T52_T51,"Patients with thyroid pathology, the treatment of which has not been stabilized for at least three months.",stabilized,69,79,,not,60,63,N
NCT00994786_exc_2669_T67_T68,Sleep medication such as oral chloral-hydrate or zopiclone are acceptable.,Sleep medication,0,16,,acceptable,63,73,N
NCT00543712_exc_1555_T93_T92,Any disorder that compromises the ability of the patient to give written informed consent and/or comply with study procedures,give written informed consent,60,89,,compromises the ability of,18,44,N
NCT00543712_exc_1555_T94_T92,Any disorder that compromises the ability of the patient to give written informed consent and/or comply with study procedures,comply with study procedures,97,125,,compromises the ability of,18,44,N
NCT00543712_exc_1555_T91_T92,Any disorder that compromises the ability of the patient to give written informed consent and/or comply with study procedures,disorder,4,12,,compromises the ability of,18,44,N
NCT02755701_inc_135_T12_T11,No administration of diuretics and BCAA within the past 1 week,diuretics,21,30,,No,0,2,N
NCT02755701_inc_135_T13_T11,No administration of diuretics and BCAA within the past 1 week,BCAA,35,39,,No,0,2,N
NCT02571179_exc_226_T13_T14,The subjects should not have received fentanyl during the previous 14 days.,fentanyl,38,46,,not,20,23,N
NCT02137369_inc_31_T9_T7,"Primary psychiatric diagnosis of Major Depressive Disorder, without psychotic features, confirmed via SCID-IV structured diagnostic interview.",psychotic features,68,86,,without,60,67,N
NCT03513874_inc_91_T7_T6,Non-obese: defined as BMI less than 28 kg/m2,obese,4,9,,Non,0,3,N
NCT03228654_inc_24_T12_T11,"presence of benign cause for the hysterectomy e.g. fibroid uterus, perimenopausal beeding not responding to medical treatment or complex endometrial hyperplasia without atypia.",atypia,169,175,,without,161,168,N
NCT03228654_inc_24_T8_T7,"presence of benign cause for the hysterectomy e.g. fibroid uterus, perimenopausal beeding not responding to medical treatment or complex endometrial hyperplasia without atypia.",responding to medical treatment,94,125,,not,90,93,N
NCT03228654_inc_201_T16_T15,Absence of significant scarring in the pelvis from previous surgeries.,significant scarring,11,31,,Absence,0,7,N
NCT03044093_inc_8_T2_T4,no allergy known to these drugs,allergy,3,10,,no,0,2,N
NCT02015494_exc_946_T70_T71,"Having cancer or have received treatment for cancer within three years (persons with a history of cancer who are disease-free without treatment for three years or more are eligible), excluding minor skin cancers, which are allowed unless located at the vaccination site",treatment,31,40,,without,126,133,N
NCT02934269_inc_173_T23_T24,"Females must have been surgically sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingo-oophorectomy; proper documentation required) at least 6 months before screening, or be postmenopausal (defined as 24 consecutive months without menses before screening, with a follicle-stimulating hormone [FSH] level of > 40 IU/L at screening).",menses,250,256,,without,242,249,N
NCT01696617_exc_756_T43_T42,"Patients taking antipsychotics, mood stabilizer or any psychotropic medications besides antidepressants, except benzodiazepines or beta blockers or hypnotics",benzodiazepines,112,127,,except,105,111,N
NCT01696617_exc_756_T44_T42,"Patients taking antipsychotics, mood stabilizer or any psychotropic medications besides antidepressants, except benzodiazepines or beta blockers or hypnotics",beta blockers,131,144,,except,105,111,N
NCT01696617_exc_756_T45_T42,"Patients taking antipsychotics, mood stabilizer or any psychotropic medications besides antidepressants, except benzodiazepines or beta blockers or hypnotics",hypnotics,148,157,,except,105,111,N
NCT01696617_exc_756_T41_T40,"Patients taking antipsychotics, mood stabilizer or any psychotropic medications besides antidepressants, except benzodiazepines or beta blockers or hypnotics",antidepressants,88,103,,besides,80,87,N
NCT03329456_exc_0_T10_T14,"Exclusion criteria are pregnancy, patients with contraindications to regional anesthesia, allergy to LAs, patients taking opioids regularly due to chronic pain, use of anticoagulation drugs other than acetylsalicylic acid or dipyridamole, atrioventricular block, diabetes.",acetylsalicylic acid,201,221,,other than,190,200,N
NCT03329456_exc_0_T11_T14,"Exclusion criteria are pregnancy, patients with contraindications to regional anesthesia, allergy to LAs, patients taking opioids regularly due to chronic pain, use of anticoagulation drugs other than acetylsalicylic acid or dipyridamole, atrioventricular block, diabetes.",dipyridamole,225,237,,other than,190,200,N
NCT03372265_exc_184_T18_T21,Pregnancy or breastfeeding (disproved by a negative pregnancy test before trial inclusion),pregnancy test,52,66,,disproved by,28,40,N
NCT02466113_inc_166_T8_T9,The patient receive no anti-cancer treatment before primary surgery.,anti-cancer treatment,23,44,,no,20,22,N
NCT02721017_exc_86_T10_T9,"pectus carinatum, Poland's syndrome, or any chest wall anomaly other than pectus excavatum",pectus excavatum,0,16,,other than,63,73,N
NCT02301039_exc_315_T18_T20,Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation < 2 weeks prior to screening or who have not recovered adequately from side effects of such therapy.,recovered,148,157,,not,144,147,N
NCT02301039_exc_315_T13_T20,Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation < 2 weeks prior to screening or who have not recovered adequately from side effects of such therapy.,wide field radiotherapy,27,50,,not,144,147,N
NCT02301039_exc_315_T15_T20,Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation < 2 weeks prior to screening or who have not recovered adequately from side effects of such therapy.,limited field radiation for palliation,64,102,,not,144,147,N
NCT02301039_exc_1467_T64_T65,Patients with hypothyroidism not from autoimmune disease that is stable on hormone replacement will not be excluded from the study.,autoimmune disease,38,56,,not,29,32,N
NCT01967420_inc_193_T9_T10,Psychiatrically stable enough to attend to completion (no hospitalisations or medication changes in last 4 weeks),hospitalisations,58,74,,no,24,26,N
NCT01967420_inc_193_T11_T10,Psychiatrically stable enough to attend to completion (no hospitalisations or medication changes in last 4 weeks),medication changes,78,96,,no,24,26,N
NCT03228017_inc_64_T7_T9,Group 2: Healthy subjects without known psoriatic disease or cardiovascular disease,psoriatic disease,40,57,,without,26,33,N
NCT03228017_inc_64_T8_T9,Group 2: Healthy subjects without known psoriatic disease or cardiovascular disease,cardiovascular disease,61,83,,without,26,33,N
NCT00943865_exc_173_T15_T14,gastrointestinal problems or musculoskeletal disorders that would prevent them to follow the test diets or exercise interventions,test diets,8,18,,prevent,66,73,N
NCT00943865_exc_173_T16_T14,gastrointestinal problems or musculoskeletal disorders that would prevent them to follow the test diets or exercise interventions,exercise interventions,107,129,,prevent,66,73,N
NCT02550080_inc_196_T10_T11,Subjects are dapsone-naive.,dapsone,13,20,,naive,21,26,N
NCT03187639_inc_43_T6_T7,No contraindication to CTA,contraindication,3,19,,No,0,2,N
NCT02564471_exc_838_T18_T20,History of mild depression or anxiety disorder that are well controlled are not exclusion criteria.,depression,16,26,,not,76,79,N
NCT02564471_exc_838_T19_T20,History of mild depression or anxiety disorder that are well controlled are not exclusion criteria.,anxiety disorder,30,46,,not,76,79,N
NCT02564471_exc_1020_T28_T29,Topical steroids will not be considered an immunosuppressive drug and their use will not be considered an exclusion criteria.,Topical steroids,0,16,,not,22,25,N
NCT02782702_exc_338_T25_T27,Application in the last 7 days at the site of injection of local treatments (apart emollients or antiseptics) or injections of botulism toxin or dynamic phototherapy or laser in the last 6 months.,emollients,83,93,,apart,77,82,N
NCT02782702_exc_338_T26_T27,Application in the last 7 days at the site of injection of local treatments (apart emollients or antiseptics) or injections of botulism toxin or dynamic phototherapy or laser in the last 6 months.,antiseptics,97,108,,apart,77,82,N
NCT02822001_inc_53_T8_T7,"Patients weighing = 80 pounds who are not -intubated prior to surgery,",intubated,43,52,,not,38,41,N
NCT02062489_inc_49_T6_T7,"The patients present with operable unilateral invasive breast cancers without distant metastasis(stage I, II, and III)",distant metastasis,78,96,,without,70,77,N
NCT02062489_inc_258_T18_T19,The patients have no history of neoadjuvant hormone therapy.,neoadjuvant hormone therapy,32,59,,no history,18,28,N
NCT02691793_inc_747_T40_T39,Patients of child-bearing potential should be using adequate contraceptive measures should not be breast feeding and must have a negative pregnancy test prior to start of dosing,breast feeding,98,112,,not be,91,97,N
NCT02958566_exc_448_T28_T32,Diverticulitis without active infection/inflammation will not be excluded.,infection,30,39,,without,15,22,N
NCT02958566_exc_448_T29_T32,Diverticulitis without active infection/inflammation will not be excluded.,inflammation,40,52,,without,15,22,N
NCT02958566_exc_448_T26_T30,Diverticulitis without active infection/inflammation will not be excluded.,Diverticulitis,0,14,,not be excluded,58,73,N
NCT02851303_inc_74_T9_T8,Primary in-utero drug exposure was opioids other than buprenorphine,buprenorphine,54,67,,other,43,48,N
NCT03225469_exc_472_T33_T34,Incomplete colonoscopy due to causes except poor bowel preparation,poor bowel preparation,44,66,,except,37,43,N
NCT03140488_exc_338_T28_T27,Estimated fetal weight greater than 4500 grams in diabetic and 5000 grams in non-diabetic mother,diabetic,50,58,,non-,77,81,N
NCT03472495_exc_156_T15_T14,Administration of other antiarrhythmics for acute heart rate control (excluding adenosine),adenosine,80,89,,excluding,70,79,N
NCT03146390_inc_60_T7_T6,No gingivitis (Community Periodontal Index score = 0).,gingivitis,3,13,,No,0,2,N
NCT03146390_inc_115_T13_T12,No periodontitis (Community Periodontal Index score = 0).,periodontitis,3,16,,No,0,2,N
NCT03146390_inc_173_T19_T20,Absence of untreated caries.,caries,21,27,,Absence,0,7,N
NCT03404479_exc_181_T13_T12,Helicobacter infected patients who have not been treated for eradication (recruitment if negative in re-examination after treatment).,treated for eradication,49,72,,not,40,43,N
NCT03404479_exc_711_T39_T38,"Hepatitis B, hepatitis C (excluding healthy carriers) or HIV positive",healthy carriers,36,52,,excluding,26,35,N
NCT03404479_exc_1109_T58_T57,"Malignant tumors other than basal cell or squamous cell carcinoma of the skin, CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma of other areas Within 5 years of consent date.",basal cell carcinoma of the skin,,,"[(28, 38), (28, 49)]",other than,33,43,N
NCT03404479_exc_1109_T59_T57,"Malignant tumors other than basal cell or squamous cell carcinoma of the skin, CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma of other areas Within 5 years of consent date.",squamous cell carcinoma of the skin,42,77,,other than,17,27,N
NCT01581749_exc_146_T7_T6,"history of an invasive malignancy (other than this prostate cancer,or basal or squamous skin cancers) within prior 5 years",prostate cancer,51,66,,other than,35,45,N
NCT01581749_exc_146_T9_T6,"history of an invasive malignancy (other than this prostate cancer,or basal or squamous skin cancers) within prior 5 years",basal skin cancers,,,"[(70, 75), (70, 82)]",other than,37,47,N
NCT01581749_exc_146_T8_T6,"history of an invasive malignancy (other than this prostate cancer,or basal or squamous skin cancers) within prior 5 years",squamous skin cancers,79,100,,other than,35,45,N
NCT02897856_inc_0_T9_T8,Children 6 month to 14 years who will be presented to the pediatric emergency or attended by emergency medical service who have active seizure and had no intravenous access would be eligible for the study.,intravenous access,154,172,,no,151,153,N
NCT01000155_exc_89_T6_T7,Subjects who have received RBC transfusions cannot have >15% adult hemoglobin,RBC transfusions,27,43,,cannot have,44,55,N
NCT01000155_exc_760_T36_T40,Subjects with a history of thrombosis or other reason (other than sickle cell disease) for enhanced thrombotic risk,sickle cell disease,66,85,,other than,41,51,N
NCT01000155_exc_1359_T60_T59,Subjects who have received any HDAC inhibitors other than valproic acid       ,valproic acid,58,71,,other than,47,57,N
NCT02462590_exc_1342_T57_T56,"Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve are not excluded providing they have no other exclusion criteria;",mitral valve prolapse,286,307,,not,139,142,N
NCT02462590_exc_1342_T58_T56,"Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve are not excluded providing they have no other exclusion criteria;",bicuspid aortic valve,311,332,,not,139,142,N
NCT02462590_exc_1342_T53_T52,"Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve are not excluded providing they have no other exclusion criteria;",coronary artery stents,170,192,,not,139,142,N
NCT02462590_exc_1342_T54_T52,"Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve are not excluded providing they have no other exclusion criteria;",coronary artery bypass grafts,170,199,,not,139,142,N
NCT02462590_exc_1342_T55_T52,"Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve are not excluded providing they have no other exclusion criteria;",neurovascular coils,234,253,,not,139,142,N
NCT02462590_exc_1342_T48_T51,"Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve are not excluded providing they have no other exclusion criteria;",central venous catheters,24,48,,not,139,142,N
NCT02462590_exc_1741_T68_T67,"Patients with a primary diagnosis of severe acute pancreatitis, without reference to a Ranson score [Ranson 1974]).",Ranson score,87,99,,without,64,71,N
NCT02462590_exc_1857_T70_T69,"However, patients with mild or moderate pancreatitis are not excluded;",pancreatitis,40,52,,not,57,60,N
NCT02652572_inc_29_T21_T22,"Diagnosis of venous leg ulcer(s), as clinically determined by the investigator by a positive venous reflux test (venous refilling <20 seconds) using Doppler ultrasound for at least 4 weeks prior to screening day, which have not adequately responded to conventional ulcer therapy.",responded,239,248,,not,224,227,N
NCT02652572_inc_725_T45_T46,"Ulcers that extend through the epidermis but not through the muscle, tendon, or bone (Stage II or III ulcers as defined by the IAET).",extend through the muscle,,,"[(12, 18), (12, 30)]",not,45,48,N
NCT02652572_inc_725_T44_T46,"Ulcers that extend through the epidermis but not through the muscle, tendon, or bone (Stage II or III ulcers as defined by the IAET).",extend through the epidermis,12,40,,not,45,48,N
NCT02652572_inc_725_T50_T46,"Ulcers that extend through the epidermis but not through the muscle, tendon, or bone (Stage II or III ulcers as defined by the IAET).",extend through the tendon,,,"[(12, 18), (12, 23), (12, 18)]",not,45,48,N
NCT02652572_inc_725_T51_T46,"Ulcers that extend through the epidermis but not through the muscle, tendon, or bone (Stage II or III ulcers as defined by the IAET).",extend through the bone,,,"[(12, 18), (12, 23), (12, 16)]",not,45,48,N
NCT02680054_exc_191_T9_T8,Food allergies (other than controlled Coeliac Disease),Coeliac Disease,38,53,,other,16,21,N
NCT03511521_exc_71_T5_T8,Steroids other than methylprednisolone or prednisone,methylprednisolone,20,38,,other than,9,19,N
NCT03511521_exc_71_T6_T8,Steroids other than methylprednisolone or prednisone,prednisone,42,52,,other than,9,19,N
NCT02301039_inc_1678_T104_T105,"Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab.",clinical progression,188,208,,without,168,175,N
NCT02301039_inc_1678_T108_T112,"Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab.",brain metastases,287,303,,no,255,257,N
NCT02301039_inc_1678_T113_T114,"Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab.",steroids,317,325,,off,313,316,N
NCT00344318_inc_323_T5_T7,Free of obvious health problems as established by medical history and clinical examination before entering into the study.,health problems,16,31,,Free,0,4,N
NCT01888965_exc_0_T5_T7,"Women of child-bearing potential, who are biologically able to conceive, not employing two forms of highly effective contraception or who are pregnant.",highly effective contraception,100,130,,not,73,76,N
NCT01888965_exc_0_T6_T7,"Women of child-bearing potential, who are biologically able to conceive, not employing two forms of highly effective contraception or who are pregnant.",pregnant,142,150,,not,73,76,N
NCT01888965_exc_700_T43_T44,"The subject has had another active malignancy within the past 5 years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.",cervical cancer in situ,81,104,,except,70,76,N
NCT01888965_exc_700_T46_T44,"The subject has had another active malignancy within the past 5 years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.",non-melanoma carcinoma of the skin,142,176,,except,70,76,N
NCT01888965_exc_700_T45_T44,"The subject has had another active malignancy within the past 5 years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.",in situ carcinoma of the bladder,50,82,,except,70,76,N
NCT01888965_exc_296_T57_T56,"Patients who have undergone major surgery (e.g., intra-thoracic, -abdominal, or -pelvic) </= 4 weeks prior to starting study treatment or who have not recovered from such therapy",recovered from such therapy,151,178,,not,147,150,N
NCT01888965_exc_296_T20_T56,"Patients who have undergone major surgery (e.g., intra-thoracic, -abdominal, or -pelvic) </= 4 weeks prior to starting study treatment or who have not recovered from such therapy",major surgery,28,41,,not,147,150,N
NCT01888965_exc_1265_T63_T68,"No concurrent use of isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate",isoniazid,21,30,,No,0,2,N
NCT01888965_exc_1265_T64_T68,"No concurrent use of isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate",labetolol,32,41,,No,0,2,N
NCT01888965_exc_1265_T65_T68,"No concurrent use of isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate",trovafloxacin,43,56,,No,0,2,N
NCT01888965_exc_1265_T66_T68,"No concurrent use of isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate",tolcapone,58,67,,No,0,2,N
NCT01888965_exc_1265_T67_T68,"No concurrent use of isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate",felbamate,73,82,,No,0,2,N
NCT01888965_exc_1349_T71_T70,No concurrent use of other investigational drugs or antineoplastic therapies.,other investigational drugs,21,48,,No,0,2,N
NCT01888965_exc_1349_T72_T70,No concurrent use of other investigational drugs or antineoplastic therapies.,antineoplastic therapies,52,76,,No,0,2,N
NCT02396420_exc_907_T48_T49,Coagulation disturbances not normalized by medical treatment,normalized,29,39,,not,25,28,N
NCT00720031_exc_382_T28_T29,No contraception.,contraception,3,16,,No,0,2,N
NCT03373318_exc_0_T2_T1,"Patients who do not meet the inclusion criteria and those who have a history of allergic reactions to human albumin, as well as those who have received iodinated contrast during the 7 days prior to surgery and pregnant women, will be excluded from the study.",meet the inclusion criteria,20,47,,not,16,19,N
NCT01943812_exc_0_T4_T3,endometrial thickness < 7 mm or no triple layer endometrium and/or functional follicles,triple layer endometrium,35,59,,no,32,34,N
NCT01943812_exc_0_T5_T3,endometrial thickness < 7 mm or no triple layer endometrium and/or functional follicles,functional follicles,67,87,,no,32,34,N
NCT03387059_inc_667_T26_T25,"Normal uterine cavity on ultrasound exam (e.g., no presence of hydrosalpinx)",hydrosalpinx,63,75,,no presence of,48,62,N
NCT02243553_exc_1435_T98_T100,Sexually active women of childbearing age who do not use an acceptable barrier method of birth control,barrier method of birth control,71,102,,not,49,52,N
NCT02974686_exc_168_T13_T14,"Evidence of any GI disorder induced by an infection, underlying medical condition, or concomitant medication other than MPA",MPA,120,123,,other than,109,119,N
NCT03344887_exc_0_T1_T2,Patients that do not have a valid Ontario Health Insurance Plan (OHIP) number at time of first transfusion,have a valid Ontario Health Insurance Plan (OHIP) number,21,77,,not,17,20,N
NCT03344887_exc_107_T8_T11,Patients that require emergent release of a RBC transfusion and in whom emergency randomization could not be completed,emergency randomization,72,95,,could not be completed,96,118,N
NCT02334722_exc_0_T2_T1,No known history of seizure activity.,history,9,16,,No,0,2,N
NCT02431442_exc_741_T52_T55,History of malignancy except for treated cervical carcinoma in situ in the past 5 years.,cervical carcinoma in situ,41,67,,except for,22,32,N
NCT02431442_exc_4302_T224_T227,History of tobacco or tobacco product use unless abstinent for at least one year prior to the Screening Visit.,abstinent,49,58,,unless,42,48,N
NCT02985242_exc_974_T31_T30,"eye diseases or pathologies that prevent clear ophthalmoscopy and evaluation of study parameters, thus not allowing study participation according to the investigator´s judgment, such as (but not only) vitreous hemorrhage, mature cataract, macular pathologies other than diabetic maculopathy",ophthalmoscopy,47,61,,prevent,33,40,N
NCT02985242_exc_974_T36_T35,"eye diseases or pathologies that prevent clear ophthalmoscopy and evaluation of study parameters, thus not allowing study participation according to the investigator´s judgment, such as (but not only) vitreous hemorrhage, mature cataract, macular pathologies other than diabetic maculopathy",diabetic maculopathy,270,290,,other,259,264,N
NCT02985242_exc_1777_T69_T68,chronic lower urinary tract infections (but not simple asymptomatic bacteriuria),asymptomatic bacteriuria,55,79,,not,44,47,N
NCT02985242_exc_2609_T103_T102,"clinical evidence of current malignancy with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia (5 years prior to randomization)",basal cell carcinoma of the skin,,,"[(58, 68), (58, 67), (58, 69)]",exception,68,77,N
NCT02985242_exc_2609_T105_T102,"clinical evidence of current malignancy with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia (5 years prior to randomization)",cervical intraepithelial neoplasia,113,147,,exception,45,54,N
NCT02985242_exc_2609_T104_T102,"clinical evidence of current malignancy with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia (5 years prior to randomization)",squamous cell carcinoma of the skin,72,107,,exception,45,54,N
NCT01994382_exc_415_T26_T27,"Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2, previous drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy).",alopecia,88,96,,except,81,87,N
NCT01994382_exc_415_T30_T27,"Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2, previous drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy).",libido,131,137,,except,81,87,N
NCT01994382_exc_415_T29_T27,"Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2, previous drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy).",hot flashes,118,129,,except,81,87,N
NCT01994382_exc_415_T28_T27,"Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2, previous drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy).",erectile impotence,98,116,,except,81,87,N
NCT01994382_exc_415_T31_T27,"Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2, previous drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy).",neuropathy,139,149,,except,81,87,N
NCT00356148_exc_287_T22_T21,Denial of signing the consent form.,signing the consent form,10,34,,Denial of,0,9,N
NCT02765035_exc_895_T24_T23,Person who is not wearing prosthesis 8hours/day on average.,prosthesis,26,36,,not,14,17,N
NCT02003339_inc_0_T3_T2,"Early, intermediate, advanced, non metastatic Hepatocellular Carcinoma.",metastatic,35,45,,non,31,34,N
NCT00609531_exc_1290_T48_T56,"Ongoing need for psychoactive medication other than study medication [excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder, or diphenhydramine (Benadryl®)for sleep]       ",study medication,52,68,,other than,41,51,N
NCT00609531_exc_1290_T52_T49,"Ongoing need for psychoactive medication other than study medication [excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder, or diphenhydramine (Benadryl®)for sleep]       ",anticonvulsant medication,133,158,,excepting,70,79,N
NCT00609531_exc_1290_T54_T49,"Ongoing need for psychoactive medication other than study medication [excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder, or diphenhydramine (Benadryl®)for sleep]       ",diphenhydramine,184,199,,excepting,70,79,N
NCT02068365_exc_803_T50_T57,Exception: patients who have had a limited (<=7 days) course of acyclovir for herpetic lesions more than 1 month prior to the first administration of test drug are not excluded.,acyclovir,64,73,,Exception,0,9,N
NCT02068365_exc_1180_T68_T67,"History or other evidence of a medical condition associated with chronic liver disease other than HBV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver diseases including Wilson's and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia).",HBV,98,101,,other than,11,21,N
NCT02068365_exc_4090_T215_T219,"Patients with a value of alpha-fetoprotein >100 ng/mL are excluded, unless stability (less than 10% increase) has been documented over at least the previous 3 months.",stability,75,84,,unless,68,74,N
NCT03062358_exc_1765_T72_T120,"Has a diagnosed additional malignancy within 3 years prior to first dose of study medication with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers",treated,126,133,,with the exception of,38,59,N
NCT03062358_exc_664_T29_T130,"Has had prior systemic therapy for HCC in the advanced (incurable) setting other than sorafenib or oxaliplatin-based chemotherapy, prior to start of study medication",chemotherapy,117,129,,other than,75,85,N
NCT03062358_exc_1765_T75_T120,"Has a diagnosed additional malignancy within 3 years prior to first dose of study medication with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers",basal cell carcinoma of the skin,134,166,,with the exception of,38,59,N
NCT03062358_exc_1765_T76_T120,"Has a diagnosed additional malignancy within 3 years prior to first dose of study medication with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers",squamous cell carcinoma of the skin,168,203,,with the exception of,38,59,N
NCT03062358_exc_1765_T77_T120,"Has a diagnosed additional malignancy within 3 years prior to first dose of study medication with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers",in situ cancers,42,57,,with the exception of,38,59,N
NCT03062358_exc_1765_T78_T120,"Has a diagnosed additional malignancy within 3 years prior to first dose of study medication with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers",resected,222,230,,with the exception of,38,59,N
NCT02219880_inc_1679_T97_T94,Not using medically approved contraception (including abstinence) if female and of childbearing age,contraception,29,42,,Not,0,3,N
NCT01320579_exc_0_T8_T13,"History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator",atopic dermatitis,153,170,,except,119,125,N
NCT01320579_exc_301_T15_T16,"Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin",chronic atopic dermatitis,48,73,,except,41,47,N
NCT00461136_exc_802_T41_T42,Second or third degree heart block without a pacemaker,pacemaker,45,54,,without,35,42,N
NCT02543710_exc_0_T2_T1,Patients who will not get surgical treatment for their endometrial cancer,surgical treatment,26,44,,not,18,21,N
NCT02543710_exc_74_T5_T6,Patients not suffering from endometrial or epithelial ovarian cancer,endometrial ovarian cancer,,,"[(28, 39), (28, 42)]",not,10,13,N
NCT02543710_exc_74_T4_T6,Patients not suffering from endometrial or epithelial ovarian cancer,epithelial ovarian cancer,43,68,,not,9,12,N
NCT02543710_exc_143_T9_T8,Patients who do not agree to the proposed treatment or will receive (part of) the treatment in a non-participating centre,agree to the proposed treatment,20,51,,not,16,19,N
NCT02543710_exc_265_T12_T13,Patients who cannot or do not want to give informed consent (including language barriers),give informed consent,38,59,,cannot,13,19,N
NCT02543710_exc_265_T16_T13,Patients who cannot or do not want to give informed consent (including language barriers),language barriers,71,88,,cannot,13,19,N
NCT03624517_exc_106_T8_T5,Use of any other endoscopic method to stop GI bleeding beyond endoscopic band ligation,endoscopic band ligation,17,41,,any other,7,16,N
NCT00279552_exc_0_T3_T4,"Patients who were pregnant, nursing or not able to give written informed consent were excluded.",able to give written informed consent,43,80,,not,39,42,N
NCT02375295_inc_177_T10_T11,Stone free after definitive surgical therapy defined as fragments less than 3mm.,Stone,0,5,,free,6,10,N
NCT03115320_exc_99_T6_T5,No frozen embryos after IVF cycle,frozen embryos,3,17,,No,0,2,N
NCT02267616_inc_273_T7_T6,Not pregnant at the time of enrollment,pregnant,4,12,,Not,0,3,N
NCT03228498_exc_3_T22_T24,Absence of objectionable cognitive impairment or presence of dementia of severe degree defined by CDR score > 2.0.,cognitive impairment,25,45,,Absence,0,7,N
NCT03228498_exc_3_T25_T24,Absence of objectionable cognitive impairment or presence of dementia of severe degree defined by CDR score > 2.0.,dementia,61,69,,Absence,0,7,N
NCT03228498_exc_122_T30_T31,"Unavailability of brain MRI (in case of absolute contraindications, the use of cranial CT is allowed).",brain MRI,18,27,,Unavailability,0,14,N
NCT03228498_exc_122_T34_T31,"Unavailability of brain MRI (in case of absolute contraindications, the use of cranial CT is allowed).",cranial CT,79,89,,Unavailability,0,14,N
NCT03228498_exc_392_T52_T51,"Diagnosis of degenerative cognitive impairment based on clinical and/or neuroradiological findings (i.e., patients with prevailing memory impairment, or with medial temporal atrophy on brain MRI in absence of evident vascular abnormalities; i.e., Alzheimer disease as defined using the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, Parkinson disease, Huntington disease, frontotemporal dementia).",vascular abnormalities,217,239,,absence,198,205,N
NCT02426944_exc_154_T11_T12,"comorbidities other than AF, which present an indication for anticoagulation;",AF,25,27,,other than,14,24,N
NCT02511574_exc_0_T2_T1,no confirmation of the gestational age,gestational age,23,38,,no,0,2,N
NCT00965900_inc_265_T20_T19,"Do not take beta-blocker, ACE inhibitor, or nitrate",beta-blocker,12,24,,Do not,0,6,N
NCT00965900_inc_265_T21_T19,"Do not take beta-blocker, ACE inhibitor, or nitrate",ACE inhibitor,26,39,,Do not,0,6,N
NCT00965900_inc_265_T22_T19,"Do not take beta-blocker, ACE inhibitor, or nitrate",nitrate,44,51,,Do not,0,6,N
NCT00965900_inc_175_T17_T12,"No previous history of endoscopic, radiologic, or surgical therapy for varices or ascites",endoscopic therapy,,,"[(23, 33), (23, 30)]",No,4,6,N
NCT00965900_inc_175_T16_T12,"No previous history of endoscopic, radiologic, or surgical therapy for varices or ascites",radiologic therapy,,,"[(35, 45), (35, 42)]",No,4,6,N
NCT00965900_inc_175_T15_T12,"No previous history of endoscopic, radiologic, or surgical therapy for varices or ascites",surgical therapy,50,66,,No,0,2,N
NCT00965900_inc_120_T11_T10,No previous history of upper gastrointestinal bleeding,upper gastrointestinal bleeding,23,54,,No,0,2,N
NCT03541980_exc_287_T21_T20,Patient not requiring IV morphine (pain score 5/10 or less),requiring,12,21,,not,8,11,N
NCT02385448_inc_192_T12_T11,No contraindication to use of progesterone or combined oral contraceptive pills,contraindication,3,19,,No,0,2,N
NCT02385448_inc_272_T16_T21,Not attempting to conceive either at the time of study entry or for at least 2 years after surgery,attempting,4,14,,Not,0,3,N
NCT02882113_inc_288_T12_T11,Patients who have been monitored without complication such as acute rejection.,complication,41,53,,without,33,40,N
NCT02102243_exc_332_T21_T22,Any history of substance abuse (other than tobacco),tobacco,43,50,,other,32,37,N
NCT02525991_inc_760_T22_T21,"Patients free of active respiratory disease such as acute respiratory signs/symptoms (e.g., wheezing) or with active airways disease (asthma, chronic obstructive pulmonary disease or emphysema).",respiratory disease,24,43,,free,9,13,N
NCT02525991_inc_760_T27_T21,"Patients free of active respiratory disease such as acute respiratory signs/symptoms (e.g., wheezing) or with active airways disease (asthma, chronic obstructive pulmonary disease or emphysema).",airways disease,117,132,,free,9,13,N
NCT02965027_inc_453_T23_T24,"If available, the Glasgow Coma Scale score must be 13-15, and head imaging findings (if imaging was performed) must be negative.",findings,75,83,,negative,119,127,N
NCT02145026_inc_331_T16_T17,Require no red blood cell transfusion or dependent on <4 units within 8 weeks prior to screening,red blood cell transfusion,11,37,,no,8,10,N
NCT02431442_inc_779_T37_T38,Females must not be pregnant and must have a negative serum pregnancy test result at the Screening Visit and Day -1.,pregnant,20,28,,not,13,16,N
NCT03131050_exc_141_T6_T5,Current Axis I primary psychiatric diagnosis other than major depressive disorder.,major depressive disorder,56,81,,other than,45,55,N
NCT03131050_exc_278_T21_T20,"History of clinically significant disease, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require treatment during the study.",stabilized,215,225,,not,211,214,N
NCT03131050_exc_278_T23_T20,"History of clinically significant disease, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require treatment during the study.",treatment,255,264,,not,211,214,N
NCT02810704_exc_615_T14_T13,Patients on chronic (longer than the prior 6 months) anticoagulation other than with antiplatelet medications;,antiplatelet,85,97,,other than,69,79,N
NCT01567605_exc_54_T8_T9,"colostomy, or do not perform regular bowel care for any reason",regular bowel care,29,47,,do not perform,14,28,N
NCT01567605_exc_54_T7_T9,"colostomy, or do not perform regular bowel care for any reason",colostomy,0,9,,do not perform,14,28,N
NCT01567605_exc_153_T13_T12,do not speak English,speak English,7,20,,not,3,6,N
NCT03208244_inc_28_T7_T5,Serum ALT within normal limits with no history of liver disease,liver disease,50,63,,no,17,19,N
NCT03208244_inc_92_T9_T8,Lack of sensitization (i.e. PRA < 20%) that would be expected to result in a high likelihood of needing aggressive immunosuppression to treat rejection,sensitization,8,21,,Lack of,0,7,N
NCT02330757_inc_0_T2_T1,Women without PCOS as defined by the Rotterdam criteria.,PCOS,14,18,,without,6,13,N
NCT02186782_exc_74_T12_T11,Presence of any infertility factor other than anovulation/oligoovulation.,anovulation,46,57,,other than,35,45,N
NCT02186782_exc_74_T13_T11,Presence of any infertility factor other than anovulation/oligoovulation.,oligoovulation,58,72,,other than,35,45,N
NCT03047538_exc_444_T34_T35,Women of childbearing age without reliable contraception,contraception,43,56,,without,26,33,N
NCT03047538_exc_444_T33_T35,Women of childbearing age without reliable contraception,reliable,34,42,,without,26,33,N
NCT02912182_inc_35_T4_T3,no pathological HINTS (examination criteria in acute vestibular syndrome),HINTS,16,21,,no,0,2,N
NCT01806558_exc_194_T10_T8,Are not scheduled to undergo conventional ultrasound       ,conventional ultrasound,29,52,,not,4,7,N
NCT03212352_inc_0_T4_T3,a crown-rump length = 6mm and no cardiac activity OR,cardiac activity,33,49,,no,30,32,N
NCT03212352_inc_53_T8_T7,a crown-rump length <6mm and no fetal growth at least one week later OR,fetal growth,32,44,,no,29,31,N
NCT03212352_inc_125_T13_T7,At least one week after diagnosis OR a discrepancy of at least one week between crown-rump length and calendar gestational age,discrepancy,39,50,,no,28,30,N
NCT03212352_inc_329_T26_T23,No signs of infection,signs of infection,3,21,,No,0,2,N
NCT03212352_inc_351_T27_T24,No signs of incomplete abortion,signs of incomplete abortion,3,31,,No,0,2,N
NCT03212352_inc_383_T30_T25,No contraindications for mifepristone or misoprostol,contraindications for,3,24,,No,0,2,N
NCT02735577_exc_81_T14_T13,"Current Moderate or Severe Substance Use Disorder, other than Alcohol, Nicotine or Caffeine Use Disorders",Alcohol Use Disorders,,,"[(62, 69), (62, 75)]",other than,52,62,N
NCT02735577_exc_81_T15_T13,"Current Moderate or Severe Substance Use Disorder, other than Alcohol, Nicotine or Caffeine Use Disorders",Nicotine Use Disorders,,,"[(71, 79), (71, 84)]",other than,52,62,N
NCT02735577_exc_81_T16_T13,"Current Moderate or Severe Substance Use Disorder, other than Alcohol, Nicotine or Caffeine Use Disorders",Caffeine Use Disorders,83,105,,other than,51,61,N
NCT02735577_exc_267_T25_T27,"Any current psychiatric disorder, other than Alcohol Use Disorder, that, in the judgment of the investigator, will require treatment that will interfere with study participation.",Alcohol Use Disorder,45,65,,other than,34,44,N
NCT02842424_exc_155_T19_T20,"Walking capacity significantly limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology,",claudication,64,76,,other than,53,63,N
NCT03122119_inc_210_T12_T10,Patient has no other comorbidities that contraindicate the procedure,comorbidities that contraindicate the procedure,21,68,,no,12,14,N
NCT03122119_inc_464_T18_T17,Patient must not have had a corticosteroid injection in the SI joint within the last three months,corticosteroid injection,28,52,,not,13,16,N
NCT03413891_inc_104_T11_T10,Not having taken the direct oral anticoagulant on the day of the extraction,anticoagulant,33,46,,Not,0,3,N
NCT02121145_exc_382_T37_T40,Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of investigational vaccine; oral corticosteroids in dosages of =0.5 mg/kg/d prednisolone or equivalent are excluded; inhaled or topical steroids are allowed,oral corticosteroids,165,185,,excluded,244,252,N
NCT00752310_exc_463_T42_T41,"no female subject of childbearing potential without use of effective nonhormonal birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period",willing to continue practicing,111,141,,not,107,110,N
NCT00752310_exc_463_T32_T23,"no female subject of childbearing potential without use of effective nonhormonal birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period",nonhormonal birth control,69,94,,without,44,51,N
NCT00752310_exc_463_T43_T23,"no female subject of childbearing potential without use of effective nonhormonal birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period",birth control methods,81,102,,without,44,51,N
NCT00236340_exc_141_T10_T11,Unability to give informed consent       ,give informed consent,13,34,,Unability to,0,12,N
NCT03249272_inc_36_T11_T9,Patients presenting for CMR with the clinical diagnosis of hypertrophic cardiomyopathy based on left ventricular wall thickness of at least =15 mm in the absence of any other cardiac or systemic cause of hypertrophy,cardiac cause of hypertrophy,,,"[(175, 182), (175, 195)]",absence,155,162,N
NCT03249272_inc_36_T10_T9,Patients presenting for CMR with the clinical diagnosis of hypertrophic cardiomyopathy based on left ventricular wall thickness of at least =15 mm in the absence of any other cardiac or systemic cause of hypertrophy,systemic cause of hypertrophy,186,215,,absence,154,161,N
NCT03249272_inc_252_T20_T19,"Patients presenting for CMR with the clinical diagnosis of idiopathic dilated cardiomyopathy based upon left ventricular ejection fraction =40%, LV end-diastolic diameter =55 mm or left ventricular end-systolic diameter =45 mm, and the absence of coronary stenoses on angiography.",coronary stenoses,247,264,,absence,236,243,N
NCT03249272_inc_533_T25_T24,Patients presenting for CMR evaluation of chest pain but without evidence of obstructive coronary artery disease either by coronary angiography or stress testing.,obstructive coronary artery disease,77,112,,without,57,64,N
NCT00917891_inc_573_T22_T23,"In the absence of the use of exogenous hormone(s), have a self-reported regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses",exogenous hormone,29,46,,absence,7,14,N
NCT00917891_inc_968_T46_T56,Willing to refrain from use of vaginal products or objects within 14 days prior to enrollment and for the duration of the study,vaginal products,31,47,,refrain,11,18,N
NCT00917891_inc_968_T47_T56,Willing to refrain from use of vaginal products or objects within 14 days prior to enrollment and for the duration of the study,objects vaginal,,,"[(51, 58), (51, 58)]",refrain,11,18,N
NCT03216967_exc_208_T21_T20,Women of child bearing potential unless they are using a birth control method,birth control method,57,77,,unless,33,39,N
NCT02713087_inc_0_T6_T5,Patients scheduled for supine-positioned elective craniotomy for supratentorial malignant and non-malignant brain tumors 3 cm or larger (measured as the largest diameter in any plane on MR images),malignant,80,89,,non,94,97,N
NCT02713087_inc_0_T4_T5,Patients scheduled for supine-positioned elective craniotomy for supratentorial malignant and non-malignant brain tumors 3 cm or larger (measured as the largest diameter in any plane on MR images),malignant,80,89,,non,94,97,N
NCT01803438_exc_1095_T40_T39,Subject has any significant congenital heart defect corrected or not (except for patent foramen ovale that is allowed).,patent foramen ovale,81,101,,except,70,76,N
NCT03475589_exc_53_T7_T9,Hypertension (high blood pressure) that can not be controlled by drugs;,controlled by drugs,51,70,,not,44,47,N
NCT03475589_exc_1050_T45_T46,Patients who can not tolerate apatinib treatment as judged by the investigator depending on the their medical history;,tolerate,21,29,,not,17,20,N
NCT01891383_exc_75_T8_T9,"History of disabling neurological or psychiatric condition such as epilepsy (besides posttraumatic epilepsy), multiple sclerosis, cortical stroke, hypoxic-ischemic encephalopathy, encephalitis, or schizophrenia",posttraumatic epilepsy,85,107,,besides,77,84,N
NCT03344042_inc_0_T4_T3,parturient in labour without cervical dilation and regular uterine contractions,cervical dilation,29,46,,without,21,28,N
NCT03344042_inc_0_T5_T3,parturient in labour without cervical dilation and regular uterine contractions,regular uterine contractions,51,79,,without,21,28,N
NCT01735955_exc_0_T4_T1,"Patient has been permanently discontinued from nilotinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason",treatment,57,66,,discontinued,29,41,N
NCT01735955_exc_0_T9_T8,"Patient has been permanently discontinued from nilotinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason",consent,167,174,,withdrawal,153,163,N
NCT01735955_exc_0_T5_T8,"Patient has been permanently discontinued from nilotinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason",unacceptable toxicity,94,115,,withdrawal,153,163,N
NCT01735955_exc_0_T10_T8,"Patient has been permanently discontinued from nilotinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason",any other reason,178,194,,withdrawal,153,163,N
NCT01735955_exc_0_T6_T8,"Patient has been permanently discontinued from nilotinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason",non-compliance,117,131,,withdrawal,153,163,N
NCT01735955_exc_943_T34_T32,"Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for 30 days after the final dose of nilotinib.",contraception,151,164,,unless,101,107,N
NCT02691793_exc_0_T4_T3,"Patients with second primary cancer, except:adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumor curatively treated with no evidence of disease for <= 5 years.",non-melanoma skin cancer,63,87,,except,37,43,N
NCT02691793_exc_0_T5_T3,"Patients with second primary cancer, except:adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumor curatively treated with no evidence of disease for <= 5 years.",in-situ cancer of the cervix,108,136,,except,37,43,N
NCT02624908_exc_993_T46_T48,Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma),basal cell carcinoma,,,"[(70, 80), (70, 79)]",except,73,79,N
NCT02624908_exc_993_T47_T48,Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma),squamous cell skin carcinoma,85,113,,except,63,69,N
NCT02557386_inc_109_T8_T11,No contraindications to general and regional anesthesia,contraindications,3,20,,No,0,2,N
NCT00061308_exc_0_T4_T3,Women of child-bearing potential that do not practice adequate contraception.,adequate contraception,54,76,,do not,38,44,N
NCT00061308_exc_157_T13_T18,"Concomitant or previous malignancies with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer from which the patient has been disease free for 5 years.",basal cell skin cancer,,,"[(78, 88), (78, 89)]",the exception of,42,58,N
NCT00061308_exc_157_T15_T18,"Concomitant or previous malignancies with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer from which the patient has been disease free for 5 years.",in situ cervical cancer,108,131,,the exception of,42,58,N
NCT00061308_exc_157_T16_T18,"Concomitant or previous malignancies with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer from which the patient has been disease free for 5 years.",incidental carcinoid,144,164,,the exception of,42,58,N
NCT00061308_exc_157_T17_T18,"Concomitant or previous malignancies with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer from which the patient has been disease free for 5 years.",other cancer,169,181,,the exception of,42,58,N
NCT00061308_exc_157_T14_T18,"Concomitant or previous malignancies with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer from which the patient has been disease free for 5 years.",squamous cell skin cancer,92,117,,the exception of,42,58,N
NCT01711801_inc_59_T6_T5,"Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, serology and urinalysis",evidence of any active or chronic disease,40,81,,absence,29,36,N
NCT01711801_inc_362_T20_T22,"Male subjects (whether surgically sterilized or not) with female partners of child-bearing potential must use two forms of contraception, one of which must be a barrier method, for the duration of the study and for 77 days after the last dose",surgically sterilized,23,44,,not,48,51,N
NCT01711801_inc_362_T21_T22,"Male subjects (whether surgically sterilized or not) with female partners of child-bearing potential must use two forms of contraception, one of which must be a barrier method, for the duration of the study and for 77 days after the last dose",surgically sterilized,23,44,,not,48,51,N
NCT03369379_inc_150_T11_T9,No previous use of vitamin D.,vitamin D,19,28,,No,0,2,N
NCT02946918_exc_83_T8_T9,Planned postoperative TSH goal other than 0.1-0.5 mU/L,0.1-0.5 mU/L,42,54,,other than,31,41,N
NCT02946918_exc_216_T18_T20,Use of medications that alter the absorption or metabolism of levothyroxine,absorption of levothyroxine,,,"[(34, 44), (34, 50)]",alter,29,34,N
NCT02946918_exc_216_T14_T20,Use of medications that alter the absorption or metabolism of levothyroxine,metabolism of levothyroxine,48,75,,alter,24,29,N
NCT01809041_inc_281_T19_T17,lack of serious hearing and vision impairment and be able to read so that neurobehavioral tests can be performed.,hearing impairment,,,"[(16, 23), (16, 26)]",lack of,2,9,N
NCT01809041_inc_281_T18_T17,lack of serious hearing and vision impairment and be able to read so that neurobehavioral tests can be performed.,vision impairment,28,45,,lack of,0,7,N
NCT03304496_inc_323_T16_T18,"Acute myocardial infarction with ST segment elevation, not perfused (without timely reperfusion therapy) with less than 4 weeks of evolution.",reperfusion therapy,84,103,,without,69,76,N
NCT03304496_inc_595_T29_T28,Acute myocardial infarction without ST segment elevation.,ST segment elevation,36,56,,without,28,35,N
NCT02370069_exc_385_T22_T23,history or records of immunosuppressive therapy (with the exception of topical corticosteroids) for more than 14 days and within 6 months of vaccination,topical corticosteroids,71,94,,exception,58,67,N
NCT03247413_exc_0_T4_T1,"patient not previously scheduled for radiofrequency ablation of the cervical, thoracic, or lumbar facets, or sacroiliac joints",radiofrequency ablation,37,60,,not,8,11,N
NCT03247413_exc_190_T15_T16,non-English speaking,English speaking,4,20,,non,0,3,N
NCT03016741_inc_1091_T36_T37,"Patients may have received chemotherapy for hormone-sensitive metastatic prostate cancer only, but it must not have lasted for more than 6 months.",lasted for more than 6 months,116,145,,not,107,110,N
NCT03017053_exc_99_T13_T14,The patient has received prior surgery for primary tumor or lymph node ( except for biopsy ),biopsy,84,90,,except for,73,83,N
NCT03017053_exc_378_T29_T31,Prior malignancy within the previous 5 years (except for cured skin basal cell carcinoma or cervical carcinoma in situ),cured skin basal cell carcinoma,57,88,,except for,46,56,N
NCT03017053_exc_378_T30_T31,Prior malignancy within the previous 5 years (except for cured skin basal cell carcinoma or cervical carcinoma in situ),cervical carcinoma in situ,92,118,,except for,46,56,N
NCT02427295_inc_228_T9_T10,No prior use of somatostatin analogues.,somatostatin analogues,16,38,,No,0,2,N
NCT03328052_inc_771_T7_T9,Patients must be either medication treatment naïve for behavioral illnesses or have no active medication treatments for at least 1 month prior to enrollment.,medication,24,34,,naïve,45,50,N
NCT03328052_inc_771_T12_T10,Patients must be either medication treatment naïve for behavioral illnesses or have no active medication treatments for at least 1 month prior to enrollment.,medication,24,34,,no,84,86,N
NCT01009359_exc_0_T14_T15,"Current unstable medical condition (e.g. unstable angina, myocardial infarction or coronary revascularization in the preceding 12 months, cardiac failure, chronic renal failure, chronic hepatic disease, severe pulmonary disease, blood disorders, poorly controlled diabetes, chronic infection)       ",controlled,253,263,,poorly,246,252,N
NCT02747940_inc_0_T3_T1,Control: devoid of any systemic or neurological diseases,systemic diseases,,,"[(23, 31), (23, 31)]",devoid,9,15,N
NCT02747940_inc_0_T2_T1,Control: devoid of any systemic or neurological diseases,neurological diseases,35,56,,devoid,9,15,N
NCT02092467_inc_40_T5_T4,Taking methotrexate without adequate control of symptoms,adequate control of symptoms,28,56,,without,20,27,N
NCT03208998_inc_0_T14_T13,"HBsAg and HBeAg positive for more than 6 months, HBV DNA detectable with ALT level abnormal lasted for three months and at least time190 IU/L or liver puncture biopsy demonstrated apparent inflammation, never treated before enrolled.",treated,209,216,,never,203,208,N
NCT02267616_exc_91_T6_T5,Not sexually active with a male partner,sexually active,4,19,,Not,0,3,N
NCT00343668_exc_434_T26_T27,"Pregnant or lactating women, women of childbearing potential not employing adequate contraception",contraception,84,97,,not employing,61,74,N
NCT00343668_exc_271_T15_T70,"Past or concurrent history of neoplasm other than stomach cancer, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri",stomach cancer,50,64,,other than,39,49,N
NCT00343668_exc_0_T1_T72,Other tumor type than adenocarcinoma,adenocarcinoma,22,36,,Other,0,5,N
NCT00343668_exc_271_T18_T71,"Past or concurrent history of neoplasm other than stomach cancer, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri",treated,88,95,,except for,66,76,N
NCT00650312_inc_32_T7_T6,"Sex: Male and non-pregnant, non-lactating female",lactating,32,41,,non,14,17,N
NCT00650312_inc_32_T4_T5,"Sex: Male and non-pregnant, non-lactating female",pregnant,18,26,,non,14,17,N
NCT01888965_inc_246_T18_T20,Patients in maintenance cohort must have had 2 consecutive CT scans showing stable disease and not be experiencing significant prior treatment-related toxicity above Grade 1.,treatment-related toxicity,133,159,,not,95,98,N
NCT01888965_inc_1280_T77_T78,Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and must not be lactating.,lactating,138,147,,not,131,134,N
NCT02546856_inc_47_T8_T7,"= 40% admitted in hospital, without contraindications for BB prescription with cardiologist up-titration prescription and without having achieved BB target dose previous discharge and signing informed consent.",contraindications,36,53,,without,28,35,N
NCT01314898_inc_59_T7_T8,Females must be of non-childbearing potential.,childbearing potential,23,45,,non,19,22,N
NCT02735902_exc_462_T31_T29,The patient does not require treatment with aspirin or any other antiplatelet agent,require,21,28,,not,17,20,N
NCT02979561_exc_955_T55_T54,Gastric ulcer or duodenal ulcer with clinical manifestations or endoscopically identified acute ulcer without signs of scarring during previous 30 days.,signs of scarring,110,127,,without,102,109,N
NCT02257580_exc_553_T40_T41,Not received neuraxial anesthesia,neuraxial anesthesia,13,33,,Not received,0,12,N
NCT02531724_exc_0_T4_T5,Ongoing treatment with inotropic drugs (not norepinephrine),norepinephrine,44,58,,not,24,27,N
NCT03253796_inc_1410_T68_T70,Has no history of untreated latent or active tuberculosis (TB) prior to Screening,tuberculosis (TB),45,62,,no,4,6,N
NCT00445029_exc_842_T43_T42,Linguistic barrier or psychological profile preventing the patient from signing the consent form.,signing the consent form,72,96,,preventing,44,54,N
NCT00397215_exc_1626_T78_T77,"Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to the first vaccination, or planned use during the study period.",study vaccine(s),86,102,,other than,71,81,N
NCT02536976_exc_896_T48_T46,"History of cancer in the preceding 2 years other than successfully treated, non-metastatic, squamous cell or basal cell carcinoma, or cervical cancer in situ.",basal cell carcinoma,109,129,,other,43,48,N
NCT02536976_exc_896_T49_T46,"History of cancer in the preceding 2 years other than successfully treated, non-metastatic, squamous cell or basal cell carcinoma, or cervical cancer in situ.",carcinoma squamous cell,,,"[(120, 129), (120, 133)]",other,51,56,N
NCT02536976_exc_896_T47_T46,"History of cancer in the preceding 2 years other than successfully treated, non-metastatic, squamous cell or basal cell carcinoma, or cervical cancer in situ.",cervical cancer in situ,134,157,,other,43,48,N
NCT02781610_exc_99_T11_T10,"Admission to the intensive care unit for current pulmonary exacerbation in the two weeks prior to Visit 2, unless admission was due to a desensitization protocol",desensitization protocol,137,161,,unless,107,113,N
NCT00989261_inc_1091_T47_T49,"Prior therapy with FLT3 inhibitors is permitted, except previous treatment with AC220.",treatment,65,74,,except,49,55,N
NCT03493919_inc_560_T23_T25,"Subjects must weigh at least 110 pounds (50 kg), but not to present obesity (BMI < 32kg/m2).",obesity,68,75,,not to present,53,67,N
NCT03493919_inc_653_T29_T28,Female subjects of non-childbearing potential may be enrolled in the study.,childbearing potential,23,45,,non-,19,23,N
NCT02595190_inc_398_T25_T24,"No Congenital,Mental and other Nervous system diseases",Congenital diseases,,,"[(3, 13), (3, 11)]",No,5,7,N
NCT02595190_inc_456_T37_T35,"No Serious Cardiac,Pulmonary,Hepatic and Nephritic disease","Cardiac,Pulmonary,Hepatic",11,36,,No,0,2,N
NCT02595190_inc_518_T33_T36,No history of drug allergy,drug,14,18,,No,0,2,N
NCT02595190_inc_548_T38_T34,"No pain(including dysmenorrhea) or drug use (e.g., antipyretics,sleeping pills) within the last month",pain,3,7,,No,0,2,N
NCT02595190_inc_548_T41_T34,"No pain(including dysmenorrhea) or drug use (e.g., antipyretics,sleeping pills) within the last month",drug,35,39,,No,0,2,N
NCT02595190_inc_398_T26_T24,"No Congenital,Mental and other Nervous system diseases",Mental disease,,,"[(14, 20), (14, 21)]",No,5,7,N
NCT00785213_inc_35_T5_T6,Non-smoking,smoking,4,11,,Non,0,3,N
NCT00785213_inc_48_T7_T8,"Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures)",pregnant,4,12,,Non,0,3,N
NCT02416765_exc_425_T46_T49,"Agents affecting gastric emptying (Motilium®, Prandase®, Victoza®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, SGLT-2 inhibitors and DPP-4 inhibitors) if not at a stable dose for 3 months.",stable dose,189,200,,not,180,183,N
NCT02416765_exc_740_T54_T52,"Oral steroids unless patients present a low stable dose (e.g. 10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef®).",low dose,,,"[(40, 43), (40, 44)]",unless,14,20,N
NCT02416765_exc_740_T53_T52,"Oral steroids unless patients present a low stable dose (e.g. 10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef®).",stable dose,44,55,,unless,14,20,N
NCT00050349_exc_773_T28_T3,Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports,warfarin,77,85,,with the exception of,9,30,N
NCT00050349_exc_983_T37_T66,"Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ",non-melanoma skin cancer,135,159,,except,109,115,N
NCT00050349_exc_983_T39_T66,"Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ",prostate cancer,161,176,,except,109,115,N
NCT00050349_exc_983_T40_T66,"Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ",cervical cancer in situ,181,204,,except,109,115,N
NCT00050349_exc_72_T5_T70,"Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start.",treated,72,79,,unless,38,44,N
NCT00050349_exc_72_T6_T70,"Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start.",been stable for,67,82,,unless,38,44,N
NCT00094861_exc_1000_T30_T28,Prior invasive malignancy during the past 3 years other than non-melanomatous skin cancer.,non-melanomatous skin cancer,61,89,,other than,50,60,N
NCT00094861_exc_1091_T32_T31,"Note: Patients with prior surgically-cured malignancies [eg, stage I breast cancer or prostate cancer, in-situ carcinoma of the cervix, etc] are not excluded; however, sponsor approval must be obtained before patient is randomized.",surgically-cured malignancies,26,55,,are not,141,148,N
NCT02062489_exc_0_T5_T4,The patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus;,controlled skin basal cell carcinoma,93,129,,except,86,92,N
NCT02062489_exc_0_T6_T4,The patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus;,skin squamous cell carcinoma,104,132,,except,86,92,N
NCT02062489_exc_0_T7_T4,The patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus;,carcinoma in situ of cervix uterus,120,154,,except,86,92,N
NCT02062489_exc_201_T12_T11,The patients have active infections that were not suitable for chemotherapy;,suitable for chemotherapy,50,75,,not,46,49,N
NCT02062489_exc_583_T23_T24,"The patients are pregnant or lactational, or they refuse to practice contraception during the whole trial.",contraception,69,82,,refuse to practice,50,68,N
NCT02062489_exc_583_T21_T24,"The patients are pregnant or lactational, or they refuse to practice contraception during the whole trial.",pregnant,17,25,,refuse to practice,50,68,N
NCT02062489_exc_583_T22_T24,"The patients are pregnant or lactational, or they refuse to practice contraception during the whole trial.",lactational,29,40,,refuse to practice,50,68,N
NCT01815580_exc_119_T9_T10,"Short course less than or equal to 21 days of corticosteroids is allowed; Systemic chemotherapeutic agents; Nephrotoxic systemic agents, including aminoglycosides, amphotericin B, cidofovir, cisplatin, foscarnet, pentamidine; Immunomodulatory treatments including Interleukin-2; Investigational agents",corticosteroids,46,61,,is allowed,62,72,N
NCT03132259_exc_63_T6_T5,No Beta-Blockers,Beta-Blockers,3,16,,No,0,2,N
NCT01446094_exc_268_T15_T16,Individuals with non-MRI compatible aneurysm clips,MRI compatible,21,35,,non,17,20,N
NCT01313676_exc_689_T37_T39,A moderate/severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable).,resolved,49,57,,not,45,48,N
NCT01313676_exc_1080_T52_T55,"Other diseases/abnormalities: Any life-threatening condition with life expectancy <3 years, other than vascular disease or COPD, that might prevent the subject from completing the study.",vascular disease,103,119,,other than,92,102,N
NCT01313676_exc_1080_T53_T55,"Other diseases/abnormalities: Any life-threatening condition with life expectancy <3 years, other than vascular disease or COPD, that might prevent the subject from completing the study.",COPD,123,127,,other than,92,102,N
NCT02529475_inc_168_T6_T8,Patients without history of inner ear disease,inner ear disease,28,45,,without,9,16,N
NCT03068897_inc_143_T8_T11,"Flank pain, that is pain originating from tissues lateral to the paraspinal muscles, will not be included.",Flank pain,0,10,,not,90,93,N
NCT03068897_inc_288_T15_T19,"Patients with non-musculoskeletal etiologies such as urinary tract infection, ovarian cysts, or influenza like illness will be excluded.",etiologies,34,44,,excluded,127,135,N
NCT03068897_inc_288_T40_T14,"Patients with non-musculoskeletal etiologies such as urinary tract infection, ovarian cysts, or influenza like illness will be excluded.",musculoskeletal,18,33,,non,14,17,N
NCT03068897_inc_899_T38_T37,Non-radicular pain.,radicular,4,13,,Non,0,3,N
NCT03068897_inc_919_T43_T42,Patients will be excluded if the pain radiates below the gluteal folds in a radicular pattern.,pain,33,37,,excluded,17,25,N
NCT03068897_inc_1155_T51_T52,"Prior to the acute attack of LBP, back pain cannot occur more frequently than once per month.",more frequently than once per month,57,92,,cannot,44,50,N
NCT02986659_inc_118_T14_T12,"Cancer, with no active treatment in the last year",active treatment,16,32,,no,13,15,N
NCT02565277_exc_0_T2_T1,"Have not received influenza vaccination in the past or cannot be vaccinated due to previous severe reaction to influenza vaccine, egg, latex, or thimerosol allergies, or refusal of vaccination",influenza vaccination,18,39,,not,5,8,N
NCT03561753_inc_392_T27_T26,"Males or non-pregnant, non-nursing females",pregnant,13,21,,non-,9,13,N
NCT03561753_inc_392_T25_T26,"Males or non-pregnant, non-nursing females",Males,0,5,,non-,9,13,N
NCT03561753_inc_392_T29_T28,"Males or non-pregnant, non-nursing females",nursing,27,34,,non-,9,13,N
NCT01491763_exc_257_T18_T16,No serious neurological abnormalities due to LAL,neurological abnormalities,11,37,,No,0,2,N
NCT02056288_exc_119_T10_T9,Known allergy to local anesthetics (7) Not scheduled for closed reduction with percutaneous pinning under general anesthesia,scheduled for,43,56,,Not,39,42,N
NCT00806273_exc_8_T2_T3,No current treatment plan at OHSU,treatment plan,11,25,,No,0,2,N
NCT01669369_inc_83_T8_T7,MRI showing no skip lesion,skip lesion,15,26,,no,12,14,N
NCT01895946_inc_24_T4_T5,"The presence of a solid, malignant tumour, excluding lymphoma, that is resistance to standard therapies or for which no standard therapies exist",lymphoma,53,61,,excluding,43,52,N
NCT02366819_inc_1045_T45_T44,2.5 x upper limit of normal for patients without liver metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver metastases,liver metastases,49,65,,without,41,48,N
NCT02570321_exc_304_T9_T8,No light perception in the affected eye,light perception,3,19,,No,0,2,N
NCT00846703_inc_56_T7_T6,No relapse of a previously unrecognized ALL,relapse,3,10,,No,0,2,N
NCT02560766_exc_0_T3_T2,History of a primary sleep disorder other than RLS that may significantly affect the symptoms of RLS.,RLS,47,50,,other,36,41,N
NCT03026088_exc_875_T58_T59,Atrioventricular block of second or third degree (without a pacemaker).,pacemaker,60,69,,without,50,57,N
NCT02106598_exc_193_T15_T16,"This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease.",chronic atrial fibrillation,52,79,,other than,166,176,N
NCT02106598_exc_193_T18_T16,"This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease.",persistent hepatitis,227,247,,other than,166,176,N
NCT02106598_exc_193_T22_T16,"This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease.",chronic active hepatitis,,,"[(52, 66), (52, 61)]",other than,166,176,N
NCT02106598_exc_193_T20_T16,"This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease.",heart disease,304,317,,other than,166,176,N
NCT02621489_exc_861_T53_T52,Patients with intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer are allowed to enter the trial.,intraepithelial squamous cell carcinoma,14,53,,allowed,136,143,N
NCT02621489_exc_861_T56_T52,Patients with intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer are allowed to enter the trial.,basal cell skin cancer,109,131,,allowed,136,143,N
NCT01715584_inc_73_T8_T9,hypertension medications taken on morning of surgery (except diuretics),diuretics,61,70,,except,54,60,N
NCT01118871_inc_699_T44_T45,no previous exposure to etravirine,etravirine,24,34,,no,0,2,N
NCT01118871_inc_957_T59_T61,"female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study:",surgically sterile,87,105,,not,83,86,N
NCT01118871_inc_957_T63_T61,"female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study:",post menopausal,128,143,,not,83,86,N
NCT03173092_exc_0_T2_T1,"Failure to have fully recovered (that is, less than or equal to [<=] Grade 1 toxicity) from the reversible effects of prior chemotherapy.",fully recovered,16,31,,Failure,0,7,N
NCT03173092_exc_1296_T72_T71,Participants with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.,complete resection,116,134,,not excluded,80,92,N
NCT02747940_exc_259_T17_T16,history of substance abuse (except painkillers),painkillers,35,46,,except,28,34,N
NCT02260700_exc_477_T45_T46,"Use of any prescription or over-the-counter medication, herbal medication, vitamins, or mineral supplements within 14 days prior to study drug administration (not including paracetamol).",paracetamol,173,184,,not,159,162,N
NCT02260700_exc_1005_T68_T69,Participant has a history of epilepsy or fits or unexplained black-outs other than vasovagal collapse       ,vasovagal collapse,83,101,,other than,72,82,N
NCT02419378_exc_1317_T31_T30,"History of malignancy, except basal skin cell carcinoma",basal skin cell carcinoma,30,55,,except,23,29,N
NCT02419378_exc_1373_T34_T35,Major psychiatric disorder that is not adequately controlled by treatment,adequately controlled,39,60,,not,35,38,N
NCT02419378_exc_1447_T37_T38,Epileptic seizures that are not adequately controlled by Treatment,adequately controlled,32,53,,not,28,31,N
NCT02419378_exc_2120_T72_T70,"Latent tuberculosis unless effective anti-tuberculosis therapy has been completed, or active tuberculosis.",completed,72,81,,unless,20,26,N
NCT02419378_exc_2280_T78_T77,Cervical cytology other than PAP I or PAP II (Papanicolaou) or cervical high risk human papillomavirus (HPV) positivity,PAP I,29,34,,other,18,23,N
NCT02419378_exc_2280_T82_T77,Cervical cytology other than PAP I or PAP II (Papanicolaou) or cervical high risk human papillomavirus (HPV) positivity,human papillomavirus,82,102,,other,18,23,N
NCT02630628_exc_0_T3_T2,"Renal disease unrelated to SLE (e.g. diabetes mellitus, other glomerular or tubulointerstitial disease, renovascular disease), or transplanted kidney.",SLE,27,30,,unrelated,14,23,N
NCT02630628_exc_1052_T65_T64,"Treatment with cyclophosphamide, leflunomide, or methotrexate for over 2 weeks, or use of biological agent(s) regardless of duration, within the past 6 months (Note: prior use of azathioprine, mizoribine, intravenous immunoglobulins and anti-malarials is allowed).",azathioprine,179,191,,allowed,255,262,N
NCT02630628_exc_1052_T67_T64,"Treatment with cyclophosphamide, leflunomide, or methotrexate for over 2 weeks, or use of biological agent(s) regardless of duration, within the past 6 months (Note: prior use of azathioprine, mizoribine, intravenous immunoglobulins and anti-malarials is allowed).",immunoglobulins,217,232,,allowed,255,262,N
NCT02630628_exc_1052_T66_T64,"Treatment with cyclophosphamide, leflunomide, or methotrexate for over 2 weeks, or use of biological agent(s) regardless of duration, within the past 6 months (Note: prior use of azathioprine, mizoribine, intravenous immunoglobulins and anti-malarials is allowed).",mizoribine,193,203,,allowed,255,262,N
NCT02630628_exc_1052_T68_T64,"Treatment with cyclophosphamide, leflunomide, or methotrexate for over 2 weeks, or use of biological agent(s) regardless of duration, within the past 6 months (Note: prior use of azathioprine, mizoribine, intravenous immunoglobulins and anti-malarials is allowed).",anti-malarials,237,251,,allowed,255,262,N
NCT03477851_exc_0_T1_T2,No consent,consent,3,10,,No,0,2,N
NCT00319748_exc_1217_T54_T55,Active coagulation disorder not controlled with medication,controlled with medication,32,58,,not,28,31,N
NCT00319748_exc_727_T32_T73,Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable),prior treated disease,50,71,,is allowable,65,77,N
NCT00319748_exc_1300_T63_T75,"Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated",localized (in-situ) disease,82,109,,except for,71,81,N
NCT00319748_exc_1300_T64_T75,"Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated",basal carcinomas,111,127,,except for,71,81,N
NCT00319748_exc_1300_T65_T75,"Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated",cutaneous squamous cell carcinomas,132,166,,except for,71,81,N
NCT00319748_exc_50_T4_T77,Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed),topical steroids,,,"[(83, 90), (83, 91)]",are allowed,111,122,N
NCT00319748_exc_50_T5_T77,Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed),inhaled steroids,94,110,,are allowed,111,122,N
NCT02426034_inc_24_T8_T7,"Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction) with measurable metastases outside the stomach (measuring = 10mm on spiral CT scan, satisfying the criteria in RECIST 1.1);",stomach,153,160,,outside,141,148,N
NCT01518946_inc_433_T22_T23,"The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out.",treated,135,142,,not,131,134,N
NCT02415257_inc_52_T6_T4,No measurable remaining vestibular function,remaining vestibular function,14,43,,No,0,2,N
NCT03445949_exc_0_T3_T2,indications to dual antiplatelet therapy other than atrial fibrillation or left atrial appendage occlusion at the time of enrollment or predicted appearance of such indications within the duration of the trial (eg. coronary artery disease),atrial fibrillation,52,71,,other than,41,51,N
NCT03445949_exc_0_T5_T2,indications to dual antiplatelet therapy other than atrial fibrillation or left atrial appendage occlusion at the time of enrollment or predicted appearance of such indications within the duration of the trial (eg. coronary artery disease),left atrial appendage occlusion,75,106,,other than,41,51,N
NCT03256864_inc_109_T8_T6,Liver Transplant Recipients have no acute rejection episodes within 3 months prior to the enrollment and are clinically stable,rejection episodes,42,60,,no,33,35,N
NCT03256864_exc_199_T14_T13,"History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.",localized basal cell carcinoma of the skin,54,96,,other than,43,53,N
NCT03256864_exc_420_T26_T24,"Existence of any surgical, medical or mental conditions, other than the current transplantation, which, in the opinion of the investigator, might interfere with the objectives of the study.",transplantation,80,95,,other than,57,67,N
NCT03407625_inc_54_T5_T6,No major fetal malformations,major fetal malformations,3,28,,No,0,2,N
NCT03407625_inc_105_T9_T8,No prior uterine scar,uterine scar,9,21,,No,0,2,N
NCT01000155_inc_854_T31_T30,Must agree not to donate blood or other bodily fluid while taking the study drug and for 28 days thereafter,Must agree to,,,"[(0, 10), (0, 2)]",not,11,14,N
NCT03056287_inc_350_T14_T16,"5) ability to walk without assistance and without an AFO on the treadmill ≥ 30 seconds at speeds ranging from 0.2-0.8 m/s,",AFO on the treadmill,53,73,,without,19,26,N
NCT03056287_inc_474_T19_T20,"6) no antidepressant medications or clinically able to discontinue medications,",antidepressant,6,20,,no,3,5,N
NCT03056287_inc_474_T21_T20,"6) no antidepressant medications or clinically able to discontinue medications,",clinically able to discontinue medications,36,78,,no,3,5,N
NCT02579928_inc_0_T9_T8,"MDD Cohort: Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID); CDRS-R score >40; Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing.",remission,135,144,,Failure,116,123,N
NCT02579928_inc_317_T39_T40,"Anxiety Cohort: Meet DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID); ADIS Clinical Severity Rating ≥4 (moderately severe) for any of the 4 included anxiety disorders; Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing; Failure to achieve remission with previous CBT or subject declines current CBT therapy",remission,339,348,,Failure,320,327,N
NCT02579928_inc_317_T60_T61,"Anxiety Cohort: Meet DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID); ADIS Clinical Severity Rating ≥4 (moderately severe) for any of the 4 included anxiety disorders; Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing; Failure to achieve remission with previous CBT or subject declines current CBT therapy",remission,339,348,,Failure,320,327,N
NCT01943409_exc_0_T2_T1,• Patients without PN during their hospitalization,PN,19,21,,without,11,18,N
NCT03536520_inc_0_T7_T6,"Healthy men and women, age 40-75 yrs, without any disease and need of medication.",disease,50,57,,without,38,45,N
NCT03536520_inc_0_T9_T6,"Healthy men and women, age 40-75 yrs, without any disease and need of medication.",medication,70,80,,without,38,45,N
NCT01322464_inc_157_T8_T14,"Subjects were to have no clinically significant abnormal findings on physical examination, ECG, medical history, or clinical laboratory results during screening.",abnormal findings,48,65,,no,22,24,N
NCT01322464_inc_320_T23_T26,"Subjects were to, in the opinion of the investigator, have no clinically significant abnormal findings of renal and hepatic function as determined by serum creatinine, total bilirubin, and transaminase levels.",abnormal findings,85,102,,no,59,61,N
NCT01322464_inc_531_T27_T28,Subjects were to be non-users of tobacco products (minimum of 6 months prior to the start of the study).,users of tobacco products,24,49,,non,20,23,N
NCT02429583_exc_498_T19_T18,"Any clinically significant abnormality or medical history or physical examination including history of immunodeficiency or autoimmune disease (in addition to HCV infection, for HCV group)",HCV infection,158,171,,in addition to,6,20,N
NCT03064867_exc_2436_T72_T19,"Major surgery, other than diagnostic surgery, within 2 weeks.",diagnostic surgery,26,44,,other than,15,25,N
NCT03064867_exc_1883_T57_T140,"Less than 2-year disease free from another primary malignancy (other than squamous or basal cell carcinoma of the skin, ""in-situ"" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen (PSA) levels).",squamous or basal cell carcinoma of the skin,74,118,,other than,37,47,N
NCT03064867_exc_1883_T59_T140,"Less than 2-year disease free from another primary malignancy (other than squamous or basal cell carcinoma of the skin, ""in-situ"" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen (PSA) levels).","""in-situ"" carcinoma of the cervix breast",,,"[(120, 153), (120, 126)]",other than,63,73,N
NCT03064867_exc_1883_T58_T140,"Less than 2-year disease free from another primary malignancy (other than squamous or basal cell carcinoma of the skin, ""in-situ"" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen (PSA) levels).","""in-situ"" carcinoma of the cervix",120,153,,other than,37,47,N
NCT03064867_exc_1883_T60_T140,"Less than 2-year disease free from another primary malignancy (other than squamous or basal cell carcinoma of the skin, ""in-situ"" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen (PSA) levels).",superficial bladder carcinoma,165,194,,other than,37,47,N
NCT03064867_exc_1883_T61_T140,"Less than 2-year disease free from another primary malignancy (other than squamous or basal cell carcinoma of the skin, ""in-situ"" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen (PSA) levels).",localized prostate cancer,218,243,,other than,37,47,N
NCT03064867_exc_2180_T65_T70,"Patients who have had completed all anti-cancer treatment for another primary malignancy more than 2 years prior to screening are eligible if they are not considered to have a ""currently active"" malignancy based on having less than a 30% risk of relapse.",anti-cancer treatment,36,57,,are eligible,126,138,N
NCT02816762_exc_48_T4,Dialysis for acute renal failure within the 6 previous months.,Dialysis,0,8,,,,,P
NCT01807897_exc_994_T37,Current use of a positive airway pressure device (including continuous or bi-level positive airway pressure or adaptive servo-ventilation) or supplemental oxygen therapy,positive airway pressure device,17,48,,,,,P
NCT02637076_exc_327_T25,radiation exposure exceeding 20mSv in last 12 months,radiation exposure,0,18,,,,,P
NCT02035904_inc_68_T7,"breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec.",DIN,16,19,,,,,P
NCT00962364_inc_107_T9,"dilated cardiomyopathy due to valvular heart disease, hypertensive heart disease, history of myocarditis (no active myocardial infection present)",myocarditis,93,104,,,,,P
NCT02109081_exc_0_T6,1) preoperative diagnosis of delirium or dementia; 2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing; 3) language barriers that would preclude testing; 4) preoperative steroid use within 3 days of surgery; or 5) anticipation of postoperative intubation.,delirium,29,37,,,,,P
NCT02573597_exc_0_T7,"<37 weeks gestation, H/o Cesarean Section, Multiple Gestation, Pre-eclampsia, Narcotics within 3 hours prior to labor epidural placement, Chronic Pain (as defined by chronic opiate consumption), Women who are participating in another study that will impact protocol",Narcotics,78,87,,,,,P
NCT02209545_inc_424_T31,"Can be previously treated with Depo-Lupron, Depo-Provera, or Oral Contraceptive pills",treated,18,25,,,,,P
NCT02109081_exc_0_T23,1) preoperative diagnosis of delirium or dementia; 2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing; 3) language barriers that would preclude testing; 4) preoperative steroid use within 3 days of surgery; or 5) anticipation of postoperative intubation.,within 3 days of surgery,264,288,,,,,P
NCT00989261_exc_519_T39,Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant,graft-versus-host disease,148,173,,,,,P
NCT02664558_exc_356_T56,Recent initiation (<8 weeks from Screening) or planned initiation of cardiopulmonary rehabilitation exercise program.,Recent,0,6,,,,,P
NCT02457442_inc_215_T17,Hypersensitivity or allergy to one of the study drugs,Hypersensitivity,0,16,,,,,P
NCT03444142_exc_402_T28,Blood Pressure =140/90 mmHg,Blood Pressure,0,14,,,,,P
NCT03168178_inc_61_T8,Admitted for labor management & develops a fever of 100.4 F or greater,fever,43,48,,,,,P
NCT02944292_inc_0_T1,Age 18 years or older,Age,0,3,,,,,P
NCT00480129_inc_0_T1,"Clinical diagnosis of allergic rhinitis based on sneeze attacks, runny/blocked/itchy nose in the absence of a common cold during the previous 12 months.",allergic rhinitis,22,39,,,,,P
NCT03589105_exc_36_T5,"Inability to complete an MRI (contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc…)",contraindications,30,47,,,,,P
NCT03336801_exc_0_T1,American Association of Anesthesiology class 1-3,American Association of Anesthesiology class,0,44,,,,,P
NCT03355469_inc_0_T4,Male or female >40 and <70 years old.,old,33,36,,,,,P
NCT00426751_exc_586_T31,Known severe renal (creatinine clearance <30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations =,Alanine transaminase (ALT),88,114,,,,,P
NCT02637076_exc_199_T17,significant unstable or uncontrolled medical/psychiatric disease,medical disease,,,"[(37, 44), (37, 44)]",,,,P
NCT02322203_exc_617_T30,Subjects with weight that varies greater than 20% over the past 3 months.,varies greater than 20%,26,49,,,,,P
NCT02965027_exc_5507_T154,"Sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra) will not be permitted during the study drug dose Titration Period, because of increased risk of hypotension in combination with alpha-1 blockers, but will be allowed at half the usual starting dose following the study drug dose Titration Period, per VA prescribing guidelines.",Sildenafil,0,10,,,,,P
NCT02664558_exc_916_T86,Chronic infection related to tuberculosis or fungal or mycobacterial disease.,infection,8,17,,,,,P
NCT02961582_inc_106_T8,Meet at least one other criterion of the Rome-IV criteria for idiopathic constipation based on the 3-week defecation diary (1),Rome-IV criteria for idiopathic constipation,41,85,,,,,P
NCT02783859_exc_284_T18,"Complicated (effusion, empyema or abscess) pneumonia, including tuberculosis",empyema,23,30,,,,,P
NCT02664558_exc_1045_T92,"Chronic infections including, but not limited to tuberculosis (TB), hepatitis B virus (HBV) or hepatitis C virus (HCV).",infections,8,18,,,,,P
NCT03119766_exc_1525_T74,Intake of medicines listed in the section 'Prohibited concomitant treatment' for 1 month prior to the enrollment in the trial.,medicines,10,19,,,,,P
NCT02816762_exc_774_T46,Previous treatment with CPAP,treatment,9,18,,,,,P
NCT02322203_exc_425_T23,Female subjects taking hormonal contraceptives or hormone replacement therapy may be included in this study only if they have been on a stable dose for at least 3 months.,stable dose,136,147,,,,,P
NCT02664558_exc_1170_T96,"History of portal hypertension or chronic liver disease, including positive serology for infection with HCV and/or HBV.",chronic liver disease,34,55,,,,,P
NCT02816762_exc_630_T43,Concomitant treatment with high doses of acetylsalicylic acid (> 500 mg/day) or continuous treatment with non-steroidal anti-inflammatory drugs,treatment,12,21,,,,,P
NCT02867618_exc_207_T27,Systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs.,prior to,102,110,,,,,P
NCT03119766_exc_660_T49,"Prior diagnosis of a class IV cardiovascular disease (according to the New York Heart Association, 1964), hypothyroidism, diabetes mellitus, chronic kidney disease (С3-5), or disease of liver with portal hypertension and/or severe decompensation (Child-Pugh score > 6).",severe decompensation,224,245,,,,,P
NCT02637076_exc_264_T19,significant history of head trauma/surgery or seizure disorder,head trauma,23,34,,,,,P
NCT00785213_exc_552_T29,Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study,drugs known to inhibit P-glycoprotein (P-gp),,,"[(27, 32), (27, 43), (27, 48)]",,,,P
NCT01807897_exc_658_T28,"Severe daytime sleepiness, defined as Epworth Sleepiness Scale score 18 or higher or a report of falling asleep driving during the previous year, and deemed a safety risk by study physician",Epworth Sleepiness Scale,38,62,,,,,P
NCT03355469_inc_306_T22,"Elevated triglycerides (=150 mg/dl), or on medication for treating the condition",triglycerides,9,22,,,,,P
NCT02431559_exc_2110_T144,"Other malignancy within 2 years prior to Day 1 of the study, except for those treated with surgical intervention only.",within 2 years prior to Day 1 of the study,17,59,,,,,P
NCT02416869_inc_0_T2,Healthy patients (ASA I),ASA,18,21,,,,,P
NCT03364036_exc_583_T35,"History of tuberculosis , presence of active tuberculosis, or latent tuberculosis",tuberculosis,11,23,,,,,P
NCT02596555_exc_989_T21,"Need for long-term treatment with a low molecular weight heparin, vitamin K antagonists or NOAC, for an indication other than the index PE episode, or for antiplatelet agents except acetylsalicylic acid at a dosage =100 mg/day;",PE episode,136,146,,,,,P
NCT02322203_exc_242_T11,Subjects with acute liver disease or active peptic ulcer disease.,peptic ulcer disease,44,64,,,,,P
NCT02765035_inc_124_T4,"Person is a K2, K3 or K4 ambulator based on Medicare Functional Classification Level (MFCL).",Medicare Functional Classification Level,44,84,,,,,P
NCT03363295_inc_136_T5,Patients over 18 years old,old,23,26,,,,,P
NCT00391690_inc_258_T16,"Patients without prostatectomy: 2 consecutive rises in PSA levels relative to a previous reference value, separated by one month.",2,32,33,,,,,P
NCT00718952_inc_22_T10,"Confirmed idiopathic pulmonary hypertension, connective tissue disease associated pulmonary hypertension, congenital heart disease(with Eisenmenger syndrome) associated pulmonary hypertension.",pulmonary hypertension,21,43,,,,,P
NCT03073603_exc_83_T4,Any new or definitely enlarging T2/FLAIR lesion or new gadolinium-enhancing lesion within the past three years (at least two scans separated by at least three years must be reviewed) on brain or spine MRI scan.,T2/FLAIR lesion,32,47,,,,,P
NCT02964416_inc_76_T4,American Society of Anaesthesiologists (ASA) 2 and stable ASA 3 patients,American Society of Anaesthesiologists,0,38,,,,,P
NCT00391690_inc_496_T23,The second confirmatory measurement taken one month after the first measurement must be greater than the first measurement.,second,4,10,,,,,P
NCT00989261_exc_519_T36,Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant,immunosuppressive drugs,89,112,,,,,P
NCT02876484_inc_0_T1,Uncomplicated RYGB performed minimum 3 months prior to the study.,RYGB,14,18,,,,,P
NCT00235170_exc_301_T11,Transmural myocardial infarction within the previous seven days and CK has not returned to normal;,Transmural myocardial infarction,0,32,,,,,P
NCT02831166_exc_589_T39,Severe concomitant disease with life expectancy below 12 months;,disease,19,26,,,,,P
NCT03355469_inc_387_T28,"Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), or on medication for treating the condition",HDL-cholesterol,8,23,,,,,P
NCT03355469_inc_115_T10,Not currently engaged in > 60 min/wk of exercise,engaged in exercise,,,"[(14, 24), (14, 22)]",,,,P
NCT02867618_inc_0_T8,Phase I: Patients must have histologically confirmed R/R NHL or HL (defined by WHO criteria).,R/R,53,56,,,,,P
NCT02323399_inc_201_T18,"Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure =128/78 mmHg (sitting, after 5 minutes of rest)",mean diastolic blood pressure,,,"[(61, 65), (61, 70), (61, 75)]",,,,P
NCT00718952_inc_264_T14,WHO pulmonary hypertension function II-III with non-responder to calcium channel blockers.,non-responder to calcium channel blockers,48,89,,,,,P
NCT02431559_exc_3105_T191,-Female subjects should refrain from breastfeeding throughout this period.,breastfeeding,37,50,,,,,P
NCT01911650_exc_309_T17,daily use of opioids for pain,opioids,13,20,,,,,P
NCT02664558_exc_1482_T118,"History of malignancy within the last 5 years, except nonmelanoma skin cancer and cervical carcinoma in situ treated with curative intent.",cervical carcinoma in situ,82,108,,,,,P
NCT00344318_exc_584_T27,"Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations",vaccination,9,20,,,,,P
NCT02804646_exc_0_T22,"1) pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;2) existing severe acute infection and is not controlled; or purulent and chronic infection, delayed healing wounds; 3) the original severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension; 4) suffering from neurological and psychiatric diseases or mental disorders is not easy to control, poor compliance, and can not be described with treatment responders; primary brain or central nervous metastasis disease has not been controlled, with significant cranial hypertension or neuropsychiatric symptoms; 5) have bleeding tendencies; 6) other researchers believe that patients should not participate in the present trial.",arrhythmias,335,346,,,,,P
NCT02858180_exc_617_T26,Hemoglobin (Hb) < 8 g/dL,Hemoglobin,0,10,,,,,P
NCT03355469_inc_306_T25,"Elevated triglycerides (=150 mg/dl), or on medication for treating the condition",medication for treating,43,66,,,,,P
NCT00785213_exc_552_T27,Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study,drugs known to inhibit cytochrome (CYP) P450 enzymes,,,"[(27, 32), (27, 43), (27, 56)]",,,,P
NCT01891513_inc_193_T12,Score ≤ 10 on the Short Physical Performance Battery OR Walking speed < 1.2 m/sec during 400 m usual-paced test,Short Physical Performance Battery,18,52,,,,,P
NCT03355469_inc_242_T16,Increased waist circumference (=102 cm in men; =88 cm in women),Increased,0,9,,,,,P
NCT02965027_exc_525_T44,"Acute or serious medical illness or unstable chronic medical illness (e.g., unstable angina, myocardial infarction within 6 months, congestive heart failure, clinically significant or concerning cardiac arrhythmias; preexisting hypotension [systolic blood pressure<110] or orthostatic hypotension [systolic drop >20 mm",cardiac arrhythmias,195,214,,,,,P
NCT03351972_exc_10_T2,severe gastroparesis requiring endoscopic placement of capsule,gastroparesis,7,20,,,,,P
NCT02867618_inc_410_T29,Phase II: Patients must have histologically confirmed R/R NHL (as defined by WHO criteria).,histologically,29,43,,,,,P
NCT01807897_inc_189_T12,No change in active cardiac medications for 4 weeks prior to randomization,cardiac medications,20,39,,,,,P
NCT02867618_inc_194_T14,"In addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.",NHL,27,30,,,,,P
NCT02109081_exc_0_T10,1) preoperative diagnosis of delirium or dementia; 2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing; 3) language barriers that would preclude testing; 4) preoperative steroid use within 3 days of surgery; or 5) anticipation of postoperative intubation.,MMSE score,54,64,,,,,P
NCT02637076_exc_327_T25,radiation exposure exceeding 20mSv in last 12 months,radiation exposure,0,18,,,,,P
NCT02437045_inc_0_T1,"Bloodstream infection with Enterobacter spp., Serratia marcescens, Providencia spp., Morganella morganii or Citrobacter freundii (i.e. likely AmpC-producer), and susceptibility to 3rd generation cephalosporins (i.e. ceftriaxone, cefotaxime or ceftazidime), meropenem and piperacillin-tazobactam from at least one blood culture draw.",Bloodstream infection,0,21,,,,,P
NCT01483118_inc_0_T3,Patients aged greater than 18 years of age,age,9,12,,,,,P
NCT00391690_inc_195_T9,Patients who have undergone prostatectomy: any rise in PSA or,prostatectomy,28,41,,,,,P
NCT02973035_exc_1234_T62,Sitting systolic BP < 100 mmHg,systolic BP,8,19,,,,,P
NCT02965027_exc_83_T5,History of TBI more severe than mild by DVBIC criteria,DVBIC criteria,40,54,,,,,P
NCT01884337_exc_193_T18,"Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days other than the elective knee/hip surgery",surgery,40,47,,,,,P
NCT02323399_inc_53_T6,Subject is scheduled for a procedure that requires general or neuraxial anesthesia,scheduled for a procedure,11,36,,,,,P
NCT00989261_exc_1774_T78,"Women who are pregnant, lactating, or unwilling to use contraception if of childbearing potential",childbearing potential,75,97,,,,,P
NCT02384850_inc_332_T28,Age ≥18 years,Age,0,3,,,,,P
NCT03323047_exc_159_T4,"Patients with chronic conditions that would limit our ability to develop the study according to objectives, such as neurodevelopmental conditions preventing patients from understanding the Oucher tool",neurodevelopmental conditions,116,145,,,,,P
NCT02783859_exc_232_T11,Severe malnutrition (weight-for-height Z-score <-3),malnutrition,7,19,,,,,P
NCT01807897_inc_300_T17,"Moderate to severe central or mixed central and obstructive sleep apnea, defined as an apnea-hypopnea index (AHI) 15 events per hour, with a central AHI >5 events/hour",central sleep apnea,,,"[(19, 26), (19, 30)]",,,,P
NCT02209545_inc_148_T9,Age = 18 years and = 50 years,Age,0,3,,,,,P
NCT02970773_inc_0_T1,Motor complete tetraplegia for at least 3 months,tetraplegia,15,26,,,,,P
NCT02590822_inc_508_T23,"Body mass index > 30Kg/m2 or > 27.5 Kg/m2 (South Asian),",Body mass index,0,15,,,,,P
NCT01205334_inc_172_T17,Life expectancy 6 weeks or greater,Life expectancy,0,15,,,,,P
NCT02573597_exc_0_T13,"<37 weeks gestation, H/o Cesarean Section, Multiple Gestation, Pre-eclampsia, Narcotics within 3 hours prior to labor epidural placement, Chronic Pain (as defined by chronic opiate consumption), Women who are participating in another study that will impact protocol",opiate,174,180,,,,,P
NCT00480129_inc_154_T9,History of positive skin prick test or blood radio-allergosorbent test (RAST) to grass and/or ragweed pollen,skin prick test,20,35,,,,,P
NCT01491295_inc_0_T4,HBsAg-positive for more than 6 months (HBeAg-positive or HBeAg-negative).,HBeAg,39,44,,,,,P
NCT02664558_exc_2080_T148,"Transaminases (alanine transaminase, aspartate transaminase) levels >3 × upper limit of normal (ULN) and/or bilirubin level >2 × ULN.",Transaminases levels,,,"[(0, 13), (0, 6)]",,,,P
NCT02141061_exc_356_T30,(ALT or AST exceeding 2.0 x ULN AND total bilirubin exceeding 1.5 x ULN at screening and confirmed on repeat).,ALT,1,4,,,,,P
NCT01314898_exc_155_T7,"Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary.",Serum potassium,0,15,,,,,P
NCT02431559_exc_3392_T199,Subjects must not donate blood while on study and for at least 90 days following the last MEDI4736 treatment.,donate blood,18,30,,,,,P
NCT00785213_exc_552_T27,Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study,drugs known to inhibit cytochrome (CYP) P450 enzymes,,,"[(27, 32), (27, 43), (27, 56)]",,,,P
NCT03323047_exc_0_T1,Patients Level III or greater on the American Society of Anesthesiologists (ASA) physical status classification system (as determined by the anesthesiologist),American Society of Anesthesiologists (ASA) physical status,37,96,,,,,P
NCT03318393_exc_0_T2,Patients with known or suspected heparin induced thrombocytopenia prior to consent,thrombocytopenia,49,65,,,,,P
NCT02664558_exc_2080_T148,"Transaminases (alanine transaminase, aspartate transaminase) levels >3 × upper limit of normal (ULN) and/or bilirubin level >2 × ULN.",Transaminases levels,,,"[(0, 13), (0, 6)]",,,,P
NCT02762851_exc_0_T1,Anaphylactic reaction to a previous dose of TIV(trivalent influenza vaccine),Anaphylactic reaction,0,21,,,,,P
NCT02437045_inc_0_T3,"Bloodstream infection with Enterobacter spp., Serratia marcescens, Providencia spp., Morganella morganii or Citrobacter freundii (i.e. likely AmpC-producer), and susceptibility to 3rd generation cephalosporins (i.e. ceftriaxone, cefotaxime or ceftazidime), meropenem and piperacillin-tazobactam from at least one blood culture draw.",Serratia marcescens,46,65,,,,,P
NCT00989261_exc_1246_T53,Major surgery within 4 weeks prior to enrollment in the study,Major surgery,0,13,,,,,P
NCT00426751_exc_465_T22,History of allergic reaction to abciximab or eptifibatide or any component used in the study (including contrast media),History,0,7,,,,,P
NCT02831166_exc_589_T40,Severe concomitant disease with life expectancy below 12 months;,life expectancy,32,47,,,,,P
NCT02590822_inc_367_T18,"Poorly managed diet controlled diabetes (with HbA1c > 6.5% , not currently taking any glucose lowering therapy, meeting BMI inclusion range)",diabetes,31,39,,,,,P
NCT03126214_exc_433_T35,"History of ""Major Bleeding"" at any point (defined as overt bleeding at a critical site including intracranial, intraspinal, intraocular, pericardial, or retroperitoneal; or bleed requiring hospitalization).",critical site,73,86,,,,,P
NCT02831166_exc_38_T4,"Chronic use of vitamin K antagonists or direct thrombin inhibitors, or oral Xa-factor antagonists;",vitamin K antagonists,15,36,,,,,P
NCT01774019_exc_53_T4,"Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers",Biliary strictures,0,18,,,,,P
NCT01807897_exc_848_T31,Awake resting oxyhemoglobin saturation <89%,oxyhemoglobin saturation,14,38,,,,,P
NCT02964416_inc_76_T7,American Society of Anaesthesiologists (ASA) 2 and stable ASA 3 patients,ASA,40,43,,,,,P
NCT02526823_exc_92_T7,"Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;",heart disease,21,34,,,,,P
NCT01177891_exc_0_T1,Blood donation of more than 450ml in the previous three months.,Blood donation,0,14,,,,,P
NCT02654912_exc_0_T13,"contraindications from manufacturer for medications including currently taking haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin",lumefantrine,242,254,,,,,P
NCT00989261_exc_519_T39,Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant,graft-versus-host disease,148,173,,,,,P
NCT00236340_inc_0_T4,Pregnant women with abdomen discumfort and ultrasound diagnosis of polyhydramnios (AFI>25cm),ultrasound,43,53,,,,,P
NCT02499185_inc_11_T4,"High risk patients: General Surgery AKI Risk Index Class III, IV or V",General Surgery AKI Risk Index,20,50,,,,,P
NCT02965027_exc_1523_T92,"Active psychosis or psychotic disorder, severe depression (as determined per clinician prescriber judgment), severe psychiatric instability or severe situational life crisis (including evidence of being actively suicidal or homicidal).",situational life crisis,150,173,,,,,P
NCT02965027_exc_525_T39,"Acute or serious medical illness or unstable chronic medical illness (e.g., unstable angina, myocardial infarction within 6 months, congestive heart failure, clinically significant or concerning cardiac arrhythmias; preexisting hypotension [systolic blood pressure<110] or orthostatic hypotension [systolic drop >20 mm",myocardial infarction,93,114,,,,,P
NCT00989261_exc_519_T46,Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant,toxicity,244,252,,,,,P
NCT03079141_exc_867_T55,"(relative) Contraindications for photodynamic treatment (pregnancy, porphyria, severely disturbed liver function).",Contraindications,11,28,,,,,P
NCT02141061_exc_3_T15,"Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy",six (6) months or more,55,77,,,,,P
NCT02862314_exc_912_T37,patients with haemodynamic instability of septic origin or a respiratory insufficiency (defined by a ratio Pa02/Fi02 = 200 mmHg and PEP = 5 cmH2O),espiratory insufficiency,62,86,,,,,P
NCT03073603_exc_1037_T54,"History of other chronic neurological illnesses that might mimic MS with chronic or intermittent symptoms (i.e. ALS, myasthenia gravis, chronic neuropathy, etc.)",chronic neurological illnesses,17,47,,,,,P
NCT03250507_inc_0_T2,"Elective open abdominal hysterectomy with midline incision, age > 18 years, American Society of Anesthesiologist classification score (ASA classification) 1-3.",open abdominal hysterectomy,9,36,,,,,P
NCT02858180_exc_819_T40,"Severe renal impairment creatinine clearance (CrCl), i.e. < 30 mL/min.",renal impairment,7,23,,,,,P
NCT03345589_inc_52_T5,Treated with Ursodeoxycholic Acid in West China Hospital for at least 6 month and suboptimal response to Ursodeoxycholic Acid,suboptimal response,82,101,,,,,P
NCT03355469_inc_387_T32,"Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), or on medication for treating the condition",men,37,40,,,,,P
NCT03663387_exc_760_T52,"Individuals taking over the counter memory enhancing or protecting medications (e.g. ginkgo biloba, vitamins) are not excluded.",over the counter memory enhancing medications,,,"[(19, 52), (19, 30)]",,,,P
NCT01816997_exc_74_T7,"Previous diabetic history, coronary artery disease",diabetic,9,17,,,,,P
NCT03073603_exc_479_T26,Use of oral steroids for no greater than 14 days given for a non-MS condition is not exclusionary.,oral steroids,7,20,,,,,P
NCT03079141_exc_670_T40,Continuous and/or progressive visual loss > 18 months or serous detachment on OCT > 18 months;,visual loss,30,41,,,,,P
NCT01807897_inc_300_T21,"Moderate to severe central or mixed central and obstructive sleep apnea, defined as an apnea-hypopnea index (AHI) 15 events per hour, with a central AHI >5 events/hour",apnea-hypopnea index,87,107,,,,,P
NCT02961582_inc_324_T25,Lumpy or hard stools in =25% of defecations,defecations,32,43,,,,,P
NCT02788045_inc_331_T15,"Female participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [beta hCG]) at the Screening visit, and a negative urine pregnancy test pre-dose on Day 1",serum pregnancy test,67,87,,,,,P
NCT02431559_exc_1378_T107,"Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit.",ischemia,29,37,,,,,P
NCT02664558_exc_1866_T136,"Concurrent regular use of another leukotriene pathway inhibitor, including over-the-counter medications or herbal remedies.",leukotriene pathway inhibitor,34,63,,,,,P
NCT00344318_exc_1085_T53,"History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease.",seizures,11,19,,,,,P
NCT02973035_exc_229_T16,Clinically significant pulmonary disease.,pulmonary disease,23,40,,,,,P
NCT00445029_inc_421_T5,Patients with allergic contact dermatitis to para-phenylenediamine (PPD) based on a history of PPD contact dermatitis and positive PPD patch tests.,allergic contact dermatitis,14,41,,,,,P
NCT02984475_exc_0_T1,Patients with renal impairment (serum creatinine more than twice the upper limit of normal).,renal impairment,14,30,,,,,P
NCT02570230_inc_0_T1,ASA physical status 1-3,ASA physical status,0,19,,,,,P
NCT00235170_exc_580_T25,Left main stenosis of 50% or more;,Left main stenosis,0,18,,,,,P
NCT00867958_inc_37_T3,Patient is scheduled for a non-emergency procedure.,non-emergency procedure,27,50,,,,,P
NCT03151603_inc_0_T2,Women (18-75 years) with suspected UTI,years,13,18,,,,,P
NCT00317148_exc_405_T20,Palpable fibroids or uterine prolapse: Grade 2 or 3.,Grade,39,44,,,,,P
NCT03045562_inc_78_T4,Subjects of STEMI who underwent primary PCI within the first 12 hours.,STEMI,12,17,,,,,P
NCT02557412_inc_306_T9,mg / dl or LDL-cholesterol = 150,LDL-cholesterol,11,26,,,,,P
NCT03373669_exc_443_T29,History of diarrhoea in 7 days prior to first dose of vaccine (defined as =3 unformed loose stools in 24 hours).,unformed loose stools in 24 hours,77,110,,,,,P
NCT00344318_exc_361_T16,Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3.,Planned,0,7,,,,,P
NCT02961582_inc_0_T4,An average defecation frequency (DF) of <3 per week based on a 3-week defecation diary (patient-reported),3-week defecation diary,63,86,,,,,P
NCT02867618_inc_0_T1,Phase I: Patients must have histologically confirmed R/R NHL or HL (defined by WHO criteria).,histologically,28,42,,,,,P
NCT00344318_exc_361_T17,Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3.,vaccine,44,51,,,,,P
NCT00718952_inc_0_T1,Subjects aged 12-65.,aged,9,13,,,,,P
NCT01491295_inc_88_T16,"Under lamivudine/adefovir treatment for more than 1 year due to previous lamivudine resistance (LAM-R), current HBV DNA is undetectable (< 20 IU/ml) during enrollment.",HBV DNA,112,119,,,,,P
NCT02961582_inc_287_T18,Straining during =25% of defecations,Straining,0,9,,,,,P
NCT02365870_exc_66_T5,Subjects with less than one year duration of Parkinson's,Parkinson's,45,56,,,,,P
NCT02003339_exc_224_T15,"Previous treatment by chemoembolization, radiofrequency less than 3 months before radioembolization",chemoembolization,22,39,,,,,P
NCT03336801_exc_234_T18,Depressed kidney function and/or AKI,kidney function,10,25,,,,,P
NCT02762851_exc_242_T12,Guillain-Barré syndrome within eight weeks of a previous influenza vaccine,Guillain-Barré syndrome,0,23,,,,,P
NCT02526823_exc_92_T9,"Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;",ventricular tachycardia,54,77,,,,,P
NCT03234816_inc_0_T2,full term singleton pregnant women,pregnant,20,28,,,,,P
NCT03056391_inc_3_T6,Patient age ≥ 12 years,age,8,11,,,,,P
NCT02526823_exc_323_T22,"patients with severe allergic constitution, or those who are allergic to or intolerant of drug composition in chemotherapy regimens; with other malignant tumors in the past 5 years;",allergic,21,29,,,,,P
NCT02678962_exc_0_T7,"Preexisting ocular diseases or conditions other than age related cataracts, have contraindications for cataract surgery;",contraindications,81,98,,,,,P
NCT02678962_exc_121_T10,Preexisting systemic diseases or conditions that may confound the results of the study;,systemic diseases,12,29,,,,,P
NCT02457442_inc_176_T14,Body mass index > 35,Body mass index,0,15,,,,,P
NCT01884337_exc_193_T18,"Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days other than the elective knee/hip surgery",surgery,40,47,,,,,P
NCT02431559_exc_963_T79,"History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti-arrhythmic medication.",ventricular arrhythmia,19,41,,,,,P
NCT02678962_exc_454_T23,Systemic or ocular medications that may confound the outcome of the intervention,Systemic medications,,,"[(0, 8), (0, 11)]",,,,P
NCT02322203_exc_0_T1,"Subjects taking any lipid modification therapy, including but not limited to statins, fibrates and bile acid sequestrants.",lipid modification therapy,20,46,,,,,P
NCT01064752_exc_3_T4,Taking a tetracycline within 6 months or history of adverse reaction to minocycline or another tetracycline.,adverse reaction,52,68,,,,,P
NCT02553226_exc_240_T15,Fetal weight estimation > 4500 g (clinical or ultrasonic),Fetal weight estimation,0,23,,,,,P
NCT02531971_inc_890_T14,"Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)",pain,73,77,,,,,P
NCT02973035_exc_271_T18,"Untreated hyperthyroidism, or hypothyroidism.",hyperthyroidism,10,25,,,,,P
NCT03364036_exc_665_T41,Evidence or suspect of Progressive Multifocal Leukoencephalopathy (PML) in Magnetic Resonance Imaging (MRI).,Progressive Multifocal Leukoencephalopathy (PML),23,71,,,,,P
NCT02867618_inc_502_T32,Patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.,NHL,14,17,,,,,P
NCT01064752_exc_327_T26,Active opportunistic infection or active neurological disease that might confound evaluation.,opportunistic infection,7,30,,,,,P
NCT02788045_inc_76_T4,"Is healthy on the basis of physical examination, medical history, electrocardiogram (ECG), and vital signs measurement performed at screening",healthy,3,10,,,,,P
NCT03119766_exc_660_T39,"Prior diagnosis of a class IV cardiovascular disease (according to the New York Heart Association, 1964), hypothyroidism, diabetes mellitus, chronic kidney disease (С3-5), or disease of liver with portal hypertension and/or severe decompensation (Child-Pugh score > 6).",cardiovascular disease,30,52,,,,,P
NCT02224040_exc_84_T11,Inability to swallow oral medication,Inability to swallow oral medication,0,36,,,,,P
NCT01884337_exc_392_T37,Creatinine clearance <30 mL/min,Creatinine clearance,0,20,,,,,P
NCT00391690_inc_258_T16,"Patients without prostatectomy: 2 consecutive rises in PSA levels relative to a previous reference value, separated by one month.",2,32,33,,,,,P
NCT02035800_inc_30_T4,Satisfying the 1987 American College of Rheumatology (ACR) criteria for RA,RA,72,74,,,,,P
NCT02431559_exc_3105_T193,-Female subjects should refrain from breastfeeding throughout this period.,throughout this period.,51,74,,,,,P
NCT03117608_exc_46_T4,"Patients participating in previous, concurrent or not, trials (ongoing or completed within three months);",trials participating in,,,"[(55, 61), (55, 71)]",,,,P
NCT00989261_exc_1313_T56,"Radiation therapy within 4 weeks prior to, or concurrent with study",Radiation therapy,0,17,,,,,P
NCT03477851_inc_0_T3,Patients with foot fracture scheduled for surgical repair in spinal anesthesia,surgical repair,42,57,,,,,P
NCT02437045_inc_490_T22,No more than 72 hours has elapsed since the first positive blood culture collection.,blood culture collection,59,83,,,,,P
NCT00426751_exc_586_T35,Known severe renal (creatinine clearance <30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations =,renal insufficiency,,,"[(13, 18), (13, 26)]",,,,P
NCT00989261_exc_397_T28,Persistent clinically significant non-hematological toxicity that is Grade >1 by NCI CTCAE v4 from prior chemotherapy,Grade >1 by NCI CTCAE v4,69,93,,,,,P
NCT01064752_exc_444_T33,Hemoglobin < 10 Gms/dL.,Hemoglobin,0,10,,,,,P
NCT00445029_inc_294_T30,Patients must be registered in a social security system or with a health insurance coverage,registered in a social security system,17,55,,,,,P
NCT01175044_exc_171_T6,Any condition requiring antibiotics 14 days prior to arriving for surgery.,antibiotics,24,35,,,,,P
NCT02384850_inc_3_T13,Patients with histologically confirmed diagnosis of colorectal cancer presenting with unresectable stage IV (UICC) disease (primary tumor may be present),disease,115,122,,,,,P
NCT02537899_exc_22_T3,Multiple significant trauma (i.e. significant intracranial and extracranial injuries including limb fractures) that would limit observation of recovery from spinal cord injury,trauma,21,27,,,,,P
NCT01794793_exc_889_T5,Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment.,Female sterilization,0,20,,,,,P
NCT02965027_exc_2162_T117,Current participation in transcranial magnetic stimulation studies,transcranial magnetic stimulation studies,25,66,,,,,P
NCT02431559_exc_1378_T102,"Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit.",peripheral ischemia,18,37,,,,,P
NCT01959425_exc_1089_T48,"Contraindication to anticoagulation (i.e., heparin, warfarin or another commercially available anticoagulation medication)",Contraindication,0,16,,,,,P
NCT02714725_inc_0_T6,"Adult patients aged (>18), males and females, undergoing elective coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).",surgery coronary artery bypass graft,,,"[(102, 109), (102, 130)]",,,,P
NCT01891513_inc_193_T14,Score ≤ 10 on the Short Physical Performance Battery OR Walking speed < 1.2 m/sec during 400 m usual-paced test,Walking speed,56,69,,,,,P
NCT02323399_inc_201_T14,"Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure =128/78 mmHg (sitting, after 5 minutes of rest)",diabetes,25,33,,,,,P
NCT02664558_exc_1866_T136,"Concurrent regular use of another leukotriene pathway inhibitor, including over-the-counter medications or herbal remedies.",leukotriene pathway inhibitor,34,63,,,,,P
NCT02964416_exc_245_T16,Obesity (women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2),body mass index,22,37,,,,,P
NCT00989261_exc_2113_T97,"History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the possible exception of patients in complete remission       ",cancer,11,17,,,,,P
NCT01907230_inc_25_T10,HBsAg-positive for more than 6 months and HBV DNA < 2000 IU/ml (Subgroup 1)or HBsAg-negative but anti-HBc positive with HBV DNA < 2000 IU/ml,anti-HBc,97,105,,,,,P
NCT01807897_exc_273_T13,Poorly controlled diabetes (HbA1c > 9.0),diabetes,18,26,,,,,P
NCT02965027_exc_525_T46,"Acute or serious medical illness or unstable chronic medical illness (e.g., unstable angina, myocardial infarction within 6 months, congestive heart failure, clinically significant or concerning cardiac arrhythmias; preexisting hypotension [systolic blood pressure<110] or orthostatic hypotension [systolic drop >20 mm",hypotension,228,239,,,,,P
NCT02862314_exc_488_T14,"immunodepressed patients (bone marrow transplant patients, patients with severe neutropenia),",immunodepressed,0,15,,,,,P
NCT01491763_inc_236_T26,"Patients without functional impairment of organs: liver function: total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease.",cardiac function,304,320,,,,,P
NCT03467750_inc_67_T5,Children undergoing elective tonsillectomy or adenotonsillectomy at Children's Healthcare of Atlanta Egleston location,tonsillectomy,29,42,,,,,P
NCT02109081_exc_0_T10,1) preoperative diagnosis of delirium or dementia; 2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing; 3) language barriers that would preclude testing; 4) preoperative steroid use within 3 days of surgery; or 5) anticipation of postoperative intubation.,MMSE score,54,64,,,,,P
NCT02644629_inc_10_T3,"Diagnosis of MDD (Major Depressive Disorder), made or affirmed by a senior psychiatrist in Shalvata",MDD,13,16,,,,,P
NCT01228279_inc_31_T6,Patients with end-stage renal disease(ESRD)/chronic kidney disease(CKD)stage 5,chronic kidney disease,44,66,,,,,P
NCT03151603_inc_0_T4,Women (18-75 years) with suspected UTI,UTI,35,38,,,,,P
NCT03249272_exc_420_T27,Advanced heart block or sinus node dysfunction,heart block,9,20,,,,,P
NCT03073603_exc_83_T5,Any new or definitely enlarging T2/FLAIR lesion or new gadolinium-enhancing lesion within the past three years (at least two scans separated by at least three years must be reviewed) on brain or spine MRI scan.,gadolinium,55,65,,,,,P
NCT01884337_exc_345_T33,Hemoglobin <9 g/dL,Hemoglobin,0,10,,,,,P
NCT02557412_exc_330_T13,Very excessive daytime sleepiness (Epworth Sleepiness Scale> 18).,daytime sleepiness,15,33,,,,,P
NCT03156855_inc_331_T30,"severe concurrent disease,",disease,18,25,,,,,P
NCT00718952_inc_264_T12,WHO pulmonary hypertension function II-III with non-responder to calcium channel blockers.,WHO pulmonary hypertension function,0,35,,,,,P
NCT02531971_inc_1155_T33,"Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",hemoglobin,64,74,,,,,P
NCT02526823_exc_323_T27,"patients with severe allergic constitution, or those who are allergic to or intolerant of drug composition in chemotherapy regimens; with other malignant tumors in the past 5 years;",malignant tumors,144,160,,,,,P
NCT01491295_inc_88_T11,"Under lamivudine/adefovir treatment for more than 1 year due to previous lamivudine resistance (LAM-R), current HBV DNA is undetectable (< 20 IU/ml) during enrollment.",lamivudine,6,16,,,,,P
NCT00344318_exc_584_T39,"Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations",vaccines,155,163,,,,,P
NCT02273791_inc_54_T5,"Presence of at least 2 cryopreserved good quality cleavage-stage embryo (good quality cleavage-stage embryos display stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments).",cleavage-stage embryo,50,71,,,,,P
NCT01997112_exc_216_T18,"Patients with chronic pain requiring treatment, with a known allergy to paracetamol, or concomitant use of non-steroidal anti-inflammatories , oral anticoagulants or corticosteroids.",known allergy,55,68,,,,,P
NCT02502734_inc_791_T43,Using one of the following asthma therapies prior to entry into the study: SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <,budesonide,328,338,,,,,P
NCT03126214_exc_762_T50,Severe cognitive impairment (defined as score = 5 on the Short Portable Mental Status Questionnaire),cognitive impairment,7,27,,,,,P
NCT03073603_exc_1037_T54,"History of other chronic neurological illnesses that might mimic MS with chronic or intermittent symptoms (i.e. ALS, myasthenia gravis, chronic neuropathy, etc.)",chronic neurological illnesses,17,47,,,,,P
NCT03033745_exc_0_T1,Ongoing serious bacterial infections at the time of screening.,bacterial infections,16,36,,,,,P
NCT03335436_exc_221_T24,contraindications to neuraxial anesthesia or require general anesthesia for CD,general anesthesia,53,71,,,,,P
NCT02964416_exc_403_T22,Patients above 65 years of age ( Physiology difference),age,27,30,,,,,P
NCT02384850_inc_3_T11,Patients with histologically confirmed diagnosis of colorectal cancer presenting with unresectable stage IV (UICC) disease (primary tumor may be present),colorectal cancer,52,69,,,,,P
NCT02109081_exc_0_T19,1) preoperative diagnosis of delirium or dementia; 2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing; 3) language barriers that would preclude testing; 4) preoperative steroid use within 3 days of surgery; or 5) anticipation of postoperative intubation.,CAM testing,173,184,,,,,P
NCT02867618_inc_322_T22,Patients with DLBCL and HL will be eligible if there is no available standard therapy.,DLBCL,14,19,,,,,P
NCT02209545_inc_178_T14,Pre-operative hemoglobin >8 g/dl,hemoglobin,14,24,,,,,P
NCT00426751_exc_586_T32,Known severe renal (creatinine clearance <30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations =,aspartate transaminase (AST),115,143,,,,,P
NCT02762851_exc_77_T4,"Known IgE( Immunoglobulin E)-mediated hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock",IgE( Immunoglobulin E)-mediated hypersensitivity,6,54,,,,,P
NCT03323047_exc_401_T12,active infection,infection,7,16,,,,,P
NCT03073603_exc_842_T48,Cancers other than basal cell skin cancers within the last 5 years,basal cell skin cancers,19,42,,,,,P
NCT02490839_inc_0_T7,Participants having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 20 years old and are willing to received eradication therapy.,eradication therapy,150,169,,,,,P
NCT02526823_exc_505_T30,"patients received doxorubicin therapy, total cumulative dose of adriamycin was more than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;",adriamycin,64,74,,,,,P
NCT02413970_exc_637_T14,Body Mass Index (BMI) of > 32,Body Mass Index,0,15,,,,,P
NCT03234816_inc_0_T2,full term singleton pregnant women,pregnant,20,28,,,,,P
NCT03156855_inc_265_T23,"contraindication to treatment drugs,",contraindication,0,16,,,,,P
NCT03373669_exc_556_T30,History of chronic diarrhea (lasting for more than 2 weeks in the past 6 months),chronic diarrhea,11,27,,,,,P
NCT01497639_exc_0_T2,previous brain surgery;,brain surgery,9,22,,,,,P
NCT03472846_exc_146_T15,Malignancies (<5 years),Malignancies,0,12,,,,,P
NCT03249272_exc_545_T40,Active bronchospasm or history of hospitalization due to bronchospasm,hospitalization,34,49,,,,,P
NCT03444142_exc_288_T20,Body Mass Index =39.9 kg/m2,Body Mass Index,0,15,,,,,P
NCT02242188_inc_0_T4,Term singleton infants (>37 weeks gestational age),gestational age,34,49,,,,,P
NCT03472846_exc_53_T4,Cirrhosis hepatis (Child B or higher),Cirrhosis hepatis,0,17,,,,,P
NCT00989261_exc_1313_T58,"Radiation therapy within 4 weeks prior to, or concurrent with study",concurrent with study,46,67,,,,,P
NCT02964416_exc_245_T13,Obesity (women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2),body mass index,22,37,,,,,P
NCT02762851_exc_242_T16,Guillain-Barré syndrome within eight weeks of a previous influenza vaccine,influenza vaccine,57,74,,,,,P
NCT02831166_exc_346_T25,Uncontrolled systemic hypertension;,systemic hypertension,13,34,,,,,P
NCT02961582_inc_106_T11,Meet at least one other criterion of the Rome-IV criteria for idiopathic constipation based on the 3-week defecation diary (1),criterion,24,33,,,,,P
NCT01997112_exc_0_T4,"History of ischaemic heart disease, cardiac failure, cerebrovascular disease, liver impairment (ALT/AST>50IU/L) or stage 3-5 chronic kidney disease.",liver impairment,78,94,,,,,P
NCT03663387_exc_888_T59,Implanted medical devices that are incompatible with MRI imaging.,medical devices,10,25,,,,,P
NCT02634541_inc_0_T4,Axial spondyloarthritis (ASAS criteria) and radiologic sacroiliitis as detected either by MRI or X-ray.,sacroiliitis,55,67,,,,,P
NCT02315287_inc_15_T5,No treatment with insulin or oral agents for 6 months,insulin,18,25,,,,,P
NCT03373669_exc_637_T37,"Current use of laxatives, antacids, or other agents to lower stomach acidity?",agents to lower stomach acidity,45,76,,,,,P
NCT02867618_inc_502_T32,Patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.,NHL,14,17,,,,,P
NCT01997112_exc_0_T10,"History of ischaemic heart disease, cardiac failure, cerebrovascular disease, liver impairment (ALT/AST>50IU/L) or stage 3-5 chronic kidney disease.",chronic kidney disease,125,147,,,,,P
NCT01794793_exc_889_T5,Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment.,Female sterilization,0,20,,,,,P
NCT03221231_exc_202_T15,"An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches;",neurological disorder,28,49,,,,,P
NCT01205334_inc_468_T26,Pulse oximetry of 90% or greater on room air,Pulse oximetry,0,14,,,,,P
NCT03221231_exc_623_T45,"Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy with medication that could interact adversely with n-acetylcysteine within 30 days prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants);",chronic therapy,68,83,,,,,P
NCT01218737_inc_0_T2,"Patient is indicated to have an ocular refractive surgery performed (myopia, astigmatism, hypermetropy) by the Lasik method.",indicated to have an ocular refractive surgery performed,11,67,,,,,P
NCT02224040_exc_0_T3,Allergy to ceftriaxone or macrolides,Allergy,0,7,,,,,P
NCT02609425_exc_0_T3,Any patient with esophageal cancer who is not deemed a surgical candidate or who is not deemed a candidate for the Ivor Lewis technique of esophagectomy (with intrathoracic anastomosis).,candidate,64,73,,,,,P
NCT00426751_exc_860_T38,Severe concomitant disease with life expectation < 1 year,Severe disease,,,"[(0, 6), (0, 7)]",,,,P
NCT02413970_exc_667_T18,"Any chronic medical illness or condition that contraindicates a surgical procedure under general anesthesia, as judged by the clinical study Investigator",surgical procedure,64,82,,,,,P
NCT02553226_exc_150_T13,"Pathological fetal heart rate pattern (cardiotocogram, CTG) before Syntocinon® initiation",Syntocinon® initiation,67,89,,,,,P
NCT03250507_inc_0_T6,"Elective open abdominal hysterectomy with midline incision, age > 18 years, American Society of Anesthesiologist classification score (ASA classification) 1-3.",American Society of Anesthesiologist classification score,76,133,,,,,P
NCT00344318_exc_860_T40,"History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b diseases.",History,0,7,,,,,P
NCT03491059_exc_584_T32,"use of medications that are inducers of CYP2A6 (a nicotine metabolizing enzyme) such as rifampicin, dexamethasone, phenobarbital, and other anti-convulsant drugs",medications,7,18,,,,,P
NCT02502734_inc_791_T42,Using one of the following asthma therapies prior to entry into the study: SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <,ICS,179,182,,,,,P
NCT02664558_exc_2219_T152,Absolute neutrophil count <1500 mm3.,Absolute neutrophil count,0,25,,,,,P
NCT01491763_inc_236_T21,"Patients without functional impairment of organs: liver function: total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease.",serum creatinine,197,213,,,,,P
NCT02816762_exc_573_T33,Severe daytime sleepiness (Epworth sleepiness scale >18),Epworth sleepiness scale,27,51,,,,,P
NCT02003339_exc_325_T23,"No antiangiogenic concomitant treatment, 15 days before and 15 days after radioembolization, including Sorafenib",antiangiogenic treatment,,,"[(3, 17), (3, 12)]",,,,P
NCT02867618_inc_0_T2,Phase I: Patients must have histologically confirmed R/R NHL or HL (defined by WHO criteria).,confirmed,43,52,,,,,P
NCT01314898_exc_264_T12,Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening.,Estimated GFR,0,13,,,,,P
NCT02537899_exc_22_T3,Multiple significant trauma (i.e. significant intracranial and extracranial injuries including limb fractures) that would limit observation of recovery from spinal cord injury,trauma,21,27,,,,,P
NCT03262038_inc_110_T10,ability to use verbal or pictorial pain assessment tools and techniques,ability,0,7,,,,,P
NCT03004209_inc_0_T2,Clinically diagnosed autoimmune encephalitis,autoimmune encephalitis,21,44,,,,,P
NCT02804646_exc_0_T10,"1) pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;2) existing severe acute infection and is not controlled; or purulent and chronic infection, delayed healing wounds; 3) the original severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension; 4) suffering from neurological and psychiatric diseases or mental disorders is not easy to control, poor compliance, and can not be described with treatment responders; primary brain or central nervous metastasis disease has not been controlled, with significant cranial hypertension or neuropsychiatric symptoms; 5) have bleeding tendencies; 6) other researchers believe that patients should not participate in the present trial.",infection,146,155,,,,,P
NCT02344888_exc_208_T13,Previous exposure to cytotoxic drugs or pelvic irradiation.,exposure,9,17,,,,,P
NCT02323399_inc_201_T19,"Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure =128/78 mmHg (sitting, after 5 minutes of rest)",mean systolic blood pressure,,,"[(61, 65), (61, 69), (61, 75)]",,,,P
NCT02531971_inc_1155_T39,"Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",bicarbonate,122,133,,,,,P
NCT03044561_inc_115_T10,(3) women have experienced two or more implantation failure attributed to inadequate endometrial development.,implantation,39,51,,,,,P
NCT02862314_exc_582_T24,"patients with an absolute indication for administration of antibiotics at the moment of ICU admission (meningitis, pneumonia) or a chronic infection for which long-term antibiotic treatment is necessary (endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis)",chronic infection,131,148,,,,,P
NCT02867618_exc_534_T45,Current malignancy or history of a prior malignancy,malignancy,8,18,,,,,P
NCT02531971_inc_1155_T43,"Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",ALT,174,177,,,,,P
NCT03126214_exc_762_T51,Severe cognitive impairment (defined as score = 5 on the Short Portable Mental Status Questionnaire),Short Portable Mental Status Questionnaire,57,99,,,,,P
NCT02678962_exc_535_T29,"Pregnant, lactating, or planning to become pregnant during the course of the trial;",pregnant,43,51,,,,,P
NCT03491059_exc_584_T32,"use of medications that are inducers of CYP2A6 (a nicotine metabolizing enzyme) such as rifampicin, dexamethasone, phenobarbital, and other anti-convulsant drugs",medications,7,18,,,,,P
NCT02384850_inc_856_T58,Women of child-bearing potential must have a negative pregnancy test,Women,0,5,,,,,P
NCT00391690_inc_1052_T44,Patients with psychiatric or addictive disorders which prevent them from giving their informed consent must not enter the study.,psychiatric disorders,,,"[(14, 25), (14, 23)]",,,,P
NCT03335436_exc_160_T18,taking prescribed gabapentin at the time of admission for CD,admission for CD,44,60,,,,,P
NCT02961582_inc_368_T29,Sensation of incomplete evacuation for =25% of defecations,Sensation of incomplete evacuation,0,34,,,,,P
NCT02003339_exc_107_T8,"Thrombosis extending into the porta(thrombosis of one of left or right branch authorized), extra hepatic metastasis",thrombosis,36,46,,,,,P
NCT02109081_exc_0_T10,1) preoperative diagnosis of delirium or dementia; 2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing; 3) language barriers that would preclude testing; 4) preoperative steroid use within 3 days of surgery; or 5) anticipation of postoperative intubation.,MMSE score,54,64,,,,,P
NCT02867618_exc_397_T32,History of allergic reactions to TGR-1202 or carfilzomib,allergic reactions,11,29,,,,,P
NCT02543710_inc_108_T9,Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment.,taxane,116,122,,,,,P
NCT02431559_exc_194_T41,"Subjects with platinum-refractory disease, defined as disease progression while receiving first line platinum-based therapy.",platinum-refractory disease,14,41,,,,,P
NCT03430284_exc_0_T2,"type 1 diabetes,specific types of diabetes,gestational diabetes or pregestational diabetes;",diabetes,7,15,,,,,P
NCT02664558_exc_1482_T119,"History of malignancy within the last 5 years, except nonmelanoma skin cancer and cervical carcinoma in situ treated with curative intent.",treated,109,116,,,,,P
NCT02224040_exc_164_T18,Treatment within the past 4 days with an antibiotic that may be effective against typhoid fever       ,effective against typhoid fever,64,95,,,,,P
NCT02242188_inc_93_T12,Breastfed exclusively or predominantly (>50% meals) at inclusion,exclusively,10,21,,,,,P
NCT01816997_exc_0_T1,A1C >7.0%,A1C,0,3,,,,,P
NCT03663387_exc_504_T36,Regular use of narcotic analgesics (>2 doses per week).,Regular use,0,11,,,,,P
NCT00989261_exc_235_T8,AML in relapse or refractory after 3 or more previous lines of chemotherapy (and/or HSCT) treatment,AML,0,3,,,,,P
NCT00426751_inc_418_T20,"ST elevation in 2 contiguous ECG leads (= 2 mm precordial lead, = 1 mm limb lead).",ST elevation,0,12,,,,,P
NCT02664558_exc_1045_T92,"Chronic infections including, but not limited to tuberculosis (TB), hepatitis B virus (HBV) or hepatitis C virus (HCV).",infections,8,18,,,,,P
NCT02631512_exc_37_T4,Uncontrolled diabetes defined as HbA1c above 70 mmol/mol and insufficient nutritional status.,HbA1c,33,38,,,,,P
NCT03282006_exc_180_T14,E.coli isolate resistant to pivmecillinam,resistant to pivmecillinam,15,41,,,,,P
NCT03663387_exc_954_T62,Radiation exposures exceeding annual Rad Worker limits.,Radiation exposures,0,19,,,,,P
NCT02965027_exc_138_T8,Diagnosis of a primary or secondary HA disorder other than PTHA,HA disorder,36,47,,,,,P
NCT03221231_exc_895_T53,Exclusion criteria for MRI: having metal in the body and/or having claustrophobia,Exclusion criteria for MRI,0,26,,,,,P
NCT02965027_exc_412_T32,"Continuous HAs of any kind (i.e., persistent daily HAs with no HA-free period less than 8 hours between attacks)",HAs,11,14,,,,,P
NCT03250507_inc_0_T4,"Elective open abdominal hysterectomy with midline incision, age > 18 years, American Society of Anesthesiologist classification score (ASA classification) 1-3.",age,60,63,,,,,P
NCT03589105_exc_1098_T67,"History or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease (e.g., lupus, anti-phospholipid antibody syndrome, Sjogren's syndrome, Behçet's disease, sarcoidosis)",progressive neurologic disease,79,109,,,,,P
NCT02502734_inc_791_T38,Using one of the following asthma therapies prior to entry into the study: SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <,SABA inhaler,75,87,,,,,P
NCT00426751_inc_0_T1,"Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e. women of child bearing potential are not allowed to be included into the study.",postmenopausal,14,28,,,,,P
NCT02526823_exc_323_T27,"patients with severe allergic constitution, or those who are allergic to or intolerant of drug composition in chemotherapy regimens; with other malignant tumors in the past 5 years;",malignant tumors,144,160,,,,,P
NCT02531971_inc_1155_T38,"Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",chloride,112,120,,,,,P
NCT03004209_inc_45_T7,"Ineffective 1st line treatment (e.g. steroid IV, IVIg) and 2nd line treatment (e.g. Rituximab or cyclophosphamide)",2nd line treatment,59,77,,,,,P
NCT02431559_exc_3_T33,"Prior exposure to doxorubicin, PLD or any other anthracycline, motolimod and other TLR agonists, MEDI4736 or checkpoint inhibitors, such as anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies.",checkpoint inhibitors,109,130,,,,,P
NCT03335436_exc_300_T26,designated ASA physical status 4 or above,ASA physical status,11,30,,,,,P
NCT03344042_exc_88_T6,"coagulopathies including platelet count of less than 100,000",coagulopathies,0,14,,,,,P
NCT01497639_exc_173_T10,marked brain atrophy as detected by magnetic resonance imaging,brain atrophy,7,20,,,,,P
NCT01774019_exc_53_T5,"Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers",malignancies,29,41,,,,,P
NCT03126214_exc_0_T1,Uncontrolled hypertension (defined as average SBP = 160 mmHg [2 readings taken at time of screening]).,hypertension,13,25,,,,,P
NCT03249272_exc_398_T25,Severe claustrophobia,claustrophobia,7,21,,,,,P
NCT02964416_exc_245_T13,Obesity (women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2),body mass index,22,37,,,,,P
NCT02965027_exc_2596_T133,Failure to record HA data for at least 80% of days during the Screening Period,Failure to record HA data,0,25,,,,,P
NCT02490839_inc_0_T4,Participants having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 20 years old and are willing to received eradication therapy.,aged,91,95,,,,,P
NCT02961582_inc_495_T35,Manual manoeuvres to facilitate =25% of defecations,defecations,40,51,,,,,P
NCT02557412_exc_0_T1,Apnea-hypopnea index of less than 5 h-1 or greater than 30 h-1.,Apnea-hypopnea index,0,20,,,,,P
NCT02714725_inc_0_T1,"Adult patients aged (>18), males and females, undergoing elective coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).",aged,15,19,,,,,P
NCT03323047_exc_632_T30,Complicating health factors precluding the use of opioids or acetaminophen,Complicating health factors,0,27,,,,,P
NCT00391690_inc_717_T32,"Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (patients that spend less than 50% of time in bed during the day)",Eastern Cooperative Oncology Group (ECOG) score,0,47,,,,,P
NCT03119766_exc_539_T32,Intestinal infection within 2 months before study entry.,within 2 months before study entry,21,55,,,,,P
NCT02242188_inc_191_T22,No previous blood transfusion,blood transfusion,12,29,,,,,P
NCT03249272_exc_545_T40,Active bronchospasm or history of hospitalization due to bronchospasm,hospitalization,34,49,,,,,P
NCT02867618_inc_194_T19,"In addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.",therapies,117,126,,,,,P
NCT02961582_inc_106_T11,Meet at least one other criterion of the Rome-IV criteria for idiopathic constipation based on the 3-week defecation diary (1),criterion,24,33,,,,,P
NCT00989261_exc_235_T9,AML in relapse or refractory after 3 or more previous lines of chemotherapy (and/or HSCT) treatment,in relapse,4,14,,,,,P
NCT02283996_inc_34_T4,"Must meet the following definition for adhesive capsulitis as defined by the American Academy of Orthopedic Surgeons: Self-limiting condition resulting from any inflammatory process about the shoulder in which capsular scar tissue is produced, resulting in pain and limited range of motion; also called frozen shoulder",American Academy of Orthopedic Surgeons,77,116,,,,,P
NCT02035904_inc_112_T11,"Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection;",nipple-sparing mastectomy,25,50,,,,,P
NCT03079141_exc_40_T6,"Previous prescription of mineralocorticoid receptor antagonists, for cCSC or for other diseases;",mineralocorticoid receptor antagonists,25,63,,,,,P
NCT02632760_exc_10_T2,Known hypersensitivity to study drug (ferric carboxymaltose or equivalent) or its excipients,hypersensitivity,6,22,,,,,P
NCT02858180_exc_642_T29,"Platelets = 50,000/mm3",Platelets,0,9,,,,,P
NCT03079141_exc_867_T60,"(relative) Contraindications for photodynamic treatment (pregnancy, porphyria, severely disturbed liver function).",disturbed liver function,88,112,,,,,P
NCT03663387_exc_114_T11,Dementia or Mild cognitive impairment at baseline,Mild cognitive impairment,12,37,,,,,P
NCT03335436_exc_221_T21,contraindications to neuraxial anesthesia or require general anesthesia for CD,contraindications,0,17,,,,,P
NCT03079141_exc_1109_T77,"(relative) Known contraindications for initiation of eplerenone treatment (hyperkalemia, abnormal renal clearance, severe hepatic insufficiency (Child-Pugh C), type 2 diabetes mellitus with microalbuminuria, concomitant use of potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent).",potassium supplements,227,248,,,,,P
NCT02323399_inc_201_T16,"Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure =128/78 mmHg (sitting, after 5 minutes of rest)",prior to entry,34,48,,,,,P
NCT03079141_exc_0_T3,Any previous treatments for active CSC;,treatments,13,23,,,,,P
NCT02965027_exc_3816_T139,"Other Medications: Participants who are taking other medications on a routine basis must be on a stable dose for at least 4 weeks prior to the Preliminary Screening Period (P1), and must intend to continue the medication at the same regimen for the duration of the trial unless lack of efficacy, safety, or tolerability dictates otherwise.",medications,53,64,,,,,P
NCT02678962_exc_302_T18,Require combined surgery that may confound the results of the study;,combined surgery,8,24,,,,,P
NCT02596555_exc_989_T18,"Need for long-term treatment with a low molecular weight heparin, vitamin K antagonists or NOAC, for an indication other than the index PE episode, or for antiplatelet agents except acetylsalicylic acid at a dosage =100 mg/day;",low molecular weight heparin,36,64,,,,,P
NCT02867618_inc_882_T56,ECOG performance status < 2,ECOG performance status,0,23,,,,,P
NCT02862314_exc_912_T37,patients with haemodynamic instability of septic origin or a respiratory insufficiency (defined by a ratio Pa02/Fi02 = 200 mmHg and PEP = 5 cmH2O),espiratory insufficiency,62,86,,,,,P
NCT02664558_exc_1170_T98,"History of portal hypertension or chronic liver disease, including positive serology for infection with HCV and/or HBV.",serology for infection HBV,,,"[(76, 98), (76, 79)]",,,,P
NCT01891513_inc_193_T14,Score ≤ 10 on the Short Physical Performance Battery OR Walking speed < 1.2 m/sec during 400 m usual-paced test,Walking speed,56,69,,,,,P
NCT03282006_exc_0_T1,Bacterial infection origin from another organ (e.g. pneumonia),Bacterial infection,0,19,,,,,P
NCT02537899_exc_22_T3,Multiple significant trauma (i.e. significant intracranial and extracranial injuries including limb fractures) that would limit observation of recovery from spinal cord injury,trauma,21,27,,,,,P
NCT03335436_exc_160_T15,taking prescribed gabapentin at the time of admission for CD,gabapentin,18,28,,,,,P
NCT01218737_inc_126_T9,Patient presents a normal eye fundus.,eye fundus,26,36,,,,,P
NCT02816762_exc_276_T16,Systolic blood pressure = 180 mmHg or diastolic blood pressure =,diastolic blood pressure,38,62,,,,,P
NCT01205334_inc_312_T24,"Bilirubin less than 1.5x upper limit of normal, AST less than 3x upper limit of normal, serum creatinine less than 1.5x normal and Hgb 8.0 g/dL or greater",AST,48,51,,,,,P
NCT03364036_exc_0_T2,"Previous exposure to drugs such as fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab.",drugs,21,26,,,,,P
NCT00391690_inc_845_T39,Adequate liver function - serum total bilirubin concentration less than 1.5 x upper limit of normal value,Adequate,0,8,,,,,P
NCT02573597_exc_0_T10,"<37 weeks gestation, H/o Cesarean Section, Multiple Gestation, Pre-eclampsia, Narcotics within 3 hours prior to labor epidural placement, Chronic Pain (as defined by chronic opiate consumption), Women who are participating in another study that will impact protocol",labor epidural placement,112,136,,,,,P
NCT02273791_inc_54_T5,"Presence of at least 2 cryopreserved good quality cleavage-stage embryo (good quality cleavage-stage embryos display stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments).",cleavage-stage embryo,50,71,,,,,P
NCT02965027_exc_844_T58,"Hg after 2 min standing accompanied by lightheadedness], chronic renal or hepatic failure, acute pancreatitis, Meniere's disease, or diagnosed but untreated sleep apnea).",sleep apnea,157,168,,,,,P
NCT00989261_exc_519_T34,Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant,transplant,54,64,,,,,P
NCT02431559_exc_2473_T160,History of severe allergic reactions to any unknown allergens or components of the study drugs.,allergic reactions,18,36,,,,,P
NCT03282006_exc_277_T22,Severe kidney failure (eGFR<15 ml/min),eGFR,23,27,,,,,P
NCT00317148_exc_187_T8,"Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to randomization.",systemic estrogen,11,28,,,,,P
NCT00989261_exc_2113_T99,"History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the possible exception of patients in complete remission       ",skin cancer,57,68,,,,,P
NCT02783859_exc_284_T15,"Complicated (effusion, empyema or abscess) pneumonia, including tuberculosis",Complicated pneumonia,,,"[(0, 11), (0, 9)]",,,,P
NCT03056391_inc_30_T10,"Presence of P. knowlesi malaria, confirmed by positive blood smear with asexual forms of P. knowlesi.",positive,46,54,,,,,P
NCT02831166_exc_497_T34,Documented chronic peripheral arterial disease preventing the use of the femoral technique;,peripheral arterial disease,19,46,,,,,P
NCT02816762_exc_111_T9,Evidence in the clinic history of relevant bilateral stenosis of renal artery (> 75%),stenosis of renal artery,53,77,,,,,P
NCT00989261_exc_519_T46,Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant,toxicity,244,252,,,,,P
NCT03119766_exc_1525_T74,Intake of medicines listed in the section 'Prohibited concomitant treatment' for 1 month prior to the enrollment in the trial.,medicines,10,19,,,,,P
NCT02431559_exc_1378_T107,"Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit.",ischemia,29,37,,,,,P
NCT02965027_exc_1759_T97,"Meets Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for any Substance Use Disorder except caffeine-related disorders, or tobacco-related disorders.",Substance Use Disorder,98,120,,,,,P
NCT03249272_exc_55_T9,Prior coronary revascularization (PCI or CABG) or myocardial infarction (as evidenced by previously elevated CPK-MB or troponin levels),CPK-MB levels,,,"[(109, 115), (109, 115)]",,,,P
NCT03117608_exc_388_T21,Varus or valgus misalignment exceeding 15°;,valgus misalignment,9,28,,,,,P
NCT02765035_inc_0_T1,Person is >18 years old.,old,20,23,,,,,P
NCT02322203_exc_1220_T53,Patients with a history of type I or type II diabetes or HbA1c greater than 6.5%.,type I diabetes,,,"[(27, 33), (27, 35)]",,,,P
NCT02384850_inc_550_T42,serum alanine transaminase (ALT) ≤ 2.5 x ULN (in case of liver metastases < 5 x ULN),serum alanine transaminase (ALT),0,32,,,,,P
NCT02490839_inc_0_T2,Participants having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 20 years old and are willing to received eradication therapy.,chronic gastritis,38,55,,,,,P
NCT02141061_exc_772_T56,Use of oral contraceptives in the preceding 2 weeks.,oral contraceptives,7,26,,,,,P
NCT02322203_exc_1220_T54,Patients with a history of type I or type II diabetes or HbA1c greater than 6.5%.,HbA1c,57,62,,,,,P
NCT03589105_exc_36_T14,"Inability to complete an MRI (contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc…)",within 6 weeks of entry into the study,216,254,,,,,P
NCT02209545_inc_388_T26,Admissible medical/surgical history,medical history,,,"[(11, 18), (11, 18)]",,,,P
NCT00317148_exc_0_T1,Body mass index (BMI) of 35 kg/m2 or more.,Body mass index (BMI),0,21,,,,,P
NCT02783859_exc_361_T22,Extra-pulmonary infection requiring antibiotic therapy (e.g. meningitis),infection,16,25,,,,,P
NCT02965027_exc_1523_T90,"Active psychosis or psychotic disorder, severe depression (as determined per clinician prescriber judgment), severe psychiatric instability or severe situational life crisis (including evidence of being actively suicidal or homicidal).",psychiatric instability,116,139,,,,,P
NCT03117608_exc_388_T19,Varus or valgus misalignment exceeding 15°;,valgus misalignment,9,28,,,,,P
NCT02035800_inc_105_T5,Receiving a prescription of Adalimumab 40 mg subcutaneous every two weeks.,Adalimumab,28,38,,,,,P
NCT02965027_exc_1214_T68,"Use of prazosin or other alpha-1 antagonist (including but not limited to alfuzosin, doxazosin, silodosin, tamsulosin, terazosin) for any purpose in the 2 weeks prior to initial screen (P1) visit and prohibited throughout the study",alpha-1 antagonist,25,43,,,,,P
NCT02579200_inc_109_T7,Reduced left ventricular ejection fraction (<50%),left ventricular ejection fraction,8,42,,,,,P
NCT00391690_inc_717_T32,"Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (patients that spend less than 50% of time in bed during the day)",Eastern Cooperative Oncology Group (ECOG) score,0,47,,,,,P
NCT02200978_exc_0_T1,"Patients who have coma, convulsion or paralysis due to intracranial hemorrhage or central nervous system leukemia at diagnosis.",coma,18,22,,,,,P
NCT02590822_inc_617_T30,Age =18 and = 65 years,Age,0,3,,,,,P
NCT02141061_exc_356_T34,(ALT or AST exceeding 2.0 x ULN AND total bilirubin exceeding 1.5 x ULN at screening and confirmed on repeat).,total bilirubin,36,51,,,,,P
NCT03119766_exc_334_T24,"Discontinuation of proton pump inhibitors, propulsives, antispasmodics, antacids, or bismuth preparations less than 7 days prior to randomization.",Discontinuation,0,15,,,,,P
NCT03323047_exc_159_T3,"Patients with chronic conditions that would limit our ability to develop the study according to objectives, such as neurodevelopmental conditions preventing patients from understanding the Oucher tool",chronic conditions,14,32,,,,,P
NCT02322203_exc_309_T13,Subjects with elevated uric acid levels greater than 10 mg/dL or gout,uric acid levels,23,39,,,,,P
NCT02537899_exc_328_T13,Refusal of treatment or contraindication to NeuroAiD,contraindication,24,40,,,,,P
NCT03648021_exc_155_T13,"Pharmacological intervention (administration of corticosteroids, NSAIDs or paracetamol) or physical intervention (external cooling technique) that may influence temperature in the last 6 hours.",Pharmacological intervention,0,28,,,,,P
NCT02431559_exc_1581_T117,"Active, suspected or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegner's granulomatosis, active Hashimoto's thyroiditis, rheumatoid arthritis, lupus, scleroderma and its variants, multiple sclerosis, myasthenia gravis).",autoimmune disease,38,56,,,,,P
NCT02816762_exc_0_T2,Non diabetic nephropathy (confirmed by biopsy).,confirmed by biopsy,26,45,,,,,P
NCT03323047_exc_159_T3,"Patients with chronic conditions that would limit our ability to develop the study according to objectives, such as neurodevelopmental conditions preventing patients from understanding the Oucher tool",chronic conditions,14,32,,,,,P
NCT02765035_inc_217_T8,Person is currently fitted with a prosthesis using a non-microprocessor controlled prosthetic knee for at least 6 months.,prosthetic knee,83,98,,,,,P
NCT03351972_exc_10_T4,severe gastroparesis requiring endoscopic placement of capsule,endoscopic placement,31,51,,,,,P
NCT02964416_inc_0_T1,Patients with craniotomy for supratentorial tumors under general anesthesia,craniotomy,14,24,,,,,P
NCT01907230_inc_25_T12,HBsAg-positive for more than 6 months and HBV DNA < 2000 IU/ml (Subgroup 1)or HBsAg-negative but anti-HBc positive with HBV DNA < 2000 IU/ml,HBV DNA,42,49,,,,,P
NCT03079141_exc_1626_T90,"Soft drusen in treated eye or fellow eye, signs of choroidal neovascularization on ophthalmoscopy and/or FA/ICGA of the study eye.",ophthalmoscopy,83,97,,,,,P
NCT02579200_inc_159_T11,Non-reversible airway obstruction (post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80 %),FEV1/FVC,55,63,,,,,P
NCT02281643_inc_115_T1,Normal renal and hepatic laboratory profiles,hepatic laboratory profile,17,43,,,,,P
NCT01175044_exc_171_T7,Any condition requiring antibiotics 14 days prior to arriving for surgery.,14 days prior to arriving for surgery,36,73,,,,,P
NCT01807897_inc_300_T21,"Moderate to severe central or mixed central and obstructive sleep apnea, defined as an apnea-hypopnea index (AHI) 15 events per hour, with a central AHI >5 events/hour",apnea-hypopnea index,87,107,,,,,P
NCT02973035_exc_1122_T54,Moderate or severe valvular disease.,valvular disease,19,35,,,,,P
NCT02415257_exc_43_T4,signs for central dysfunction,central dysfunction,10,29,,,,,P
NCT02209545_inc_0_T1,Patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging (pelvic ultrasound or MRI) within in last 12 months,abdominal myomectomy,24,44,,,,,P
NCT02431559_exc_1524_T115,History of pneumonitis or interstitial lung disease.,interstitial lung disease,26,51,,,,,P
NCT03663387_exc_760_T52,"Individuals taking over the counter memory enhancing or protecting medications (e.g. ginkgo biloba, vitamins) are not excluded.",over the counter memory enhancing medications,,,"[(19, 52), (19, 30)]",,,,P
NCT02965027_exc_288_T21,HAs of any kind of moderate or severe intensity on an average of more than 2 days per month preceding the concussive trauma,HAs,0,3,,,,,P
NCT03430284_exc_218_T18,allergic history or contraindication for any drugs in trials;,contraindication,20,36,,,,,P
NCT03193684_exc_0_T1,eGFR <,eGFR,0,4,,,,,P
NCT03663387_exc_114_T10,Dementia or Mild cognitive impairment at baseline,Dementia,0,8,,,,,P
NCT03663387_exc_338_T25,Concurrent medication limiting validity of neuropsychological tests or imaging.,Concurrent,0,10,,,,,P
NCT03151603_inc_0_T1,Women (18-75 years) with suspected UTI,Women,0,5,,,,,P
NCT02431559_exc_416_T62,"Subjects with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or, within six months prior to Day 1 of this study, history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage.",cerebrovascular accident,247,271,,,,,P
NCT00344318_exc_1514_T70,Administration of immunoglobulins and/or any blood products since birth or planned administration during the active phase of the study.,immunoglobulins,18,33,,,,,P
NCT02788045_inc_76_T4,"Is healthy on the basis of physical examination, medical history, electrocardiogram (ECG), and vital signs measurement performed at screening",healthy,3,10,,,,,P
NCT02714725_inc_0_T6,"Adult patients aged (>18), males and females, undergoing elective coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).",surgery coronary artery bypass graft,,,"[(102, 109), (102, 130)]",,,,P
NCT03011476_exc_0_T1,Significant motor complication affecting daily activities,motor complication,12,30,,,,,P
NCT01064752_exc_116_T10,"Enhanced risk from lumbar puncture, including documented or suspected cerebral mass lesion predisposing to brain herniation or bleeding diathesis.",cerebral mass lesion,70,90,,,,,P
NCT02965027_exc_2060_T112,Structural brain abnormalities on any prior imaging with associated clinically evident manifestations,imaging,44,51,,,,,P
NCT02035800_inc_0_T1,"Patients aged of 18 and over,",aged,9,13,,,,,P
NCT02973035_exc_901_T44,"Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 3 times upper limit of normal).",ALT,87,90,,,,,P
NCT00426751_inc_0_T2,"Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e. women of child bearing potential are not allowed to be included into the study.",Women,0,5,,,,,P
NCT01884337_exc_147_T15,Active bleeding or at high risk for bleeding.,bleeding,7,15,,,,,P
NCT03345589_inc_52_T2,Treated with Ursodeoxycholic Acid in West China Hospital for at least 6 month and suboptimal response to Ursodeoxycholic Acid,Ursodeoxycholic Acid,13,33,,,,,P
NCT02431559_exc_963_T86,"History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti-arrhythmic medication.",cardiac arrhythmias,105,124,,,,,P
NCT00426751_inc_418_T21,"ST elevation in 2 contiguous ECG leads (= 2 mm precordial lead, = 1 mm limb lead).",precordial lead,47,62,,,,,P
NCT02965027_exc_3816_T139,"Other Medications: Participants who are taking other medications on a routine basis must be on a stable dose for at least 4 weeks prior to the Preliminary Screening Period (P1), and must intend to continue the medication at the same regimen for the duration of the trial unless lack of efficacy, safety, or tolerability dictates otherwise.",medications,53,64,,,,,P
NCT02531971_inc_1155_T31,"Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",white blood cells,39,56,,,,,P
NCT02862314_exc_372_T10,"surgical interventions within the last 4 days,",surgical interventions,0,22,,,,,P
NCT00445029_inc_18_T1,Patients aged from 18 to 65 years old.,aged,9,13,,,,,P
NCT02531971_inc_1155_T33,"Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",hemoglobin,64,74,,,,,P
NCT02965027_exc_412_T25,"Continuous HAs of any kind (i.e., persistent daily HAs with no HA-free period less than 8 hours between attacks)",HAs,11,14,,,,,P
NCT00236340_inc_0_T5,Pregnant women with abdomen discumfort and ultrasound diagnosis of polyhydramnios (AFI>25cm),polyhydramnios,67,81,,,,,P
NCT02961582_inc_233_T14,Refractory to conservative treatment,conservative treatment,14,36,,,,,P
NCT00426751_exc_435_T20,Major surgery within 6 weeks,Major surgery,0,13,,,,,P
NCT00391690_inc_621_T27,Previous chemotherapy or radiotherapy must have been performed ≥ 8 weeks prior to study entry.,chemotherapy,9,21,,,,,P
NCT02858180_exc_665_T31,"alanine aminotransferase (ALT), aspartase aminotransferase (AST), or alkaline phosphatase =",alanine aminotransferase,0,24,,,,,P
NCT02973035_exc_901_T42,"Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 3 times upper limit of normal).",hepatic enzyme elevation,61,85,,,,,P
NCT02502734_inc_183_T11,Subjects must be pre-adolescent without any signs of puberty (Tanner Stage 1).,signs of puberty,44,60,,,,,P
NCT03079141_exc_822_T51,(relative) Contraindications for FA or ICGA;,Contraindications,11,28,,,,,P
NCT02555163_exc_42_T4,Anteriorly located tumor,tumor,19,24,,,,,P
NCT00426751_exc_586_T30,Known severe renal (creatinine clearance <30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations =,hepatic insufficiency,55,76,,,,,P
NCT00426751_exc_372_T15,Evidence of an active gastrointestinal or urogenital bleeding,gastrointestinal bleeding,,,"[(22, 38), (22, 30)]",,,,P
NCT02579200_inc_293_T24,Persistent dyspnea on daily life (Baseline Dyspnea Index focal score <or= 8).,Dyspnea Index focal score,43,68,,,,,P
NCT02664558_exc_49_T34,History of uncontrolled hypertension,hypertension,24,36,,,,,P
NCT02765035_inc_587_T18,Person is walking on average 1km/day.,walking,10,17,,,,,P
NCT02964416_exc_245_T11,Obesity (women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2),Obesity,0,7,,,,,P
NCT01959425_exc_413_T23,Previous myocardial infarction (MI) or a percutaneous coronary intervention PCI within the past 3 months,myocardial infarction,9,30,,,,,P
NCT02965027_exc_1446_T79,Allergy or previous adverse reaction to prazosin or other alpha-1 antagonist,adverse reaction,20,36,,,,,P
NCT02437045_inc_0_T8,"Bloodstream infection with Enterobacter spp., Serratia marcescens, Providencia spp., Morganella morganii or Citrobacter freundii (i.e. likely AmpC-producer), and susceptibility to 3rd generation cephalosporins (i.e. ceftriaxone, cefotaxime or ceftazidime), meropenem and piperacillin-tazobactam from at least one blood culture draw.",3rd generation cephalosporins (,180,211,,,,,P
NCT01807897_inc_189_T12,No change in active cardiac medications for 4 weeks prior to randomization,cardiac medications,20,39,,,,,P
NCT02141061_exc_3_T15,"Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy",six (6) months or more,55,77,,,,,P
NCT02322203_exc_692_T41,"Subjects taking the following medications for at least six weeks, which may interfere with the study, will be excluded: BAS, antibiotics, anticoagulants, anticonvulsants, antiarrhythmic, Cyclosporine, Mycophenolate and Synthroid.",and,215,218,,,,,P
NCT03119766_exc_189_T12,"Diagnosis of other functional diseases of the digestive system, such as dyskinesia of cystic duct or gallbladder, irritable bowel syndrome, etc.",functional diseases,19,38,,,,,P
NCT02862314_exc_582_T24,"patients with an absolute indication for administration of antibiotics at the moment of ICU admission (meningitis, pneumonia) or a chronic infection for which long-term antibiotic treatment is necessary (endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis)",chronic infection,131,148,,,,,P
NCT02499185_inc_11_T3,"High risk patients: General Surgery AKI Risk Index Class III, IV or V",High risk,0,9,,,,,P
NCT02590822_inc_101_T4,HbA1c = 9% if on triple therapy or = 10% on diet & exercise or monotherapy or dual therapy,HbA1c,0,5,,,,,P
NCT00785213_exc_274_T18,Recent (2-year) history or evidence of alcoholism or drug abuse,alcoholism,39,49,,,,,P
NCT02590822_inc_367_T19,"Poorly managed diet controlled diabetes (with HbA1c > 6.5% , not currently taking any glucose lowering therapy, meeting BMI inclusion range)",HbA1c,46,51,,,,,P
NCT02858180_exc_43_T5,Amiodarone.,Amiodarone,0,10,,,,,P
NCT03430284_exc_318_T23,obviously poor compliance.,poor compliance,10,25,,,,,P
NCT00235170_exc_619_T31,Intention to treat more than 1 totally occluded major epicardial vessel;,totally occluded major epicardial vessel,31,71,,,,,P
NCT02537899_exc_0_T1,Non survivable injury,injury,15,21,,,,,P
NCT02965027_exc_6225_T169,Use of prescribed stimulants (such as amphetamine or dextroamphetamine containing medications) is exclusionary in the 2 weeks prior to the initial screen (P1) visit and prohibited throughout the study.,prescribed stimulants,7,28,,,,,P
NCT02664558_exc_1729_T129,"Prior treatment with B cell or lymphocyte-depleting agents (eg, rituximab, Campath)",B cell -depleting agents,,,"[(21, 27), (21, 38)]",,,,P
NCT02961582_inc_0_T1,An average defecation frequency (DF) of <3 per week based on a 3-week defecation diary (patient-reported),average defecation frequency,3,31,,,,,P
NCT00989261_exc_519_T35,Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant,transplant,54,64,,,,,P
NCT03373669_exc_443_T25,History of diarrhoea in 7 days prior to first dose of vaccine (defined as =3 unformed loose stools in 24 hours).,diarrhoea,11,20,,,,,P
NCT02334722_inc_0_T6,Adult (>18 years of age and older) patients who have or will have undergone surgical resection or biopsy of a supratentorial brain tumor and are able to consent for themselves.,surgical resection,76,94,,,,,P
NCT03355469_inc_242_T15,Increased waist circumference (=102 cm in men; =88 cm in women),waist circumference,10,29,,,,,P
NCT03126214_exc_146_T16,"Valvular Heart Disease including those with prosthetic valve, mitral stenosis (moderate to severe) or valve repair.",mitral stenosis,62,77,,,,,P
NCT02867618_inc_792_T51,"Evaluable Disease in the Phase I, and measurable disease in the Phase II",in the Phase I,18,32,,,,,P
NCT03364036_exc_774_T47,Active malignancy or history of malignancy.,malignancy,7,17,,,,,P
NCT02952378_inc_0_T7,"For healthy individuals: Healthy, without allergies and with the age of 18 years or above.",age,65,68,,,,,P
NCT02384850_inc_3_T13,Patients with histologically confirmed diagnosis of colorectal cancer presenting with unresectable stage IV (UICC) disease (primary tumor may be present),disease,115,122,,,,,P
NCT02431559_exc_2574_T163,"Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders).",illnesses,14,23,,,,,P
NCT02431559_exc_3392_T199,Subjects must not donate blood while on study and for at least 90 days following the last MEDI4736 treatment.,donate blood,18,30,,,,,P
NCT00426751_exc_70_T3,Thrombolytic therapy within 24 hours before randomization,within 24 hours before randomization,21,57,,,,,P
NCT03355469_inc_601_T44,"Elevated fasting glucose (=100 mg/dl), or on medication for treating the condition",fasting glucose,9,24,,,,,P
NCT02964416_inc_76_T7,American Society of Anaesthesiologists (ASA) 2 and stable ASA 3 patients,ASA,40,43,,,,,P
NCT02281643_inc_0_T9,M. perstans mg-positive status Good general health without any clinical condition requiring long-term medication.,requiring long-term medication,82,112,,,,,P
NCT01959425_exc_518_T29,Awaiting cardiac transplantation or other cardiac surgery within the next 365 days (12 months),cardiac transplantation,9,32,,,,,P
NCT03073603_exc_83_T4,Any new or definitely enlarging T2/FLAIR lesion or new gadolinium-enhancing lesion within the past three years (at least two scans separated by at least three years must be reviewed) on brain or spine MRI scan.,T2/FLAIR lesion,32,47,,,,,P
NCT02974660_inc_0_T1,patients who underwent successful TAVI,TAVI,34,38,,,,,P
NCT02804646_exc_0_T40,"1) pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;2) existing severe acute infection and is not controlled; or purulent and chronic infection, delayed healing wounds; 3) the original severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension; 4) suffering from neurological and psychiatric diseases or mental disorders is not easy to control, poor compliance, and can not be described with treatment responders; primary brain or central nervous metastasis disease has not been controlled, with significant cranial hypertension or neuropsychiatric symptoms; 5) have bleeding tendencies; 6) other researchers believe that patients should not participate in the present trial.",cranial hypertension,706,726,,,,,P
NCT00235170_exc_301_T13,Transmural myocardial infarction within the previous seven days and CK has not returned to normal;,CK,68,70,,,,,P
NCT01774019_exc_265_T15,Neoadjuvant chemotherapy for current malignancy,Neoadjuvant chemotherapy,0,24,,,,,P
NCT02431559_exc_1378_T102,"Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit.",peripheral ischemia,18,37,,,,,P
NCT02867618_exc_3_T11,Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.,chemotherapy,26,38,,,,,P
NCT02831166_exc_198_T19,"Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance < 30 mL/min, platelets count < 100.000 mm3);",peptic ulcer,68,80,,,,,P
NCT01891513_inc_306_T19,"Sedentary lifestyle, defined as <150 min/wk of moderate physical activity as assessed by CHAMPS questionnaire",moderate physical activity,47,73,,,,,P
NCT02431559_exc_1378_T107,"Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit.",ischemia,29,37,,,,,P
NCT02035904_inc_68_T6,"breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec.",breast cancer,0,13,,,,,P
NCT03355469_inc_38_T5,Has a body mass index >27 and <47 kg/m2.,body mass index,6,21,,,,,P
NCT03282006_exc_180_T13,E.coli isolate resistant to pivmecillinam,E.coli isolate,0,14,,,,,P
NCT02415257_exc_168_T9,"hearing is better than 30 deciBel (dB) in pure tone average (500, 1000, 2000, 3-4000 Hz) and speech discrimination better than 70%",pure tone average,42,59,,,,,P
NCT03079141_exc_137_T10,"Current treatment with corticosteroids (topical or systemic), corticosteroid use within 3 months before possible start of trial treatment, or anticipated start of corticosteroid treatment within the first 2 years from the start of the trial period;",corticosteroids,23,38,,,,,P
NCT01911650_exc_165_T13,history of surgery on the Achilles tendon or systemic diseases (general inflammatory diseases such as rheumatologic disorders and diabetes),general inflammatory diseases,64,93,,,,,P
NCT00989261_exc_397_T29,Persistent clinically significant non-hematological toxicity that is Grade >1 by NCI CTCAE v4 from prior chemotherapy,chemotherapy,105,117,,,,,P
NCT00989261_exc_397_T22,Persistent clinically significant non-hematological toxicity that is Grade >1 by NCI CTCAE v4 from prior chemotherapy,toxicity,52,60,,,,,P
NCT03355469_inc_387_T27,"Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), or on medication for treating the condition",Reduced,0,7,,,,,P
NCT02867618_exc_397_T32,History of allergic reactions to TGR-1202 or carfilzomib,allergic reactions,11,29,,,,,P
NCT01205334_inc_0_T4,Histopathological verification of glioblastoma multiforme (GBM: WHO grade IV) in remission (Group A) or with active disease (Group B).,WHO,64,67,,,,,P
NCT02109081_exc_0_T24,1) preoperative diagnosis of delirium or dementia; 2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing; 3) language barriers that would preclude testing; 4) preoperative steroid use within 3 days of surgery; or 5) anticipation of postoperative intubation.,surgery,281,288,,,,,P
NCT00989261_exc_3_T2,Patients over the age of 85 years except at the discretion of the Investigator and with agreement of the Sponsor.,age,18,21,,,,,P
NCT02965027_exc_2596_T133,Failure to record HA data for at least 80% of days during the Screening Period,Failure to record HA data,0,25,,,,,P
NCT02867618_inc_194_T19,"In addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.",therapies,117,126,,,,,P
NCT02526823_exc_92_T7,"Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;",heart disease,21,34,,,,,P
NCT00962364_inc_107_T6,"dilated cardiomyopathy due to valvular heart disease, hypertensive heart disease, history of myocarditis (no active myocardial infection present)",dilated cardiomyopathy,0,22,,,,,P
NCT02200978_exc_0_T6,"Patients who have coma, convulsion or paralysis due to intracranial hemorrhage or central nervous system leukemia at diagnosis.",leukemia,105,113,,,,,P
NCT02315287_inc_15_T4,No treatment with insulin or oral agents for 6 months,treatment,3,12,,,,,P
NCT03336801_exc_271_T22,Depressed liver function,liver function,10,24,,,,,P
NCT02003339_exc_439_T25,Associated disease which could prevent patient from receiving treatment,Associated disease,0,18,,,,,P
NCT02543710_inc_108_T9,Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment.,taxane,116,122,,,,,P
NCT02664558_exc_2313_T158,Hepatic dysfunction as defined by Child-Pugh Class B or C       ,Hepatic dysfunction,0,19,,,,,P
NCT03073603_exc_83_T10,Any new or definitely enlarging T2/FLAIR lesion or new gadolinium-enhancing lesion within the past three years (at least two scans separated by at least three years must be reviewed) on brain or spine MRI scan.,scans,125,130,,,,,P
NCT02579733_inc_192_T11,Endoscopic Mayo subscore >0,Endoscopic Mayo subscore,0,24,,,,,P
NCT02035904_inc_278_T19,immediate sub-pectoral prosthetic reconstruction;,sub-pectoral prosthetic reconstruction,10,48,,,,,P
NCT03156855_inc_131_T16,"previous allergic reaction to antibiotics (bismuth, amoxicillin, metronidazole, clarithromycin, tetracycline) and PPI (esomeprazole),",PPI,114,117,,,,,P
NCT03355469_inc_494_T37,"High blood pressure (=130 mmHg systolic or =85mmHg diastolic), or on medication for treating the condition",blood pressure,5,19,,,,,P
NCT01816997_exc_10_T3,2hr glucose during OGTT >200 mg/dL,2hr glucose during OGTT,0,23,,,,,P
NCT02664558_exc_2034_T142,Significant/chronic renal insufficiency.,chronic renal insufficiency,12,39,,,,,P
NCT03079141_exc_1109_T64,"(relative) Known contraindications for initiation of eplerenone treatment (hyperkalemia, abnormal renal clearance, severe hepatic insufficiency (Child-Pugh C), type 2 diabetes mellitus with microalbuminuria, concomitant use of potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent).",contraindications,17,34,,,,,P
NCT01997112_exc_0_T8,"History of ischaemic heart disease, cardiac failure, cerebrovascular disease, liver impairment (ALT/AST>50IU/L) or stage 3-5 chronic kidney disease.",stage,115,120,,,,,P
NCT03117608_exc_303_T16,Patients used to alcohol or drug (medication) abuse;,drug abuse,,,"[(28, 32), (28, 33)]",,,,P
NCT03589105_exc_1098_T66,"History or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease (e.g., lupus, anti-phospholipid antibody syndrome, Sjogren's syndrome, Behçet's disease, sarcoidosis)",systemic autoimmune disorders,29,58,,,,,P
NCT03045562_inc_78_T5,Subjects of STEMI who underwent primary PCI within the first 12 hours.,primary PCI,32,43,,,,,P
NCT02816762_exc_630_T38,Concomitant treatment with high doses of acetylsalicylic acid (> 500 mg/day) or continuous treatment with non-steroidal anti-inflammatory drugs,treatment,12,21,,,,,P
NCT02952378_inc_91_T11,For patients: Burn injury exceeding 6-8 Total Burned Surface Area %,Total Burned Surface Area,40,65,,,,,P
NCT00235170_exc_301_T11,Transmural myocardial infarction within the previous seven days and CK has not returned to normal;,Transmural myocardial infarction,0,32,,,,,P
NCT02867618_exc_3_T12,Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.,within 2 weeks prior,55,75,,,,,P
NCT02548013_inc_365_T20,Maternal and fetal condition remain stable after hospitalization for 72 hours,Maternal condition,,,"[(0, 8), (0, 9)]",,,,P
NCT02579200_inc_159_T14,Non-reversible airway obstruction (post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80 %),FEV1,55,59,,,,,P
NCT02664558_exc_289_T50,Acute decompensated heart failure within 1 month of Screening.,heart failure,20,33,,,,,P
NCT02788045_inc_331_T15,"Female participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [beta hCG]) at the Screening visit, and a negative urine pregnancy test pre-dose on Day 1",serum pregnancy test,67,87,,,,,P
NCT00989261_exc_2054_T94,Active hepatitis B or C or other active liver disease,liver disease,40,53,,,,,P
NCT01064752_exc_116_T10,"Enhanced risk from lumbar puncture, including documented or suspected cerebral mass lesion predisposing to brain herniation or bleeding diathesis.",cerebral mass lesion,70,90,,,,,P
NCT03073603_exc_83_T5,Any new or definitely enlarging T2/FLAIR lesion or new gadolinium-enhancing lesion within the past three years (at least two scans separated by at least three years must be reviewed) on brain or spine MRI scan.,gadolinium,55,65,,,,,P
NCT02939872_inc_139_T19,"No history of death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding",bleeding,95,103,,,,,P
NCT03249272_exc_744_T51,Severe renal insufficiency with estimated glomerular filtration rate <30 ml/min/ 1.73 m2,renal insufficiency,7,26,,,,,P
NCT02557412_exc_64_T6,"Predominance of central apneas and hypopneas, defined as more than 25% of all respiratory events.",Predominance,0,12,,,,,P
NCT03648021_exc_80_T8,"Severe hepatocellular insufficiency (ASAT or ALAT > 5N, or bilirubin > 2N)",ALAT,45,49,,,,,P
NCT03221231_exc_449_T31,"An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders;",psychiatric disorder,28,48,,,,,P
NCT02961582_inc_106_T8,Meet at least one other criterion of the Rome-IV criteria for idiopathic constipation based on the 3-week defecation diary (1),Rome-IV criteria for idiopathic constipation,41,85,,,,,P
NCT01218737_inc_0_T2,"Patient is indicated to have an ocular refractive surgery performed (myopia, astigmatism, hypermetropy) by the Lasik method.",indicated to have an ocular refractive surgery performed,11,67,,,,,P
NCT02783859_exc_361_T22,Extra-pulmonary infection requiring antibiotic therapy (e.g. meningitis),infection,16,25,,,,,P
NCT03119766_exc_0_T1,"Organic diseases of the digestive system (gastro-oesophageal reflux disease (GERD), ulcer, chronic pancreatitis, cholelithiasis, fatty liver disease, hepatitis, cirrhosis of liver, etc.) .",Organic diseases,0,16,,,,,P
NCT03336801_exc_146_T12,Sensistivity/allergy against anesthetic agents,Sensistivity,0,12,,,,,P
NCT03073603_exc_1037_T54,"History of other chronic neurological illnesses that might mimic MS with chronic or intermittent symptoms (i.e. ALS, myasthenia gravis, chronic neuropathy, etc.)",chronic neurological illnesses,17,47,,,,,P
NCT01177891_exc_65_T5,Subject with an abnormal karyotype in favor of Turner syndrome or having a premutation of the FMR1 gene or a syndromic form,abnormal karyotype,16,34,,,,,P
NCT02788045_inc_331_T14,"Female participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [beta hCG]) at the Screening visit, and a negative urine pregnancy test pre-dose on Day 1",childbearing potential,23,45,,,,,P
NCT00391690_inc_258_T14,"Patients without prostatectomy: 2 consecutive rises in PSA levels relative to a previous reference value, separated by one month.",PSA levels,55,65,,,,,P
NCT03477851_inc_0_T3,Patients with foot fracture scheduled for surgical repair in spinal anesthesia,surgical repair,42,57,,,,,P
NCT03228654_exc_141_T10,presence of significant scarring in the pelvic area from previous surgery.,significant scarring,12,32,,,,,P
NCT03262038_inc_28_T6,scheduled for urologic or orthopedic procedure necessitating intrathecal morphine,urologic procedure,,,"[(14, 22), (14, 23)]",,,,P
NCT02644629_inc_0_T1,Age 18-65,Age,0,3,,,,,P
NCT03228654_exc_141_T10,presence of significant scarring in the pelvic area from previous surgery.,significant scarring,12,32,,,,,P
NCT03364036_exc_583_T37,"History of tuberculosis , presence of active tuberculosis, or latent tuberculosis",tuberculosis,11,23,,,,,P
NCT00235170_exc_619_T32,Intention to treat more than 1 totally occluded major epicardial vessel;,treat,13,18,,,,,P
NCT02526823_exc_505_T30,"patients received doxorubicin therapy, total cumulative dose of adriamycin was more than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;",adriamycin,64,74,,,,,P
NCT03044561_inc_115_T12,(3) women have experienced two or more implantation failure attributed to inadequate endometrial development.,inadequate endometrial development,74,108,,,,,P
NCT02664558_exc_90_T37,Persistent hypotension at Screening.,Persistent hypotension,0,22,,,,,P
NCT02431559_exc_767_T69,Subjects with clinically significant cardiovascular disease.,cardiovascular disease,37,59,,,,,P
NCT03079141_exc_1109_T71,"(relative) Known contraindications for initiation of eplerenone treatment (hyperkalemia, abnormal renal clearance, severe hepatic insufficiency (Child-Pugh C), type 2 diabetes mellitus with microalbuminuria, concomitant use of potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent).",Child-Pugh,145,155,,,,,P
NCT02965027_exc_1446_T82,Allergy or previous adverse reaction to prazosin or other alpha-1 antagonist,alpha-1 antagonist,58,76,,,,,P
NCT01807897_exc_848_T31,Awake resting oxyhemoglobin saturation <89%,oxyhemoglobin saturation,14,38,,,,,P
NCT03079141_exc_1109_T70,"(relative) Known contraindications for initiation of eplerenone treatment (hyperkalemia, abnormal renal clearance, severe hepatic insufficiency (Child-Pugh C), type 2 diabetes mellitus with microalbuminuria, concomitant use of potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent).",severe hepatic insufficiency,115,143,,,,,P
NCT02209545_inc_178_T12,Pre-operative hemoglobin >8 g/dl,operative,4,13,,,,,P
NCT01491763_inc_236_T26,"Patients without functional impairment of organs: liver function: total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease.",cardiac function,304,320,,,,,P
NCT01314898_exc_155_T7,"Serum potassium >=5.1 mmol/L or <3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary.",Serum potassium,0,15,,,,,P
NCT02273791_inc_54_T5,"Presence of at least 2 cryopreserved good quality cleavage-stage embryo (good quality cleavage-stage embryos display stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments).",cleavage-stage embryo,50,71,,,,,P
NCT02678962_exc_0_T1,"Preexisting ocular diseases or conditions other than age related cataracts, have contraindications for cataract surgery;",ocular diseases,12,27,,,,,P
NCT01491295_inc_0_T1,HBsAg-positive for more than 6 months (HBeAg-positive or HBeAg-negative).,HBsAg,0,5,,,,,P
NCT02413970_exc_0_T4,Central + mixed apneas > 25% of the total apnea-hypopnea index (AHI),total apnea-hypopnea index,36,62,,,,,P
NCT02209545_inc_388_T24,Admissible medical/surgical history,surgical history,19,35,,,,,P
NCT02965027_exc_412_T32,"Continuous HAs of any kind (i.e., persistent daily HAs with no HA-free period less than 8 hours between attacks)",HAs,11,14,,,,,P
NCT02831166_exc_198_T20,"Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance < 30 mL/min, platelets count < 100.000 mm3);",creatinine clearance,82,102,,,,,P
NCT03318393_exc_83_T11,Patients with hepatic failure defined as coagulopathy with elevated transaminases more than three times normal values,transaminases,68,81,,,,,P
NCT03323047_exc_159_T6,"Patients with chronic conditions that would limit our ability to develop the study according to objectives, such as neurodevelopmental conditions preventing patients from understanding the Oucher tool",preventing,146,156,,,,,P
NCT02867618_inc_322_T24,Patients with DLBCL and HL will be eligible if there is no available standard therapy.,and,20,23,,,,,P
NCT00391690_inc_258_T16,"Patients without prostatectomy: 2 consecutive rises in PSA levels relative to a previous reference value, separated by one month.",2,32,33,,,,,P
NCT03056391_inc_30_T8,"Presence of P. knowlesi malaria, confirmed by positive blood smear with asexual forms of P. knowlesi.",P. knowlesi malaria,12,31,,,,,P
NCT02200978_exc_0_T4,"Patients who have coma, convulsion or paralysis due to intracranial hemorrhage or central nervous system leukemia at diagnosis.",intracranial hemorrhage,55,78,,,,,P
NCT00989261_exc_2113_T99,"History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the possible exception of patients in complete remission       ",skin cancer,57,68,,,,,P
NCT00391690_inc_952_T42,Age: ≥ 18 years,Age,0,3,,,,,P
NCT02596555_exc_1584_T53,Renal insufficiency with estimated creatinine clearance <30 ml/min/1.73m2,estimated creatinine clearance,25,55,,,,,P
NCT02678962_exc_535_T26,"Pregnant, lactating, or planning to become pregnant during the course of the trial;",Pregnant,0,8,,,,,P
NCT02965027_exc_1523_T92,"Active psychosis or psychotic disorder, severe depression (as determined per clinician prescriber judgment), severe psychiatric instability or severe situational life crisis (including evidence of being actively suicidal or homicidal).",situational life crisis,150,173,,,,,P
NCT03221231_exc_0_T2,"Currently dependent on any substance other than cannabis, alcohol or nicotine;",substance,27,36,,,,,P
NCT02961582_inc_495_T37,Manual manoeuvres to facilitate =25% of defecations,Manual manoeuvres,0,17,,,,,P
NCT03226080_exc_0_T8,Inability to consent/refusal Allergy to any of the study medications Multiple traumatic injuries Contraindication to neuraxial or general anesthesia Pregnancy,Allergy,29,36,,,,,P
NCT02557412_inc_409_T20,"A concentration of LDL-cholesterol above 100 mg / dl, in the month prior to inclusion.",LDL-cholesterol,19,34,,,,,P
NCT02804646_exc_0_T14,"1) pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;2) existing severe acute infection and is not controlled; or purulent and chronic infection, delayed healing wounds; 3) the original severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension; 4) suffering from neurological and psychiatric diseases or mental disorders is not easy to control, poor compliance, and can not be described with treatment responders; primary brain or central nervous metastasis disease has not been controlled, with significant cranial hypertension or neuropsychiatric symptoms; 5) have bleeding tendencies; 6) other researchers believe that patients should not participate in the present trial.",infection,146,155,,,,,P
NCT01959425_exc_1264_T56,Life expectancy less than 360 days (12 months),Life expectancy,0,15,,,,,P
NCT00785213_exc_65_T4,Recent significant blood donation or plasma donation,blood donation,19,33,,,,,P
NCT02783859_exc_232_T13,Severe malnutrition (weight-for-height Z-score <-3),weight-for-height Z-score,21,46,,,,,P
NCT02209545_inc_211_T16,Willing to have buccal administration of misoprostol or a placebo at least one hour pre-procedure.,buccal administration,16,37,,,,,P
NCT03472846_exc_170_T17,"Eating Disorder (anorexia nervosa, bulimia)",Eating Disorder,0,15,,,,,P
NCT02548013_inc_365_T19,Maternal and fetal condition remain stable after hospitalization for 72 hours,fetal condition,13,28,,,,,P
NCT02788045_inc_331_T13,"Female participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [beta hCG]) at the Screening visit, and a negative urine pregnancy test pre-dose on Day 1",Female,0,6,,,,,P
NCT03124329_inc_64_T7,"Multiple contiguous gingival recession defects on a minimum of two adjacent teeth, exhibiting 3mm or more recession on at least one of those teeth",recession,29,38,,,,,P
NCT02831166_exc_198_T22,"Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance < 30 mL/min, platelets count < 100.000 mm3);",platelets count,116,131,,,,,P
NCT03073603_exc_344_T20,Significant (as defined by the PI) intolerance of presently-used DMT,DMT,65,68,,,,,P
NCT02323399_inc_201_T23,"Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure =128/78 mmHg (sitting, after 5 minutes of rest)",after 5 minutes of rest,130,153,,,,,P
NCT02437045_inc_0_T1,"Bloodstream infection with Enterobacter spp., Serratia marcescens, Providencia spp., Morganella morganii or Citrobacter freundii (i.e. likely AmpC-producer), and susceptibility to 3rd generation cephalosporins (i.e. ceftriaxone, cefotaxime or ceftazidime), meropenem and piperacillin-tazobactam from at least one blood culture draw.",Bloodstream infection,0,21,,,,,P
NCT03156855_inc_131_T21,"previous allergic reaction to antibiotics (bismuth, amoxicillin, metronidazole, clarithromycin, tetracycline) and PPI (esomeprazole),",allergic reaction,9,26,,,,,P
NCT03079141_exc_460_T23,Best-corrected visual acuity < 20/200,Best-corrected visual acuity,0,28,,,,,P
NCT02664558_exc_2313_T159,Hepatic dysfunction as defined by Child-Pugh Class B or C       ,Child-Pugh,34,44,,,,,P
NCT02765035_inc_625_T20,Person is walking not slower than 3km/h (~0.8m/s) (based on 10m walk test conducted during recruiting).,walking,10,17,,,,,P
NCT02344888_exc_0_T1,Age < 20 or > 35 years.,Age,0,3,,,,,P
NCT03373669_exc_443_T26,History of diarrhoea in 7 days prior to first dose of vaccine (defined as =3 unformed loose stools in 24 hours).,in 7 days prior to first dose of vaccine,21,61,,,,,P
NCT00344318_exc_984_T49,History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.,History,0,7,,,,,P
NCT03444142_exc_341_T24,Total cholesterol =,Total cholesterol,0,17,,,,,P
NCT00989261_exc_519_T36,Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant,immunosuppressive drugs,89,112,,,,,P
NCT00344318_exc_584_T36,"Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations",first dose can be given,174,197,,,,,P
NCT01205334_inc_690_T33,Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study.,for one month prior to entry in this study,75,117,,,,,P
NCT01807897_exc_314_T17,Severe renal failure with estimated glomerular filtration rate <30 ml/min,renal failure,7,20,,,,,P
NCT02531971_inc_1155_T31,"Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",white blood cells,39,56,,,,,P
NCT02323399_inc_356_T27,Females must have a urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1,urine pregnancy test,,,"[(20, 25), (20, 34)]",,,,P
NCT00989261_exc_1718_T71,Uncontrolled or significant cardiovascular disease,cardiovascular disease,28,50,,,,,P
NCT02431559_exc_2110_T146,"Other malignancy within 2 years prior to Day 1 of the study, except for those treated with surgical intervention only.",malignancy,6,16,,,,,P
NCT02322203_exc_617_T29,Subjects with weight that varies greater than 20% over the past 3 months.,weight,14,20,,,,,P
NCT02678962_exc_0_T5,"Preexisting ocular diseases or conditions other than age related cataracts, have contraindications for cataract surgery;",cataracts,65,74,,,,,P
NCT02548013_inc_3_T8,PPROM with gestational age between 27 to 34 weeks,gestational age,11,26,,,,,P
NCT01491763_inc_236_T13,"Patients without functional impairment of organs: liver function: total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease.",AST,83,86,,,,,P
NCT03117608_exc_46_T6,"Patients participating in previous, concurrent or not, trials (ongoing or completed within three months);",completed,74,83,,,,,P
NCT02862314_exc_582_T24,"patients with an absolute indication for administration of antibiotics at the moment of ICU admission (meningitis, pneumonia) or a chronic infection for which long-term antibiotic treatment is necessary (endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis)",chronic infection,131,148,,,,,P
NCT02242188_inc_158_T19,No previous iron supplementation,iron supplementation,12,32,,,,,P
NCT03663387_exc_580_T38,"Use of anti-dementia medications (Aricept, Exelon, Razadyne) and memantine (Namenda)) or anti-Parkinsonian medications (Sinemet, amantadine, bromocriptine, pergolide, selegeline).",anti-dementia medications,7,32,,,,,P
NCT00391690_inc_717_T34,"Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (patients that spend less than 50% of time in bed during the day)",spend time in bed during the day,,,"[(76, 81), (76, 102)]",,,,P
NCT02973035_exc_1234_T62,Sitting systolic BP < 100 mmHg,systolic BP,8,19,,,,,P
NCT02862314_exc_582_T24,"patients with an absolute indication for administration of antibiotics at the moment of ICU admission (meningitis, pneumonia) or a chronic infection for which long-term antibiotic treatment is necessary (endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis)",chronic infection,131,148,,,,,P
NCT02224040_exc_38_T5,Major typhoid fever-associated complications,typhoid fever-associated,6,30,,,,,P
NCT02209545_inc_0_T3,Patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging (pelvic ultrasound or MRI) within in last 12 months,pelvic imaging,81,95,,,,,P
NCT02315287_inc_0_T1,HbA1c > 13.0 %,HbA1c,0,5,,,,,P
NCT02664558_exc_1400_T106,Body mass index ≥35.0 at Screening.,Body mass index,0,15,,,,,P
NCT03472846_exc_91_T9,Chronic alcohol abuse,alcohol abuse,8,21,,,,,P
NCT03663387_exc_192_T20,Baseline scores =16 on the 17-item Hamilton Depression Scale at baseline.,at baseline,61,72,,,,,P
NCT03663387_exc_580_T43,"Use of anti-dementia medications (Aricept, Exelon, Razadyne) and memantine (Namenda)) or anti-Parkinsonian medications (Sinemet, amantadine, bromocriptine, pergolide, selegeline).",memantine,65,74,,,,,P
NCT02579200_inc_293_T24,Persistent dyspnea on daily life (Baseline Dyspnea Index focal score <or= 8).,Dyspnea Index focal score,43,68,,,,,P
NCT02416869_inc_25_T4,Bilateral symmetrically impacted lower third molars according to Pel-Gregory's and Winter's classification,Pel-Gregory's and Winter's classification,65,106,,,,,P
NCT02437045_inc_490_T19,No more than 72 hours has elapsed since the first positive blood culture collection.,No more than 72 hours since the first positive blood culture collection,,,"[(0, 21), (0, 49)]",,,,P
NCT02965027_exc_5507_T158,"Sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra) will not be permitted during the study drug dose Titration Period, because of increased risk of hypotension in combination with alpha-1 blockers, but will be allowed at half the usual starting dose following the study drug dose Titration Period, per VA prescribing guidelines.",vardenafil,41,51,,,,,P
NCT02632760_exc_10_T3,Known hypersensitivity to study drug (ferric carboxymaltose or equivalent) or its excipients,study drug,26,36,,,,,P
NCT01911650_exc_165_T11,history of surgery on the Achilles tendon or systemic diseases (general inflammatory diseases such as rheumatologic disorders and diabetes),surgery on the Achilles tendon,11,41,,,,,P
NCT03589105_exc_377_T26,Gadolinium intolerance,intolerance,11,22,,,,,P
NCT02209545_inc_178_T14,Pre-operative hemoglobin >8 g/dl,hemoglobin,14,24,,,,,P
NCT03221231_exc_202_T25,"An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches;",prolonged loss of consciousness,177,208,,,,,P
NCT01959425_exc_205_T14,"Any cardiac surgery within the past 60 days (2 months) or valvular cardiac surgical procedure at any time (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)",within the past 60 days,20,43,,,,,P
NCT03589105_exc_400_T28,"History of ischemic cerebrovascular disorders (e.g., stroke, transient ischemic attack) or ischemia of the spinal cord",ischemic cerebrovascular disorders,11,45,,,,,P
NCT02526823_exc_92_T14,"Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;",myocardial infarction,123,144,,,,,P
NCT03073603_exc_744_T38,"uncontrolled hypertension,",hypertension,13,25,,,,,P
NCT03119766_exc_1342_T65,"Planned hospitalization during the study period, for any diagnostic or treatment procedures.",hospitalization,8,23,,,,,P
NCT02714725_inc_0_T8,"Adult patients aged (>18), males and females, undergoing elective coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).",cardiopulmonary bypass,115,137,,,,,P
NCT00445029_inc_421_T5,Patients with allergic contact dermatitis to para-phenylenediamine (PPD) based on a history of PPD contact dermatitis and positive PPD patch tests.,allergic contact dermatitis,14,41,,,,,P
NCT01959425_exc_1264_T57,Life expectancy less than 360 days (12 months),less than 360 days,16,34,,,,,P
NCT03491059_exc_201_T9,"unstable medical condition like heart disease, uncontrolled hypertension, thyroid disease, diabetes, renal or liver impairment, or glaucoma",medical condition,9,26,,,,,P
NCT02526823_exc_92_T11,"Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;",atrial fibrillation,84,103,,,,,P
NCT02973035_exc_1033_T48,History of intolerance to ARB or amlodipine.,intolerance,11,22,,,,,P
NCT03033745_exc_0_T1,Ongoing serious bacterial infections at the time of screening.,bacterial infections,16,36,,,,,P
NCT02858180_exc_1125_T55,Active or recent history (= 1 year) of drug or alcohol abuse,drug abuse,,,"[(39, 43), (39, 44)]",,,,P
NCT03079141_exc_1626_T85,"Soft drusen in treated eye or fellow eye, signs of choroidal neovascularization on ophthalmoscopy and/or FA/ICGA of the study eye.",Soft drusen,0,11,,,,,P
NCT02573168_inc_26_T5,"Suffer from schizophrenia/schizoaffective disorder meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria;","Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision",59,143,,,,,P
NCT02437045_inc_575_T17,Patient is aged 18 years and over (>=21y in Singapore).,aged,11,15,,,,,P
NCT02531971_inc_1155_T36,"Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",sodium,93,99,,,,,P
NCT03221231_exc_79_T8,"History of any major internal disease (including diabetes, cardiovascular disease, lung disease, liver or kidney disease);",major internal disease,15,37,,,,,P
NCT02876484_inc_66_T10,"Fasting plasma glucose < 7,0 mM, HbA1c < 48 mmol/mol 3 months after RYGB",RYGB,68,72,,,,,P
NCT02209545_inc_211_T16,Willing to have buccal administration of misoprostol or a placebo at least one hour pre-procedure.,buccal administration,16,37,,,,,P
NCT03318393_exc_201_T14,Patients with plan to decannulate from ECMO within 48 hours,decannulate from ECMO,22,43,,,,,P
NCT01807897_inc_96_T5,"Physician diagnosis of chronic heart failure, American Heart Association Stage C-D",chronic heart failure,23,44,,,,,P
NCT03073603_exc_0_T2,"Any MS relapse in the last five years, as determined at the screen visit by the PI",relapse,7,14,,,,,P
NCT02548013_inc_365_T20,Maternal and fetal condition remain stable after hospitalization for 72 hours,Maternal condition,,,"[(0, 8), (0, 9)]",,,,P
NCT03663387_exc_1337_T82,"Stroke when meeting criteria for total anterior, partial anterior or posterior circulation infarct according to the Oxford Community Stroke Project classification.",circulation infarct,79,98,,,,,P
NCT02664558_exc_616_T67,Uncorrected congenital systemic-to-pulmonary shunt.,congenital systemic-to-pulmonary shunt,12,50,,,,,P
NCT02816762_exc_374_T23,"Stroke, transient ischemic attack, acute coronary syndrome, or hospitalization for heart failure worsening, within the previous 30 days.",hospitalization,63,78,,,,,P
NCT02431559_exc_2110_T146,"Other malignancy within 2 years prior to Day 1 of the study, except for those treated with surgical intervention only.",malignancy,6,16,,,,,P
NCT03221231_exc_202_T15,"An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches;",neurological disorder,28,49,,,,,P
NCT02804646_exc_0_T35,"1) pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;2) existing severe acute infection and is not controlled; or purulent and chronic infection, delayed healing wounds; 3) the original severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension; 4) suffering from neurological and psychiatric diseases or mental disorders is not easy to control, poor compliance, and can not be described with treatment responders; primary brain or central nervous metastasis disease has not been controlled, with significant cranial hypertension or neuropsychiatric symptoms; 5) have bleeding tendencies; 6) other researchers believe that patients should not participate in the present trial.",primary brain disease,,,"[(612, 625), (612, 619)]",,,,P
NCT03119766_exc_1059_T57,Allergy/intolerance to any of the components of medications used in the treatment.,Allergy,0,7,,,,,P
NCT03373669_exc_0_T2,"Presence of a significant medical or psychiatric condition (Examples include: Diagnosis and treatment of tuberculosis (TB) or HIV; renal insufficiency; hepatic disease; oral or parenteral medication known to affect the immune function, such as corticosteroids, other immunosuppressant drugs; or behavioural or memory issues)",medical condition,,,"[(26, 33), (26, 35)]",,,,P
NCT00344318_exc_1243_T61,Acute disease at the time of enrolment,at the time of enrolment,14,38,,,,,P
NCT02431559_exc_416_T62,"Subjects with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or, within six months prior to Day 1 of this study, history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage.",cerebrovascular accident,247,271,,,,,P
NCT02162433_inc_114_T8,ASA 1 & 2,ASA,0,3,,,,,P
NCT02858180_exc_580_T24,Hepatitis B surface antigen positive,Hepatitis B surface antigen,0,27,,,,,P
NCT03228654_exc_141_T13,presence of significant scarring in the pelvic area from previous surgery.,from previous surgery,52,73,,,,,P
NCT02965027_exc_525_T46,"Acute or serious medical illness or unstable chronic medical illness (e.g., unstable angina, myocardial infarction within 6 months, congestive heart failure, clinically significant or concerning cardiac arrhythmias; preexisting hypotension [systolic blood pressure<110] or orthostatic hypotension [systolic drop >20 mm",hypotension,228,239,,,,,P
NCT00480129_inc_0_T6,"Clinical diagnosis of allergic rhinitis based on sneeze attacks, runny/blocked/itchy nose in the absence of a common cold during the previous 12 months.",common cold,110,121,,,,,P
NCT00426751_exc_0_T57,Subjects not able to give informed consent,give informed consent,21,42,,,,,P
NCT03355469_inc_387_T31,"Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), or on medication for treating the condition",women,55,60,,,,,P
NCT02762851_exc_317_T17,Anaphylactic reaction to neomycin,Anaphylactic reaction,0,21,,,,,P
NCT03589105_exc_36_T13,"Inability to complete an MRI (contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc…)",surgery,208,215,,,,,P
NCT02431559_exc_2871_T181,Lack of availability for immunological and clinical follow-up assessment.,immunological follow-up assessment,,,"[(25, 38), (25, 45)]",,,,P
NCT02862314_exc_229_T7,"situation in which the procalcitonin concentration could be increased without correlation to an infectious process (poly-traumatised patients,",procalcitonin concentration,23,50,,,,,P
NCT01631058_exc_0_T1,Allergy to any of proposed medications,Allergy,0,7,,,,,P
NCT03491059_exc_394_T22,"psychiatric conditions such as schizophrenia, adult ADHD, or bipolar disorder",psychiatric conditions,0,22,,,,,P
NCT02502734_inc_183_T13,Subjects must be pre-adolescent without any signs of puberty (Tanner Stage 1).,Tanner Stage,62,74,,,,,P
NCT02431559_exc_1378_T105,"Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit.",brief,50,55,,,,,P
NCT02831166_exc_589_T39,Severe concomitant disease with life expectancy below 12 months;,disease,19,26,,,,,P
NCT02322203_exc_597_T27,BMI less than 18.5,BMI,0,3,,,,,P
NCT00426751_inc_371_T16,Angina or equivalent symptoms > 20 min and,Angina,0,6,,,,,P
NCT02543710_inc_345_T13,Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence.,tissue biopsy,38,51,,,,,P
NCT01907230_inc_25_T6,HBsAg-positive for more than 6 months and HBV DNA < 2000 IU/ml (Subgroup 1)or HBsAg-negative but anti-HBc positive with HBV DNA < 2000 IU/ml,HBV DNA,42,49,,,,,P
NCT02531971_inc_1155_T37,"Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",potassium,101,110,,,,,P
NCT02384850_inc_550_T44,serum alanine transaminase (ALT) ≤ 2.5 x ULN (in case of liver metastases < 5 x ULN),liver metastases,57,73,,,,,P
NCT03648021_exc_155_T13,"Pharmacological intervention (administration of corticosteroids, NSAIDs or paracetamol) or physical intervention (external cooling technique) that may influence temperature in the last 6 hours.",Pharmacological intervention,0,28,,,,,P
NCT02965027_exc_2229_T119,"Women of childbearing potential must not be pregnant, planning to become pregnant during the study period, or nursing.",childbearing potential,9,31,,,,,P
NCT02816762_exc_774_T46,Previous treatment with CPAP,treatment,9,18,,,,,P
NCT02579200_inc_246_T19,"Respiratory muscle weakness (Pi,max < 70cmH2O)","Pi,max",29,35,,,,,P
NCT02156999_exc_0_T6,"Kidney, parathyroid, congenital bone metabolic disease",disease,47,54,,,,,P
NCT00235170_exc_404_T19,"Chest pain lasting longer than 30 minutes within 12 hours pre-procedure, if CK enzymes positive (≥ 2x the normal upper limit).",CK enzymes,76,86,,,,,P
NCT01314898_exc_264_T12,Estimated GFR <60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening.,Estimated GFR,0,13,,,,,P
NCT00236340_inc_94_T10,Single or twin pregnancies,Single,0,6,,,,,P
NCT01491295_inc_74_T9,Age > 20 y/o.,Age,0,3,,,,,P
NCT01807897_exc_589_T24,"Severe chronic insomnia, with reported usual sleep duration <4 hours",chronic insomnia,7,23,,,,,P
NCT02637076_exc_0_T1,"use of any sedative hypnotics, tranquilizers, anticonvulsants, antihistamines (except non-sedating), benzodiazepines, clonidine or any medication known to affect dopamine at start of baseline period",sedative hypnotics,11,29,,,,,P
NCT02557412_inc_409_T20,"A concentration of LDL-cholesterol above 100 mg / dl, in the month prior to inclusion.",LDL-cholesterol,19,34,,,,,P
NCT02384850_inc_856_T59,Women of child-bearing potential must have a negative pregnancy test,pregnancy test,54,68,,,,,P
NCT01497639_exc_96_T7,moderate-to-severe depression (> 25 points on the Beck Depression Inventory),depression,19,29,,,,,P
NCT02323399_inc_356_T27,Females must have a urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1,urine pregnancy test,,,"[(20, 25), (20, 34)]",,,,P
NCT01228279_inc_31_T6,Patients with end-stage renal disease(ESRD)/chronic kidney disease(CKD)stage 5,chronic kidney disease,44,66,,,,,P
NCT00989261_exc_397_T22,Persistent clinically significant non-hematological toxicity that is Grade >1 by NCI CTCAE v4 from prior chemotherapy,toxicity,52,60,,,,,P
NCT02531971_inc_1386_T48,Have normal screening laboratories for urine protein and urine glucose,urine protein,39,52,,,,,P
NCT01765231_exc_0_T2,younger than 18 years old,old,22,25,,,,,P
NCT00989261_exc_2054_T91,Active hepatitis B or C or other active liver disease,hepatitis B,7,18,,,,,P
NCT03079141_exc_867_T55,"(relative) Contraindications for photodynamic treatment (pregnancy, porphyria, severely disturbed liver function).",Contraindications,11,28,,,,,P
NCT02323399_inc_201_T19,"Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure =128/78 mmHg (sitting, after 5 minutes of rest)",mean systolic blood pressure,,,"[(61, 65), (61, 69), (61, 75)]",,,,P
NCT02876484_inc_66_T5,"Fasting plasma glucose < 7,0 mM, HbA1c < 48 mmol/mol 3 months after RYGB",Fasting plasma glucose,0,22,,,,,P
NCT03344042_exc_48_T4,contraindications to epidural analgesia,contraindications,0,17,,,,,P
NCT00989261_exc_2113_T97,"History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the possible exception of patients in complete remission       ",cancer,11,17,,,,,P
NCT01959425_exc_0_T10,"OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis, previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard echo performed at 3-months follow-up).",spontaneous echo contrast,122,147,,,,,P
NCT03126214_exc_433_T31,"History of ""Major Bleeding"" at any point (defined as overt bleeding at a critical site including intracranial, intraspinal, intraocular, pericardial, or retroperitoneal; or bleed requiring hospitalization).",Major Bleeding,12,26,,,,,P
NCT02509091_inc_0_T1,Age=18 years and =80 years;,Age,0,3,,,,,P
NCT03044561_inc_115_T10,(3) women have experienced two or more implantation failure attributed to inadequate endometrial development.,implantation,39,51,,,,,P
NCT03589105_exc_36_T20,"Inability to complete an MRI (contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc…)",MRI,25,28,,,,,P
NCT02816762_exc_630_T38,Concomitant treatment with high doses of acetylsalicylic acid (> 500 mg/day) or continuous treatment with non-steroidal anti-inflammatory drugs,treatment,12,21,,,,,P
NCT03282006_exc_123_T9,Pyonephrosis requiring drainage,drainage,23,31,,,,,P
NCT01064752_exc_267_T23,Pregnancy or expectation of pregnancy during the study.,pregnancy,28,37,,,,,P
NCT01807897_exc_67_T5,Hospitalization for myocardial infarction or cardiac surgery within previous 90 days,myocardial infarction,20,41,,,,,P
NCT00718952_inc_22_T6,"Confirmed idiopathic pulmonary hypertension, connective tissue disease associated pulmonary hypertension, congenital heart disease(with Eisenmenger syndrome) associated pulmonary hypertension.",congenital heart disease,106,130,,,,,P
NCT03073603_exc_842_T46,Cancers other than basal cell skin cancers within the last 5 years,Cancers,0,7,,,,,P
NCT03156855_inc_131_T18,"previous allergic reaction to antibiotics (bismuth, amoxicillin, metronidazole, clarithromycin, tetracycline) and PPI (esomeprazole),",antibiotics,30,41,,,,,P
NCT03491059_exc_0_T1,not a regular user of e-cigarettes,regular user,6,18,,,,,P
NCT03663387_exc_1078_T69,"Chronic kidney disease in stages = 4, as defined per National Kidney Foundation (8).",Chronic kidney disease,0,22,,,,,P
NCT03360981_exc_0_T4,"acute myocardial infarction, heart failure, neoplastic disease, chronic diseases that may affect the inflammatory profile both systemic and epicardial (cancer, chronic intestinal inflammation, hepatitis, AIDS); life expectancy < 6 months, previous CABG and/or other open heart surgery intervention, acute coronary syndrome",chronic diseases,64,80,,,,,P
NCT03335436_exc_68_T10,positive drug screen at the time of delivery,at the time of delivery,21,44,,,,,P
NCT02705222_inc_160_T12,Failure of medical treatment for at least 3 months.,Failure,0,7,,,,,P
NCT00480129_inc_154_T11,History of positive skin prick test or blood radio-allergosorbent test (RAST) to grass and/or ragweed pollen,blood radio-allergosorbent test (RAST),39,77,,,,,P
NCT03648021_exc_155_T13,"Pharmacological intervention (administration of corticosteroids, NSAIDs or paracetamol) or physical intervention (external cooling technique) that may influence temperature in the last 6 hours.",Pharmacological intervention,0,28,,,,,P
NCT00391690_inc_0_T3,Patients with histologically confirmed diagnosis of prostate cancer who have not yet developed bone metastases,prostate cancer,52,67,,,,,P
NCT02831166_exc_589_T39,Severe concomitant disease with life expectancy below 12 months;,disease,19,26,,,,,P
NCT02862314_exc_582_T22,"patients with an absolute indication for administration of antibiotics at the moment of ICU admission (meningitis, pneumonia) or a chronic infection for which long-term antibiotic treatment is necessary (endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis)",indication,26,36,,,,,P
NCT02431559_exc_963_T88,"History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti-arrhythmic medication.",requiring anti-arrhythmic medications,125,162,,,,,P
NCT02965027_exc_202_T19,Lifetime history of 5 or more migraine or probable migraine headaches pre-dating mTBI,mTBI,81,85,,,,,P
NCT02323399_inc_201_T14,"Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure =128/78 mmHg (sitting, after 5 minutes of rest)",diabetes,25,33,,,,,P
NCT01491295_inc_88_T12,"Under lamivudine/adefovir treatment for more than 1 year due to previous lamivudine resistance (LAM-R), current HBV DNA is undetectable (< 20 IU/ml) during enrollment.",adefovir,17,25,,,,,P
NCT00236340_inc_0_T6,Pregnant women with abdomen discumfort and ultrasound diagnosis of polyhydramnios (AFI>25cm),AFI,83,86,,,,,P
NCT03430284_exc_218_T19,allergic history or contraindication for any drugs in trials;,drugs in trials,45,60,,,,,P
NCT02788045_inc_76_T4,"Is healthy on the basis of physical examination, medical history, electrocardiogram (ECG), and vital signs measurement performed at screening",healthy,3,10,,,,,P
NCT03079141_exc_670_T40,Continuous and/or progressive visual loss > 18 months or serous detachment on OCT > 18 months;,visual loss,30,41,,,,,P
NCT01314898_exc_0_T1,Subjects with a supine BP >140 mm Hg systolic or >90 mm,supine BP,16,25,,,,,P
NCT01891513_inc_24_T5,Hypertension - untreated (Systolic Blood Pressure (SBP) ≥,Systolic Blood Pressure (SBP),26,55,,,,,P
NCT03355469_inc_115_T10,Not currently engaged in > 60 min/wk of exercise,engaged in exercise,,,"[(14, 24), (14, 22)]",,,,P
NCT02965027_exc_83_T3,History of TBI more severe than mild by DVBIC criteria,TBI,11,14,,,,,P
NCT02952378_inc_0_T2,"For healthy individuals: Healthy, without allergies and with the age of 18 years or above.",healthy,4,11,,,,,P
NCT02322203_exc_692_T33,"Subjects taking the following medications for at least six weeks, which may interfere with the study, will be excluded: BAS, antibiotics, anticoagulants, anticonvulsants, antiarrhythmic, Cyclosporine, Mycophenolate and Synthroid.",BAS,120,123,,,,,P
NCT03355469_inc_306_T23,"Elevated triglycerides (=150 mg/dl), or on medication for treating the condition",Elevated,0,8,,,,,P
NCT03336801_exc_296_T25,Genetic malignant hyperthermia,malignant hyperthermia,8,30,,,,,P
NCT00989261_exc_397_T27,Persistent clinically significant non-hematological toxicity that is Grade >1 by NCI CTCAE v4 from prior chemotherapy,NCI CTCAE v4,81,93,,,,,P
NCT01483118_inc_143_T15,"Patients meeting the Rotterdam PCOS workshop criteria for polycystic ovary syndrome, defined by oligomenorrhea or amenorrhea and at least one of the following two signs: clinical or biochemical evidence of hyperandrogenism or ultrasound finding of polycystic appearing ovaries.",ultrasound,226,236,,,,,P
NCT02867618_exc_534_T47,Current malignancy or history of a prior malignancy,malignancy,8,18,,,,,P
NCT02431559_exc_963_T79,"History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti-arrhythmic medication.",ventricular arrhythmia,19,41,,,,,P
NCT01794793_exc_1185_T13,Male sterilization (at least 6 months prior to screening).,Male sterilization,0,18,,,,,P
NCT01807897_exc_0_T1,Hospitalization for acute decompensated HF within previous 30 days,Hospitalization,0,15,,,,,P
NCT02380118_exc_62_T5,"reversible aetiology for agitation (e.g. hypotension, hypoxia, hypoglycaemia)",reversible aetiology,0,20,,,,,P
NCT00989261_exc_2009_T89,Human immunodeficiency virus positivity,Human immunodeficiency virus,0,28,,,,,P
NCT02862314_exc_582_T24,"patients with an absolute indication for administration of antibiotics at the moment of ICU admission (meningitis, pneumonia) or a chronic infection for which long-term antibiotic treatment is necessary (endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis)",chronic infection,131,148,,,,,P
NCT02664558_exc_1170_T97,"History of portal hypertension or chronic liver disease, including positive serology for infection with HCV and/or HBV.",serology for infection with HCV,76,107,,,,,P
NCT03079141_exc_615_T35,Visual loss and/or serous detachment on OCT < 6 weeks;,OCT,40,43,,,,,P
NCT00785213_exc_65_T4,Recent significant blood donation or plasma donation,blood donation,19,33,,,,,P
NCT02664558_exc_1441_T110,History of obstructive sleep apnea.,obstructive sleep apnea,11,34,,,,,P
NCT02209545_inc_178_T11,Pre-operative hemoglobin >8 g/dl,Pre-operative,0,13,,,,,P
NCT03589105_exc_893_T53,"History of genetically inherited progressive CNS degenerative disorder (e.g., hereditary paraparesis; MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, stroke] syndrome)",progressive CNS degenerative disorder,33,70,,,,,P
NCT02531971_inc_1155_T42,"Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin",creatinine,162,172,,,,,P
NCT00989261_exc_339_T21,AML or antecedent MDS secondary to prior chemotherapy,chemotherapy,41,53,,,,,P
NCT00426751_exc_1112_T52,Subjects who will be inaccessible due to geographic or social factors during treatment or follow-up,during treatment or follow-up,70,99,,,,,P
NCT03044561_inc_0_T3,"(1) cases of infertility, older than 20 years of age and not older than 40 years.",age,49,52,,,,,P
NCT02973035_exc_84_T3,Planned cardiac surgery or planned major non-cardiac surgery within the study period.,surgery,16,23,,,,,P
NCT02109081_exc_0_T14,1) preoperative diagnosis of delirium or dementia; 2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing; 3) language barriers that would preclude testing; 4) preoperative steroid use within 3 days of surgery; or 5) anticipation of postoperative intubation.,cognitive impairment,123,143,,,,,P
NCT02557412_inc_348_T13,"Lipid-lowering treatment and diet, stable in the last month.",stable,35,41,,,,,P
NCT02858180_exc_819_T42,"Severe renal impairment creatinine clearance (CrCl), i.e. < 30 mL/min.",creatinine clearance,24,44,,,,,P
NCT01424020_exc_109_T6,Unable to walk (ex: wheelchair subjects),Unable to walk,0,14,,,,,P
NCT02664558_exc_2080_T148,"Transaminases (alanine transaminase, aspartate transaminase) levels >3 × upper limit of normal (ULN) and/or bilirubin level >2 × ULN.",Transaminases levels,,,"[(0, 13), (0, 6)]",,,,P
NCT03073603_exc_83_T4,Any new or definitely enlarging T2/FLAIR lesion or new gadolinium-enhancing lesion within the past three years (at least two scans separated by at least three years must be reviewed) on brain or spine MRI scan.,T2/FLAIR lesion,32,47,,,,,P
NCT02867618_inc_792_T49,"Evaluable Disease in the Phase I, and measurable disease in the Phase II",Disease,10,17,,,,,P
NCT02654912_exc_0_T1,"contraindications from manufacturer for medications including currently taking haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin",contraindications,0,17,,,,,P
NCT03663387_exc_1337_T81,"Stroke when meeting criteria for total anterior, partial anterior or posterior circulation infarct according to the Oxford Community Stroke Project classification.",Stroke,0,6,,,,,P
NCT03079141_exc_40_T6,"Previous prescription of mineralocorticoid receptor antagonists, for cCSC or for other diseases;",mineralocorticoid receptor antagonists,25,63,,,,,P
NCT02783859_exc_434_T25,Beta-lactam allergy,allergy,12,19,,,,,P
NCT02323399_inc_0_T1,"Subject's age is between =12 and 16 years, inclusive",age,10,13,,,,,P
NCT03335436_exc_68_T8,positive drug screen at the time of delivery,drug screen,9,20,,,,,P
NCT02973035_exc_317_T22,A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.,cancer,15,21,,,,,P
NCT03663387_exc_888_T61,Implanted medical devices that are incompatible with MRI imaging.,incompatible with MRI imaging,35,64,,,,,P
NCT02431559_exc_323_T47,Clinically significant persistent immune-related adverse events following prior therapy.,following prior therapy,64,87,,,,,P
NCT03126214_exc_640_T45,Foreshortened life-expectancy or severe comorbidities precluding study follow-up period,life-expectancy,14,29,,,,,P
NCT02543710_inc_0_T4,All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.,endometrial cancer,88,106,,,,,P
NCT03360981_exc_0_T19,"acute myocardial infarction, heart failure, neoplastic disease, chronic diseases that may affect the inflammatory profile both systemic and epicardial (cancer, chronic intestinal inflammation, hepatitis, AIDS); life expectancy < 6 months, previous CABG and/or other open heart surgery intervention, acute coronary syndrome",open heart surgery intervention,266,297,,,,,P
NCT02431559_exc_1219_T93,Baseline ejection fraction ≤ 50% as assessed by echocardiogram or MUGA.,ejection fraction,9,26,,,,,P
NCT03323047_exc_632_T27,Complicating health factors precluding the use of opioids or acetaminophen,precluding,28,38,,,,,P
NCT02664558_exc_289_T50,Acute decompensated heart failure within 1 month of Screening.,heart failure,20,33,,,,,P
NCT02858180_exc_890_T45,History of major organ transplantation with an existing functional graft.,major organ transplantation,11,38,,,,,P
NCT02961582_inc_368_T31,Sensation of incomplete evacuation for =25% of defecations,defecations,47,58,,,,,P
NCT02970773_inc_0_T1,Motor complete tetraplegia for at least 3 months,tetraplegia,15,26,,,,,P
NCT02590822_inc_192_T9,"Current glucose lowering therapy either mono, dual or triple of any combination of metformin, sulphonylurea, DPP-IV inhibitor, GLP-1 therapy or an SGLT2 +/- diet and exercise",glucose lowering therapy,8,32,,,,,P
NCT01205334_inc_0_T1,Histopathological verification of glioblastoma multiforme (GBM: WHO grade IV) in remission (Group A) or with active disease (Group B).,glioblastoma multiforme,34,57,,,,,P
NCT02952378_inc_91_T3,For patients: Burn injury exceeding 6-8 Total Burned Surface Area %,patients,4,12,,,,,P
NCT02939872_inc_0_T1,Age 19 and more,Age,0,3,,,,,P
NCT00391690_inc_112_T8,Prostate cancer patients with a rise in PSA under hormone therapy.,hormone therapy,50,65,,,,,P
NCT02867618_exc_3_T17,Prior Therapy Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.,adverse events,135,149,,,,,P
NCT02964416_inc_166_T11,Patients with Glasgow Coma Scale (GCS) 15/15,Glasgow Coma Scale,14,32,,,,,P
NCT02579733_inc_0_T1,Ulcerative colitis patients with moderate to severe activity who achieved a clinical remission by the first course of corticosteroids,Ulcerative colitis,0,18,,,,,P
NCT01175044_exc_360_T14,Patients scheduled to undergo revision total knee arthroplasty for infectious reasons.,revision total knee arthroplasty,30,62,,,,,P
NCT03126214_exc_433_T31,"History of ""Major Bleeding"" at any point (defined as overt bleeding at a critical site including intracranial, intraspinal, intraocular, pericardial, or retroperitoneal; or bleed requiring hospitalization).",Major Bleeding,12,26,,,,,P
NCT00445029_inc_146_T21,Feasibility of patch testing.,patch testing,15,28,,,,,P
NCT02457442_inc_141_T13,Chronic intake of CNS active drugs,CNS active drugs,18,34,,,,,P
NCT02502734_inc_791_T36,Using one of the following asthma therapies prior to entry into the study: SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <,prior to entry into the study,44,73,,,,,P
NCT00391690_inc_195_T10,Patients who have undergone prostatectomy: any rise in PSA or,PSA,55,58,,,,,P
NCT01205334_inc_690_T31,Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study.,antineoplastic therapy,52,74,,,,,P
NCT02961582_inc_0_T1,An average defecation frequency (DF) of <3 per week based on a 3-week defecation diary (patient-reported),average defecation frequency,3,31,,,,,P
NCT00344318_exc_201_T13,Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.,Chronic,0,7,,,,,P
NCT02431559_exc_963_T89,"History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled with anti-arrhythmic medication.",atrial fibrillation,175,194,,,,,P
NCT03360981_exc_0_T4,"acute myocardial infarction, heart failure, neoplastic disease, chronic diseases that may affect the inflammatory profile both systemic and epicardial (cancer, chronic intestinal inflammation, hepatitis, AIDS); life expectancy < 6 months, previous CABG and/or other open heart surgery intervention, acute coronary syndrome",chronic diseases,64,80,,,,,P
NCT02557412_inc_131_T7,"It is also considered patients who have an altered analytical, using the following cutoffs: total cholesterol = 200 mg / dl, triglycerides = 180 mg / dl, HDL-cholesterol = 40",HDL-cholesterol,154,169,,,,,P
NCT02579733_inc_0_T5,Ulcerative colitis patients with moderate to severe activity who achieved a clinical remission by the first course of corticosteroids,first course of corticosteroids,102,133,,,,,P
NCT03124329_inc_64_T3,"Multiple contiguous gingival recession defects on a minimum of two adjacent teeth, exhibiting 3mm or more recession on at least one of those teeth",gingival recession defects,20,46,,,,,P
NCT01175044_exc_171_T8,Any condition requiring antibiotics 14 days prior to arriving for surgery.,arriving for surgery,53,73,,,,,P
NCT02595190_exc_491_T19,"Patients with Magnetic resonance imaging contraindication ,including claustrophobic syndrome patients",contraindication,41,57,,,,,P
NCT02961582_inc_324_T24,Lumpy or hard stools in =25% of defecations,Lumpy stools,,,"[(0, 5), (0, 6)]",,,,P
NCT03663387_exc_580_T45,"Use of anti-dementia medications (Aricept, Exelon, Razadyne) and memantine (Namenda)) or anti-Parkinsonian medications (Sinemet, amantadine, bromocriptine, pergolide, selegeline).",anti-Parkinsonian medications,89,118,,,,,P
NCT03119766_exc_596_T36,Known history of/suspected malignant neoplasm of various sites.,malignant neoplasm,27,45,,,,,P
NCT03119766_exc_596_T36,Known history of/suspected malignant neoplasm of various sites.,malignant neoplasm,27,45,,,,,P
NCT02281643_inc_115_T3,Normal renal and hepatic laboratory profiles,renal laboratory profile,,,"[(7, 12), (7, 25)]",,,,P
NCT01824537_exc_134_T12,Being pregnant or plan on immediately becoming pregnant,pregnant,6,14,,,,,P
NCT02209545_inc_211_T16,Willing to have buccal administration of misoprostol or a placebo at least one hour pre-procedure.,buccal administration,16,37,,,,,P
NCT01891513_inc_24_T3,Hypertension - untreated (Systolic Blood Pressure (SBP) ≥,Hypertension,0,12,,,,,P
NCT02035904_inc_0_T2,F; age 18 to 70,age,3,6,,,,,P
NCT02664558_exc_1866_T136,"Concurrent regular use of another leukotriene pathway inhibitor, including over-the-counter medications or herbal remedies.",leukotriene pathway inhibitor,34,63,,,,,P
NCT02531971_inc_0_T4,Men or non-pregnant women of any ethnic background between the age of 18 and 45 years old,age,63,66,,,,,P
NCT02531971_inc_2577_T64,Temperature 35-37.9°C (95-100.3°F),35-37.9°C,12,21,,,,,P
NCT03079141_exc_615_T35,Visual loss and/or serous detachment on OCT < 6 weeks;,OCT,40,43,,,,,P
NCT03663387_exc_1078_T70,"Chronic kidney disease in stages = 4, as defined per National Kidney Foundation (8).",stages,26,32,,,,,P
NCT02867618_inc_617_T42,Patients with DLBCL will be eligible if there is no available standard therapy.,DLBCL,14,19,,,,,P
NCT02553226_exc_150_T8,"Pathological fetal heart rate pattern (cardiotocogram, CTG) before Syntocinon® initiation",Pathological fetal heart rate pattern,0,37,,,,,P
NCT02965027_exc_1945_T104,"History of delirium within the prior 3 months, epilepsy, stroke, dementia, psychotic disorder, or bipolar disorder",delirium,11,19,,,,,P
NCT02431559_exc_323_T46,Clinically significant persistent immune-related adverse events following prior therapy.,immune-related adverse events,34,63,,,,,P
NCT02816762_exc_374_T20,"Stroke, transient ischemic attack, acute coronary syndrome, or hospitalization for heart failure worsening, within the previous 30 days.",Stroke,0,6,,,,,P
NCT02831166_exc_137_T9,Hypersensitivity to antiplatelet and/or anticoagulant drugs;,Hypersensitivity,0,16,,,,,P
NCT02553226_exc_150_T8,"Pathological fetal heart rate pattern (cardiotocogram, CTG) before Syntocinon® initiation",Pathological fetal heart rate pattern,0,37,,,,,P
NCT02431559_exc_2673_T174,Prior treatment in any other interventional clinical trial within 4 weeks prior to Day 1 of the study.,treatment,6,15,,,,,P
NCT00989261_exc_519_T44,Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant,persistent,215,225,,,,,P
NCT02431559_exc_3_T33,"Prior exposure to doxorubicin, PLD or any other anthracycline, motolimod and other TLR agonists, MEDI4736 or checkpoint inhibitors, such as anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies.",checkpoint inhibitors,109,130,,,,,P
NCT02944292_inc_127_T8,Spontaneous breathing activity of at least 6 breaths/minute,Spontaneous breathing activity,0,30,,,,,P
NCT03337581_exc_186_T14,a history of use of alpha 2 receptor agonists or antagonists.,alpha 2 receptor agonists,20,45,,,,,P
NCT02224040_inc_0_T1,Blood culture-proven typhoid fever (S. typhi or S. paratyphi),Blood culture,0,13,,,,,P
NCT01774019_exc_187_T12,"Surgically altered biliary tract anatomy, not including prior cholecystectomy",cholecystectomy,62,77,,,,,P
NCT03373669_exc_443_T25,History of diarrhoea in 7 days prior to first dose of vaccine (defined as =3 unformed loose stools in 24 hours).,diarrhoea,11,20,,,,,P
NCT01205334_inc_208_T19,Karnofsky/Lansky score 50 or greater,Karnofsky/Lansky,0,16,,,,,P
NCT03234816_inc_76_T8,Aged between 18 and 40 years,Aged,0,4,,,,,P
NCT02437045_inc_0_T3,"Bloodstream infection with Enterobacter spp., Serratia marcescens, Providencia spp., Morganella morganii or Citrobacter freundii (i.e. likely AmpC-producer), and susceptibility to 3rd generation cephalosporins (i.e. ceftriaxone, cefotaxime or ceftazidime), meropenem and piperacillin-tazobactam from at least one blood culture draw.",Serratia marcescens,46,65,,,,,P
NCT01884337_exc_40_T8,"Known or suspected, acquired or bleeding or coagulation disorder in the subject or a first degree relative",acquired disorder,,,"[(20, 28), (20, 28)]",,,,P
NCT00344318_exc_361_T17,Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3.,vaccine,44,51,,,,,P
NCT00235170_exc_404_T20,"Chest pain lasting longer than 30 minutes within 12 hours pre-procedure, if CK enzymes positive (≥ 2x the normal upper limit).",positive,87,95,,,,,P
NCT01959425_exc_413_T25,Previous myocardial infarction (MI) or a percutaneous coronary intervention PCI within the past 3 months,percutaneous coronary intervention,41,75,,,,,P
NCT02664558_exc_1295_T104,Evidence of active infection requiring intravenous or oral antibiotics within 4 weeks of Screening.,within 4 weeks of Screening,71,98,,,,,P
NCT02579200_inc_159_T9,Non-reversible airway obstruction (post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80 %),airway obstruction,15,33,,,,,P
NCT02964416_inc_166_T11,Patients with Glasgow Coma Scale (GCS) 15/15,Glasgow Coma Scale,14,32,,,,,P
NCT02596555_exc_1658_T55,Chronic liver disease with aminotransferase levels two times or more above the local upper limit of normal range,Chronic liver disease,0,21,,,,,P
NCT02783859_exc_284_T15,"Complicated (effusion, empyema or abscess) pneumonia, including tuberculosis",Complicated pneumonia,,,"[(0, 11), (0, 9)]",,,,P
NCT02502734_inc_594_T27,A pre-bronchodilatory forced expiratory flow in 1 second (FEV1) at Visit 1 (Screening) >,forced expiratory flow in 1 second (FEV1),22,63,,,,,P
NCT03044561_inc_82_T5,(2) Body mass index (BMI):20-29.,Body mass index,4,19,,,,,P
NCT02431559_exc_1378_T103,"Grade 2 or higher peripheral ischemia, except for brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit.",Grade 2 or higher,0,17,,,,,P
NCT02765035_inc_217_T7,Person is currently fitted with a prosthesis using a non-microprocessor controlled prosthetic knee for at least 6 months.,prosthesis,34,44,,,,,P
NCT03663387_exc_338_T25,Concurrent medication limiting validity of neuropsychological tests or imaging.,Concurrent,0,10,,,,,P
NCT02858180_exc_617_T26,Hemoglobin (Hb) < 8 g/dL,Hemoglobin,0,10,,,,,P
NCT02344888_exc_138_T10,Previous history of ovarian surgery or surgical removal of one ovary.,surgical removal,39,55,,,,,P
NCT02209545_inc_178_T11,Pre-operative hemoglobin >8 g/dl,Pre-operative,0,13,,,,,P
NCT01807897_inc_0_T1,Veteran receiving care within the Veterans Health Administration healthcare system,Veteran,0,7,,,,,P
NCT03663387_exc_47_T5,Neurodegenerative disorders (i.e. Parkinson disease.,Neurodegenerative disorders,0,27,,,,,P
NCT03033745_exc_0_T3,Ongoing serious bacterial infections at the time of screening.,at the time of screening,37,61,,,,,P
NCT02984475_exc_242_T11,regular consumption of medication with potential hepatotoxicity.,hepatotoxicity,49,63,,,,,P
NCT02531971_inc_890_T18,"Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)",pain,73,77,,,,,P
NCT02273791_exc_0_T1,Moderate or severe endometriosis.,endometriosis,19,32,,,,,P
NCT02420015_exc_0_T1,Have a history of myocardial infarction in the past 6 months,myocardial infarction i,18,41,,,,,P
NCT03589105_exc_0_T1,Diagnosis of primary progressive MS,progressive MS,21,35,,,,,P
NCT01911650_exc_309_T17,daily use of opioids for pain,opioids,13,20,,,,,P
NCT02595190_exc_491_T19,"Patients with Magnetic resonance imaging contraindication ,including claustrophobic syndrome patients",contraindication,41,57,,,,,P
NCT02595190_exc_3_T1,Patients with lumbar common diseases(e.g.,lumbar diseases,,,"[(14, 20), (14, 22)]",,,,P
NCT03336801_exc_234_T20,Depressed kidney function and/or AKI,Depressed kidney function,0,25,,,,,P
NCT01907230_inc_180_T18,"Inflammatory arthritis patients who plan to treat with biological agents, including Humira or Enbrel or Simponi or Orencia or Mabthera or Actemra; as first line biologic treatment is indicated.",biological agents,55,72,,,,,P
NCT03589105_exc_36_T17,"Inability to complete an MRI (contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc…)",implanted,271,280,,,,,P
NCT02973035_exc_1185_T60,Atrial fibrillation with a heart rate > 120/min.,heart rate,27,37,,,,,P
NCT01175044_exc_246_T10,Patients with chronic immunosuppression (such as HIV/AIDS).,immunosuppression,22,39,,,,,P
NCT00989261_exc_1313_T56,"Radiation therapy within 4 weeks prior to, or concurrent with study",Radiation therapy,0,17,,,,,P
NCT03589105_exc_736_T45,"History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, human T-lymphotropic virus 1 (HTLV-1), herpes zoster myelopathy)",infectious causes,29,46,,,,,P
NCT02224040_exc_164_T17,Treatment within the past 4 days with an antibiotic that may be effective against typhoid fever       ,antibiotic,41,51,,,,,P
NCT01816997_exc_199_T18,Serum Cr > 2.0 mg/dL,Serum Cr,0,8,,,,,P
NCT02413970_exc_0_T4,Central + mixed apneas > 25% of the total apnea-hypopnea index (AHI),total apnea-hypopnea index,36,62,,,,,P
NCT03373669_exc_443_T25,History of diarrhoea in 7 days prior to first dose of vaccine (defined as =3 unformed loose stools in 24 hours).,diarrhoea,11,20,,,,,P
NCT03117608_exc_388_T20,Varus or valgus misalignment exceeding 15°;,Varus misalignment,,,"[(0, 5), (0, 12)]",,,,P
NCT02867618_exc_590_T49,Patient known to be Human Immunodeficiency Virus (HIV)-positive,Human Immunodeficiency Virus (HIV),20,54,,,,,P
NCT02384850_inc_3_T13,Patients with histologically confirmed diagnosis of colorectal cancer presenting with unresectable stage IV (UICC) disease (primary tumor may be present),disease,115,122,,,,,P
NCT01175044_exc_246_T10,Patients with chronic immunosuppression (such as HIV/AIDS).,immunosuppression,22,39,,,,,P
NCT03234816_inc_35_T7,Scheduled for elective Cesarean Delivery,Cesarean Delivery,23,40,,,,,P
NCT01807897_inc_96_T6,"Physician diagnosis of chronic heart failure, American Heart Association Stage C-D",American Heart Association Stage,46,78,,,,,P
NCT03491059_exc_201_T9,"unstable medical condition like heart disease, uncontrolled hypertension, thyroid disease, diabetes, renal or liver impairment, or glaucoma",medical condition,9,26,,,,,P
NCT02664558_exc_1482_T112,"History of malignancy within the last 5 years, except nonmelanoma skin cancer and cervical carcinoma in situ treated with curative intent.",malignancy,11,21,,,,,P
NCT02141061_exc_594_T44,"Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study.",testosterone,22,34,,,,,P
NCT02431559_exc_323_T46,Clinically significant persistent immune-related adverse events following prior therapy.,immune-related adverse events,34,63,,,,,P
NCT03335436_exc_0_T4,use illicit drugs or relapse during the last trimester of pregnancy,the last trimester of pregnancy,36,67,,,,,P
NCT02705222_inc_0_T3,"Perimenopausal women complaining of abnormal uterine bleeding (menorrhagia, metrorrhagia, polymenorrhoea or polymenorrhagia) without local gynecological cause.",abnormal uterine bleeding,36,61,,,,,P
NCT02858180_exc_819_T42,"Severe renal impairment creatinine clearance (CrCl), i.e. < 30 mL/min.",creatinine clearance,24,44,,,,,P
NCT03364036_exc_583_T36,"History of tuberculosis , presence of active tuberculosis, or latent tuberculosis",tuberculosis,11,23,,,,,P
NCT01491295_inc_88_T19,"Under lamivudine/adefovir treatment for more than 1 year due to previous lamivudine resistance (LAM-R), current HBV DNA is undetectable (< 20 IU/ml) during enrollment.",during enrollment,149,166,,,,,P
NCT00426751_inc_557_T29,Planned primary percutaneous coronary intervention,Planned,0,7,,,,,P
NCT03589105_exc_36_T7,"Inability to complete an MRI (contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc…)",weight,90,96,,,,,P
NCT03221231_exc_202_T24,"An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches;",head trauma,160,171,,,,,P
NCT02380118_exc_0_T1,known hypersensitivity or contraindication to the study drugs,hypersensitivity,6,22,,,,,P
NCT02579200_inc_293_T21,Persistent dyspnea on daily life (Baseline Dyspnea Index focal score <or= 8).,dyspnea on daily life,11,32,,,,,P
NCT00344318_exc_1514_T75,Administration of immunoglobulins and/or any blood products since birth or planned administration during the active phase of the study.,during the active phase of the study,98,134,,,,,P
NCT03079141_exc_1109_T68,"(relative) Known contraindications for initiation of eplerenone treatment (hyperkalemia, abnormal renal clearance, severe hepatic insufficiency (Child-Pugh C), type 2 diabetes mellitus with microalbuminuria, concomitant use of potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent).",renal clearance,98,113,,,,,P
NCT01907230_inc_25_T3,HBsAg-positive for more than 6 months and HBV DNA < 2000 IU/ml (Subgroup 1)or HBsAg-negative but anti-HBc positive with HBV DNA < 2000 IU/ml,HBsAg,0,5,,,,,P
NCT01491763_inc_236_T15,"Patients without functional impairment of organs: liver function: total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease.",alfa-GT,93,100,,,,,P
NCT03430284_exc_92_T7,acute cardiovascular or cerebrovascular accidents within past 3 months;,cerebrovascular accidents,24,49,,,,,P
NCT02816762_exc_276_T14,Systolic blood pressure = 180 mmHg or diastolic blood pressure =,Systolic blood pressure,0,23,,,,,P
NCT03124329_inc_274_T13,Minimum of 2 mm of keratinized gingiva,keratinized gingiva,19,38,,,,,P
NCT01614041_inc_70_T7,HAMA score=17,HAMA score,0,10,,,,,P
NCT02557412_inc_131_T3,"It is also considered patients who have an altered analytical, using the following cutoffs: total cholesterol = 200 mg / dl, triglycerides = 180 mg / dl, HDL-cholesterol = 40",total cholesterol,92,109,,,,,P
NCT02141061_exc_594_T44,"Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study.",testosterone,22,34,,,,,P
NCT03364036_exc_255_T20,Current or previous history of immune deficiency disorders including a positive human immunodeficiency virus (HIV) result.,immune deficiency disorders,31,58,,,,,P
NCT03117608_exc_152_T9,Patients surgically treated for the same defect within one year;,surgically treated,9,27,,,,,P
NCT02502734_inc_698_T32,There should be no Short acting beta-agonist (SABA) use within 4 hours of this measurement.,within 4 hours of this measurement,56,90,,,,,P
NCT03088280_inc_0_T1,"Primary kidney transplant recipients, adults",kidney transplant,8,25,,,,,P
NCT03228654_exc_141_T12,presence of significant scarring in the pelvic area from previous surgery.,surgery,66,73,,,,,P
NCT02965027_exc_525_T47,"Acute or serious medical illness or unstable chronic medical illness (e.g., unstable angina, myocardial infarction within 6 months, congestive heart failure, clinically significant or concerning cardiac arrhythmias; preexisting hypotension [systolic blood pressure<110] or orthostatic hypotension [systolic drop >20 mm",systolic blood pressure,241,264,,,,,P
NCT02537899_exc_22_T3,Multiple significant trauma (i.e. significant intracranial and extracranial injuries including limb fractures) that would limit observation of recovery from spinal cord injury,trauma,21,27,,,,,P
NCT02965027_exc_5870_T164,Use of supplements containing nitrates and supplements containing stimulants (such as ephedra) are exclusionary in the two weeks prior to initial screen (P1) visit and prohibited throughout the study.,nitrates,30,38,,,,,P
NCT02431559_exc_1295_T99,New York Heart Association (NYHA) Class II or higher congestive heart failure.,New York Heart Association (NYHA),0,33,,,,,P
NCT00989261_exc_519_T39,Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant,graft-versus-host disease,148,173,,,,,P
NCT02816762_exc_630_T43,Concomitant treatment with high doses of acetylsalicylic acid (> 500 mg/day) or continuous treatment with non-steroidal anti-inflammatory drugs,treatment,12,21,,,,,P
NCT03344042_exc_88_T7,"coagulopathies including platelet count of less than 100,000",platelet count,25,39,,,,,P
NCT03589105_exc_36_T17,"Inability to complete an MRI (contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc…)",implanted,271,280,,,,,P
NCT01959425_exc_0_T7,"OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis, previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard echo performed at 3-months follow-up).",standard echo,157,170,,,,,P
NCT00989261_exc_1973_T85,"Active, uncontrolled infection",infection,21,30,,,,,P
NCT03336801_exc_85_T5,BMI >37,BMI,0,3,,,,,P
NCT01228279_inc_31_T4,Patients with end-stage renal disease(ESRD)/chronic kidney disease(CKD)stage 5,end-stage renal disease,14,37,,,,,P
NCT02537899_exc_22_T3,Multiple significant trauma (i.e. significant intracranial and extracranial injuries including limb fractures) that would limit observation of recovery from spinal cord injury,trauma,21,27,,,,,P
NCT00344318_exc_201_T10,Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.,immunosuppressants,57,75,,,,,P
NCT03491059_exc_584_T32,"use of medications that are inducers of CYP2A6 (a nicotine metabolizing enzyme) such as rifampicin, dexamethasone, phenobarbital, and other anti-convulsant drugs",medications,7,18,,,,,P
NCT02858180_exc_793_T38,Total bilirubin > 3 mg/dl,Total bilirubin,0,15,,,,,P
NCT02762851_exc_77_T4,"Known IgE( Immunoglobulin E)-mediated hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock",IgE( Immunoglobulin E)-mediated hypersensitivity,6,54,,,,,P
NCT03073603_exc_83_T7,Any new or definitely enlarging T2/FLAIR lesion or new gadolinium-enhancing lesion within the past three years (at least two scans separated by at least three years must be reviewed) on brain or spine MRI scan.,lesion,41,47,,,,,P
NCT02413970_exc_637_T14,Body Mass Index (BMI) of > 32,Body Mass Index,0,15,,,,,P
NCT02019160_exc_0_T4,"Children who are uncooperative and difficult to manage, have major systemic diseases, or are on long-term medication will be excluded.",systemic diseases,67,84,,,,,P
NCT01614041_inc_122_T14,"Agree to be washed-out for two weeks if receiving SSRI, SNRI or NASA.",washed-out,12,22,,,,,P
NCT02788045_inc_331_T21,"Female participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [beta hCG]) at the Screening visit, and a negative urine pregnancy test pre-dose on Day 1",urine pregnancy test,174,194,,,,,P
NCT02322203_exc_309_T14,Subjects with elevated uric acid levels greater than 10 mg/dL or gout,elevated,14,22,,,,,P
NCT02973035_exc_84_T2,Planned cardiac surgery or planned major non-cardiac surgery within the study period.,within the study period,61,84,,,,,P
NCT01807897_exc_314_T17,Severe renal failure with estimated glomerular filtration rate <30 ml/min,renal failure,7,20,,,,,P
NCT03663387_exc_418_T31,Anti-depressants with anti-cholinergic properties,anti-cholinergic properties,22,49,,,,,P
NCT03228654_exc_45_T5,uterine size >12 weeks.,uterine size,0,12,,,,,P
NCT00344318_exc_1085_T55,"History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease.",febrile convulsion,100,118,,,,,P
NCT02965027_exc_525_T49,"Acute or serious medical illness or unstable chronic medical illness (e.g., unstable angina, myocardial infarction within 6 months, congestive heart failure, clinically significant or concerning cardiac arrhythmias; preexisting hypotension [systolic blood pressure<110] or orthostatic hypotension [systolic drop >20 mm",orthostatic hypotension,273,296,,,,,P
NCT02531971_inc_2684_T70,Heart rate 55-100 beats per minute,Heart rate,0,10,,,,,P
NCT02595190_exc_385_T13,"Patients with other nervous system diseases(e.g., cerebral tumor, neurinoma, trigeminal neuralgia,etc)",nervous system diseases,20,43,,,,,P
NCT02224040_exc_38_T7,Major typhoid fever-associated complications,complications,31,44,,,,,P
NCT02788045_inc_331_T15,"Female participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [beta hCG]) at the Screening visit, and a negative urine pregnancy test pre-dose on Day 1",serum pregnancy test,67,87,,,,,P
NCT02557412_inc_409_T22,"A concentration of LDL-cholesterol above 100 mg / dl, in the month prior to inclusion.",in the month prior to inclusion,54,85,,,,,P
NCT02816762_exc_573_T32,Severe daytime sleepiness (Epworth sleepiness scale >18),daytime sleepiness,7,25,,,,,P
NCT02563535_exc_74_T5,contraindication for combined antiplatelet treatment,contraindication,0,16,,,,,P
NCT02548013_inc_108_T13,Oral temperature > 38 C,Oral temperature,0,16,,,,,P
NCT03045562_inc_64_T2,Age>18 years.,Age,0,3,,,,,P
NCT02526823_exc_505_T34,"patients received doxorubicin therapy, total cumulative dose of adriamycin was more than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;",epirubicin,125,135,,,,,P
NCT02876484_inc_0_T3,Uncomplicated RYGB performed minimum 3 months prior to the study.,minimum 3 months prior to the study,29,64,,,,,P
NCT03337581_exc_0_T1,"allergic to dexmedetomidine, similar active ingredients or excipients",dexmedetomidine,12,27,,,,,P
NCT02323399_inc_201_T19,"Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure =128/78 mmHg (sitting, after 5 minutes of rest)",mean systolic blood pressure,,,"[(61, 65), (61, 69), (61, 75)]",,,,P
NCT02035904_inc_16_T4,American Society of Anesthesiologists (ASA) I e II;,American Society of Anesthesiologists (ASA),0,43,,,,,P
NCT02415257_exc_168_T11,"hearing is better than 30 deciBel (dB) in pure tone average (500, 1000, 2000, 3-4000 Hz) and speech discrimination better than 70%",speech discrimination,93,114,,,,,P
NCT02631512_exc_37_T3,Uncontrolled diabetes defined as HbA1c above 70 mmol/mol and insufficient nutritional status.,Uncontrolled diabetes,0,21,,,,,P
NCT02384850_inc_451_T35,hemoglobin ≥ 9 g/dl or 5.59 mmol/l,hemoglobin,0,10,,,,,P
NCT01205334_inc_0_T3,Histopathological verification of glioblastoma multiforme (GBM: WHO grade IV) in remission (Group A) or with active disease (Group B).,Histopathological verification,0,30,,,,,P
NCT02664558_exc_1295_T101,Evidence of active infection requiring intravenous or oral antibiotics within 4 weeks of Screening.,infection requiring antibiotics,,,"[(19, 38), (19, 30)]",,,,P
NCT02964416_exc_245_T16,Obesity (women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2),body mass index,22,37,,,,,P
NCT02862314_exc_582_T24,"patients with an absolute indication for administration of antibiotics at the moment of ICU admission (meningitis, pneumonia) or a chronic infection for which long-term antibiotic treatment is necessary (endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis)",chronic infection,131,148,,,,,P
NCT01884337_exc_193_T18,"Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days other than the elective knee/hip surgery",surgery,40,47,,,,,P
NCT00344318_exc_361_T17,Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3.,vaccine,44,51,,,,,P
NCT00989261_exc_1877_T82,Men who are unwilling to use contraception if their partners are of childbearing potential,contraception,29,42,,,,,P
NCT03079141_exc_0_T3,Any previous treatments for active CSC;,treatments,13,23,,,,,P
NCT03499639_inc_60_T5,"HCV genotype 4,",HCV genotype,0,12,,,,,P
NCT02644629_inc_110_T5,MADRS score > 20,MADRS score,0,11,,,,,P
NCT03221231_exc_449_T31,"An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders;",psychiatric disorder,28,48,,,,,P
NCT02637076_exc_264_T22,significant history of head trauma/surgery or seizure disorder,history,12,19,,,,,P
NCT03364036_exc_255_T21,Current or previous history of immune deficiency disorders including a positive human immunodeficiency virus (HIV) result.,human immunodeficiency virus (HIV),80,114,,,,,P
NCT02431559_exc_1849_T135,"Vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted.",requiring hormone replacement,93,122,,,,,P
NCT02431559_exc_1295_T101,New York Heart Association (NYHA) Class II or higher congestive heart failure.,congestive heart failure,53,77,,,,,P
NCT02816762_exc_111_T9,Evidence in the clinic history of relevant bilateral stenosis of renal artery (> 75%),stenosis of renal artery,53,77,,,,,P
NCT03262038_inc_28_T7,scheduled for urologic or orthopedic procedure necessitating intrathecal morphine,morphine,73,81,,,,,P
NCT03589105_exc_736_T45,"History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, human T-lymphotropic virus 1 (HTLV-1), herpes zoster myelopathy)",infectious causes,29,46,,,,,P
NCT01997112_exc_216_T20,"Patients with chronic pain requiring treatment, with a known allergy to paracetamol, or concomitant use of non-steroidal anti-inflammatories , oral anticoagulants or corticosteroids.",non-steroidal anti-inflammatories,107,140,,,,,P
NCT03119766_exc_1342_T65,"Planned hospitalization during the study period, for any diagnostic or treatment procedures.",hospitalization,8,23,,,,,P
NCT03117608_exc_454_T26,Patients with trauma within 6 months pre-operative.,trauma,14,20,,,,,P
NCT02557412_exc_330_T13,Very excessive daytime sleepiness (Epworth Sleepiness Scale> 18).,daytime sleepiness,15,33,,,,,P
NCT02531971_inc_2315_T54,"Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block.",ECG,14,17,,,,,P
NCT02431559_exc_3392_T201,Subjects must not donate blood while on study and for at least 90 days following the last MEDI4736 treatment.,while on study,31,45,,,,,P
NCT02964416_exc_201_T9,Patients with clinical signs of raised ICP.,ICP,39,42,,,,,P
NCT03119766_exc_189_T12,"Diagnosis of other functional diseases of the digestive system, such as dyskinesia of cystic duct or gallbladder, irritable bowel syndrome, etc.",functional diseases,19,38,,,,,P
NCT02664558_exc_289_T50,Acute decompensated heart failure within 1 month of Screening.,heart failure,20,33,,,,,P
NCT00480129_inc_0_T5,"Clinical diagnosis of allergic rhinitis based on sneeze attacks, runny/blocked/itchy nose in the absence of a common cold during the previous 12 months.",itchy nose,79,89,,,,,P
NCT01911650_exc_39_T5,local steroid injection within 6 weeks or physical therapy within 4 weeks,physical therapy,42,58,,,,,P
NCT02816762_exc_374_T24,"Stroke, transient ischemic attack, acute coronary syndrome, or hospitalization for heart failure worsening, within the previous 30 days.",heart failure,83,96,,,,,P
NCT02965027_exc_2229_T124,"Women of childbearing potential must not be pregnant, planning to become pregnant during the study period, or nursing.",pregnant,44,52,,,,,P
NCT03156855_inc_72_T7,"gastric malignancy, including adenocarcinoma and lymphoma,",gastric malignancy,0,18,,,,,P
NCT03249272_exc_635_T45,Recent cerebrovascular accident,cerebrovascular accident,7,31,,,,,P
NCT02862314_exc_582_T22,"patients with an absolute indication for administration of antibiotics at the moment of ICU admission (meningitis, pneumonia) or a chronic infection for which long-term antibiotic treatment is necessary (endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis)",indication,26,36,,,,,P
NCT02431559_exc_873_T75,Myocardial infarction or unstable angina within 6 months prior to Day 1 of the study.,Myocardial infarction,0,21,,,,,P
